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Summary 
Polymer nanomedicine is an attractive approach for the delivery of anticancer drugs. 
Firstly designed to increase drug bioavailability, polymer conjugates and polymer 
nanoparticles have rapidly emerged in the field of cancer therapy after the discovery of 
the enhanced permeation and retention (EPR) effect. The leaky and disordered tumor 
neovascularization provides opportunities to guide the accumulation of polymer 
nanomedicines to the tumor tissue therefore enhancing therapy selectivity and reducing 
off-target-associated side effects. However, since many chemotherapeutics act on targets 
that are located in well-defined subcellular compartments, controlling the intracellular 
fate of polymer nanomedicines and/or their payload is another important factor that 
contributes to therapy efficiency. Polymer conjugates and polymer nanoparticles 
generally access the cell interior via endocytosis. The physiochemical and biochemical 
parameters that distinguish the endolysosomal compartments from the extracellular 
environment have been widely exploited to trigger intracellular drug release from the 
polymer carriers. 
Amongst a range of other polymers and polymer nanoparticles that have been 
investigated over the past 30 years, poly(N-(2-hydroxypropyl) methacrylamide) 
(PHPMA)-based conjugates have been extensively explored for the endolysosomal 
release of anticancer drugs. While the modern polymer chemistry toolbox provides many 
opportunities to tailor the molecular weight and functionality of PHPMA and to introduce 
features that allow the polymer to respond to the different endolysosomal environments, 
the development of tools and methods to monitor these processes is also crucial for the 
future development of advanced delivery systems.  
The aim of this Thesis is to design dual-functional PHPMA polymers that offer the 
possibility to control the endolysosomal release of anticancer drug combinations as well 
as to monitor the PHPMA endolysosomal trafficking.  
Chapter 1 of this Thesis provides an overview of the different approaches that have 
been described in literature to control and monitor the intracellular delivery of polymer 
nanomedicines. 
Chapter 2 describes a synthetic approach to prepare α- and α,ω-fluorine labeled 
pentafluorophenyl methacrylate (PPFMA) polymers via reversible addition fragmentation 
chain transfer (RAFT) polymerization. Both R- and R, Z-fluorinated chain transfer agents 
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(F-CTAs) will be used to introduce fluorine labels at the α- and α,ω- end groups of the 
polymer. These labels will be further used to investigate RAFT polymerization 
parameters via 19F-NMR studies. The synthesized α-fluorinated PPFMA will serve in 
Chapter 3 and Chapter 4 as a polymer precursor for the preparation of the dual 
functional PHPMA polymers. 
Chapter 3 describes the preparation of a dual PHPMA conjugate for the reversion of P-
glycoprotein-mediated multidrug resistance in ovarian carcinoma cells. Post-
polymerization modification of the PPFMA precursor will be used to prepare a series of 
PHPMA conjugates carrying either the anticancer drug doxorubicin (Dox) or the P-
glycoprotein inhibitor zosuquidar (Zos) or both drugs at the polymer side chains. The first 
part of this Chapter will investigate the feasibility of PHPMA conjugates bearing a 
pendant zosuquidar derivative via hydrazone linker to overcome doxorubicin efflux in 
resistant ovarian carcinoma cells. In the second part, the cytotoxic activity of the dual 
delivery system in which both drugs are conjugated to the PHPMA backbone via 
orthogonal cleavable linkers will be assessed. 
Finally, Chapter 4 will study the cellular internalization and endolysosomal trafficking 
of PHPMA. First, the synthesis of a dual-labeled PHPMA polymer containing both a 
fluorescent as well as a fluorinated label will be described. Second, the fluorescent label 
will be used to investigate cellular internalization and endolysosomal trafficking via flow 
cytometry and confocal fluorescence microscopy, respectively. In a final step, the 
potential of nanoscale secondary ion mass spectrometry (NanoSIMS) to map and localize 
fluorine-containing polymers in cells will be assessed.  
 
 
 
 
 
 
 
Keywords: polymer nanomedicine, PHPMA-conjugates, PPFMA, post-polymerization 
modification, multidrug resistance, intracellular trafficking, co-localization studies, 
NanoSIMS. 
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Riassunto 
L’uso di nanomedicine di matrice polimerica rappresenta un approccio interessante per 
il trasporto e il rilascio controllato dei farmaci antitumorali. Inizialmente ideati per 
incrementare la disponibilità dei farmaci, i coniugati e le nanoparticelle di natura 
polimerica sono emersi rapidamente nel campo della terapia anticancro grazie alla 
scoperta dell’enhanced permeation and retention (EPR) effect. La maggiore permeabilità 
che caratterizza i vasi sanguigni tumorali offre infatti l’ opportunità di dirigere 
l’accumulo dei polimeri coniugati e delle nanoparticelle nel tessuto tumorale, aumentando 
di coseguenza la selettività e riducendo gli effetti collaterali dei farmaci trasportati. 
Tuttavia, dato che molti farmaci antitumorali agiscono in target localizzati in organelli 
cellulari, il controllo della destinazione intracellulare del polimero e/o del farmaco 
trasportato è un fattore altrettanto determinante per l’efficacia della terapia. I coniugati 
polimerici e le nanoparticelle, in genere, vengono internalizzati dalle cellule via 
endocitosi. Di conseguenza, i parametri fisiochimici e biochimici che contraddistinguono 
gli endosomi e lisosomi dall’ambiente extracellulare sono stati ampiamente utilizzati per 
stimolare il rilascio dei farmaci dalla matrice polimerica nei compartimenti 
endolisosomali.  
Tra una vasta gamma di polimeri e di nanoparticelle esaminati negli ultimi 30 anni, i 
coniugati polimerici di poli(N-(2-idrossipropil) metacrilammide) (PHPMA) sono stati 
ampiamente esplorati per il rilascio di farmaci antitumorali in risposta ai diversi ambienti 
che caratterizzano gli endosomi e lisosomi. Nonostante la chimica dei polimeri moderna 
fornisca svariate opportunità per controllare il peso molecolare e le funzionalità dei 
coniugati polimerici di PHPMA e per introdurre caratteristiche che permettono al 
polimero di rispondere ai diversi ambienti che caratterizzano endosomi e lisosomi, lo 
sviluppo di mezzi e metodi per monitorare questi processi sono considerati cruciali per lo 
sviluppo di sistemi avanzati di trasporto dei farmaci. 
L’obiettivo di questa Tesi è quello di preparare polimeri bifunzionali di PHPMA per il 
rilascio controllato di combinazioni di farmaci antitumorali negli endosomi e lisosomi e 
per il monitoraggio di questi processi.  
Il Capitolo 1 di questa Tesi fornisce una panoramica dei diversi approcci che sono stati 
descritti in letteratura per controllare e monitorare il trasporto e il rilasco intracellulare di 
nanomedicine di matrice polimerica.  
Riassunto 
 
4 
 
Il Capitolo 2 descrive un approccio sintetico per preparare polimeri di 
pentafluorofenile metacrilato (PPFMA) contenete sonde fluorurate nei due gruppi 
terminali attraverso polimerizzazione reversible addition fragmentation chain transfer 
(RAFT). Due chain transfer agents fluorurati (F-CTAs) contenenti una sonda nel gruppo 
R, o in entrambi i gruppi R e Z, saranno utilizzati per introdurre le sonde fluorurate in 
entrambi i gruppi terminali α e α,ω del polimero. Queste sonde saranno poi utilizzate per 
determinare i diversi parametri della polimerizzazione RAFT attraverso studi di 19F-
NMR. Il PPFMA analogo contenente la sonda fluorurata in posizione α sarà 
successivamente utlizzato nei capitoli Capitoli 3 e 4 di questa Tesi come precursore per 
la preparazione dei polimeri bifunzionali di PHPMA.  
Il Capitolo 3 descrive la preparazione di un PHPMA bifunzionale per evadere i 
meccanismi di resistenza multifarmaco in cellule di carcinoma ovarico resistenti 
attraverso l’inibizione della P-glicoproteina. Il precursore polimerico PPFMA sarà 
modificato al fine di sintetizzare una serie di coniugati contenenti il farmaco antitumorale 
doxorubicina (Dox), o l’inibitore della P-glicoproteina zosuquidar (Zos) o una 
combinazione dei due farmaci. La prima parte di questo capitolo investigherà l’abilità dei 
coniugati di PHPMA contenenti un derivato di zosuquidar coniugato attraverso un linker 
di idrazone, di minimizzare l’efflusso di doxorubicina dalle cellule di carcinoma ovarico 
resistente. Nella seconda parte invece, sarà investigata l’attivita citotossica del polimero 
contenente la combinazione dei due farmaci collegati attraverso linkers ortogonali.  
Infine, il Capitolo 4 studia l’internalizzazione cellulare e il trafficking nel tratto 
endolisosomiale di un polimero di PHPMA. In un primo step, sarà descritta la sintesi di 
un PHPMA bifunzionale contenente sia una sonda fluorescente che una fluorurata. 
Successivamente, la sonda flurescente sarà usata per investigare l’internalizzazione 
cellulare del polimero e il trafficking endolisosomiale utilizzando citometria a flusso e 
microscopia di fluorescenza. Lo step finale consisterà nel dimostrare il potenziale di 
nanoscale secondary ion mass spectrometry (NanoSIMS) di mappare e localizzare 
polimeri fluorurati nei compartimenti endolisosomiali.  
 
 
 
Parole chiave: nanomedicine polimeriche, coniugati polimerici di PHPMA, PPFMA, 
modificazione post-polimerizzazione, resistenza multifarmaco, trafficking intracellulare, 
studi di colocalizzazione, NanoSIMS. 
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1. Controlling and Monitoring Intracellular Delivery of 
Anticancer Polymer Nanomedicines 
 
 
1.1. Introduction 
Conventional chemotherapeutic agents are small molecule drugs that once administered 
diffuse throughout the body without any particular selectivity toward the tumor. As a 
consequence, the use of such drugs is limited, in terms of dose and frequency, by the 
onset of severe side effects. In order to achieve a balance between proper dose, generating 
the desired response and tolerable adverse effects, strategies that allow to deliver 
chemotherapeutics with a higher selectivity toward the tumor are needed. Polymer 
nanomedicine has emerged as an attractive approach to enhance the efficacy of small 
molecule therapeutics for the treatment of cancer and beyond.1 Polymer conjugates and 
polymer nanocarriers can help to prevent rapid renal clearance and recognition from the 
reticuloendothelial system (RES) thereby increasing plasma half-life and drug 
bioavailability.1,2 Another asset of the use of polymers and polymer nanoparticles for the 
delivery of cancer chemotherapeutics is that it allows passive tumor targeting by the 
enhanced permeation and retention (EPR) effect.2,3 The EPR effect was discovered by 
Maeda et al. who recognized the rapid and disordered tumor neovascularization, together 
with the defective or absent lymphatic drainage of solid tumors, as an attractive way to 
selectively and passively deliver macromolecules to the cancer tissue.3  
The most common route for polymers, polymer nanoparticles, or nanomaterials in 
general, to be internalized by cells is via clathrin-mediated endocytosis.4,5 This pathway, 
which uses dynamic vesicles that transport the cargo from the plasma membrane to the 
cell inward, begins with the engulfment of the cargo in the cell membrane. This can occur 
as a consequence of specific ligand targeting, as in the case of receptor-mediated 
endocytosis, or via a nonspecific adsorptive mechanism. The thus formed intracellular 
vesicles, which are called early endosomes and characterized by slightly acidic pH, 
represent the main cargo sorting station. The internalized material can either be recycled 
Chapter 1: Controlling and Monitoring Intracellular Delivery of Anticancer Polymer 
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to the cell membrane or shuttled from early endosomes to the more acidic late endosomes 
before finally being sorted to the lysosomes, where enzymatic digestion occurs.6,7 To 
further enhance the selectivity toward the cancer cells and to maximize cellular 
internalization, polymer-based delivery systems have been decorated with targeting 
ligands that bind to receptors that are overexpressed by cancer cells.8 The folate receptor 
is frequently used as target since it is overexpressed in the plasma membrane of several 
types of cancers such as epithelial, ovarian, cervical, breast, lung, kidney, colorectal, and 
brain.9 The decoration of nanoparticles, micelles and linear polymers with folic acid (FA) 
has been shown to result in enhanced intracellular accumulation in folate positive cell 
lines as compared to the receptor-negative cells.9-11 The ?v?3 integrin is another receptor 
that is frequently targeted and exploited to enhance cellular internalization by decorating 
delivery systems with the arginine-glycine-aspartic acid (RGD) tripeptide ligand.12-14 A 
third example of a receptor that is exploited for tumor targeting is the epidermal growth 
factor receptor (EGFR), which is generally overexpressed and therefore used in the 
treatment of neck cancer, glioblastoma and lung adenocarcinoma.15 To this purpose, 
antibodies, aptamers and peptides were designed as targeting ligands.16,17 Targeting the 
human epidermal growth factor receptor-2 (HER2) via the monoclonal antibody 
Trastuzumab has been reported to facilitate breast cancer cellular internalization of block 
copolymer micelle-based nanoparticles as well as polyplexes.18,19 Upregulation of the 
transferrin receptor in pancreas, colon, lung and bladder cancers was also exploited using 
transferrin-nanoparticle and linear polymer conjugates,20-23 as well as transferrin-modified 
polyplexes.24 Another example of a ligand used for prostate and lung cancer targeting is 
anisamide, which binds to the overexpressed sigma receptor.25-27 
Efficient tumor targeting and cellular internalization are important to maximize the 
efficacy of anticancer drugs and reduce side effects. Another important factor that 
determines drug action is intracellular transport. This is due to the fact that many drugs 
act on targets that are located in well-defined subcellular compartments. The aim of this 
chapter is to give an overview of the different approaches that have been developed to 
control intracellular delivery of polymer nanomedicines and to present the methods that 
can be used to monitor these processes. While a range of other nanomaterials, including 
inorganic or metal nanoparticles or liposomes are also intensively used as carriers in 
nanomedicine, this chapter will exclusively focus on polymers and polymer nanoparticle-
based nanomedicines. The remainder of this chapter will first describe the advances that 
have been made in the field of polymer nanomedicine to enhance delivery to specific 
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subcellular targets. The second part of this chapter will present an overview of techniques 
that have been used to monitor intracellular trafficking of polymer nanomedicines.  
 
 
1.2. Controlling intracellular delivery 
This part of this chapter will provide an overview of the different strategies that have 
been developed to guide delivery of polymer nanomedicines to specific subcellular 
compartments. In what follows below, first, the various approaches that have been used to 
enhance access to the cytosol will be summarized. After that, strategies will be described, 
which have been elaborated to target specific organelles including the mitochondria, the 
nucleus as well as the Golgi apparatus (GA) and endoplasmic reticulum (ER). A 
schematic illustration of the different approaches reported to control intracellular delivery 
is shown in Figure 1. 
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1.2.1. Cytosolic Delivery 
Endocytosis represents a very attractive strategy to facilitate cellular internalization of 
polymer nanomedicines. The entrapment of polymers or polymer nanoparticles in 
intracellular endosomal compartments, however, also presents an additional barrier that 
needs to be overcome in order to deliver the drug to the appropriate target site in the cell. 
In addition to the fact that the membrane of these intracellular vesicles (endosomal and 
lysosomal) prevents translocation to the cytoplasm, lysosomal accumulation may also 
result in enzymatic degradation of therapeutic cargo. Table 1 provides an overview of the 
different approaches that have been explored to enhance cytosolic delivery. The different 
approaches can be organized in two main classes. One group of approaches are those that 
involve release of the drug in the endosomes or lysosomes by taking advantage of 
specific environmental parameters (pH, redox, enzyme) in these compartments. While 
other stimuli, such as UV-light can also be used, Table 1 only lists those strategies that 
explore endogenous stimuli that are characteristic of the intracellular (micro)environment. 
The second class of approaches focuses on disrupting the endosomal membrane using 
endosomolytic polymers, either alone or in combination with membrane-disrupting 
peptides. The entries in Table 1 are organized according to the mechanism that is 
exploited to trigger endolysosomal release or endosomal disruption. For each of these 
mechanisms, Table 1 lists a number of functionalities that have been incorporated in the 
polymer conjugates and polymer nanoparticles and which have been successfully used to 
mediate endolysosomal release or endosomal disruption. For several of the functionalities 
listed in Table 1, however, the number of examples that have been reported in the 
literature is too numerous to be included. Therefore, for each functionality, Table 1 cites 
several key review articles as well as selected examples, some of which are highlighted in 
the text below. 
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Table 1. Overview of the various strategies that have been explored to enhance cytosolic 
delivery of polymer nanomedicines. 
 Mechanism Intracellular location Functionality Examples 
 
pH Endosomes/Lysosomes Acetal  28,29,30,31,32,33 
Linear 
polymers 
34,35,36 
 Micelles 37 
 Polymersomes 38,39 
 Nanoparticles 40 
Ortho ester  28,30,31 
Micelles 41,42 
 Polymersomes 43 
Imine  28,30,31, 32 
Micelles 44,45,46,47 
Oxime  29,30,32 
Nanoparticles 48 
 Micelles 49,50 
Cis-aconityl  28,31,33 
Micelles 51 
 Nanoparticles 52 
Hydrazone  29,33,28,30,31,32 
Linear 
polymers 
53,54,55,56,57,58,59,60 
Nanoparticles 10,61 
Dendrimers 62,63 
Micelles 64,65,66,67,26,68 
Enzyme Lysosomes GFLG  69,33,29, 
Linear 
polymers 
70,71,72,73,74,75 
76,77,78,79 
Dendrimers 80,81,82,83 
Micelles 84,85 
Polymersomes 17 
Redox Endosomes/Lysosomes/ 
Cytoplasm 
Disulfide  33,86 
Linear polymer  87,88 
Micelle 89,90,91,92,93 
Polymersomes 94,95,96 
?,?-unsaturated 
carbonyl  
Micelles 97 
Selenium-based 
compounds 
 98,86 
Nanogels 99 
Micelles 100,101 
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Table 1. (Continued). 
 Mechanism Intracellular location Functionality Examples 
 
Endosomolytic 
polymers 
Endosomes/Lysosomes Positive charges  102 
Linear 
polymers 
103,104,105,106,107,108,109,24, 
110,111,112,113,114,115,116 
Branched 
polymers 
104,117,118,119,109,24,115,120 
Dendrimers 121,122,123, 124,125,109 
Charge-reversal  102 
Linear 
polymers 
22,126,127,11,128,129 
Micelles 130,131,132,133,134 
Dendrimers 135 
Volumetric 
expansion 
Nanoparticles 136 
Membrane-
disrupting 
peptides 
Endosomes/Lysosomes N-terminal HA2 
peptide derivative 
 137 
Linear 
polymers 
21 
INF-7 peptide Linear 
polymers 
138,139 
GALA PEGylated 
liposomes 
23 
Dendrimers 123 
KALA Micelles 140 
Nanoparticles 112 
HIV gp41 
derivative 
Branched 
polymers 
141 
Melittin Linear 
polymers 
142,143 
 
 
1.2.1.1. Endolysosomal Release  
This approach involves the use of polymer conjugates or polymer nanoparticles, which 
are stable in the blood stream but allow rapid drug release in the endolysosomal 
environment. The use of stimuli responsive carriers is particularly suitable for the 
delivery of small molecule drugs since after release from the carrier, these molecules can 
passively diffuse through the endolysosomal membrane and reach the cytoplasm. There is 
a number of physiochemical (pH, glutathione concentration) and biochemical (enzymes) 
parameters that differentiate the endolysosomal from the extracellular environment and 
which have been explored to trigger drug release.29,33 In what follows below, the use of 
pH, enzyme and redox responsive polymer conjugates and polymer nanoparticles to 
trigger endolysosomal release will be discussed.  
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pH-triggered release. Acid-labile chemical bonds that are stable in the bloodstream 
(pH 7.4) but upon endocytic internalization are cleaved in the slightly acidic late 
endosomal (pH 5-6) and lysosomal (pH 4-5) environments, have been used to promote 
endolysosomal release.28,30,31 Among the different pH sensitive linkers, which are 
available, such as acetal/ketal,28-40 ortho ester,28,30,31,41-43 imine,28,30-32,44-47 oxime29,30,32,48-50 
and cis-aconityl,28,31,33,51,52 the hydrazone linker28-33 is the most widely used.30 In order to 
illustrate the various possibilities in which the pH-responsiveness of these linkers can be 
used to enhance endolysosomal drug release, some examples of hydrazone-based polymer 
nanomedicines will be highlighted here. Hydrazone-linked polymer nanomedicines can 
be obtained by coupling ketone or aldehyde functional drugs to hydrazide modified 
polymers or polymer nanoparticles, or vice versa. Doxorubicin (Dox) is a particularly 
attractive candidate for the preparation of pH sensitive polymer nanomedicines as it 
contains a ketone group. Both linear poly(N-(2-hydroxypropyl)methacrylamide) 
(PHPMA) as well as poly(amidoamine) (PAMAM) dendrimers modified with hydrazide 
groups have been used to couple Dox via hydrazone linkers. 31,53-58,60,62,63 HPMA polymers 
bearing hydrazone linkages have also been explored for the delivery of other anticancer 
drugs such as paclitaxel and docetaxel.59 The hydrazone motif has also been used to 
prepare micelles and nanoparticles that allow pH-dependent release of doxorubicin as 
well as other anticancer drugs.32,66,67 For instance, Dox has been coupled to poly(ethylene 
glycol) (PEG)-folic acid (FA) conjugates to generate hydrophobically modified PEG 
derivatives that self-assembled into nanoparticles, which showed an enhanced Dox 
release at pH 5 as compared to pH 7.4.10 Instead of using the hydrazone bond to couple 
the drug to a polymer carrier, this pH sensitive motif can also be used to connect the 
hydrophobic and hydrophilic segments of amphiphiles that are designed to self-assemble 
into polymer micelles or nanoparticles. Cleaving the hydrazone bond in the 
endolysosomal compartments lead to dissociation of these nanoparticles and concomitant 
release of the entrapped drug.26,32,33,64,65 Another interesting example are sub 200-nm 
polymeric nanoparticles that are designed to simultaneously deliver doxorubicin and 
docetaxel. These particles were obtained via self-assembly of the aliphatic copolymer 
poly(butylene succinate-co-butylene dilinoleate) (PBS-co-PBDL) and a hydrophobically 
modified HPMA copolymer. The hydrophobic drug docetaxel (DTX) was physically 
entrapped within the (PBS-co-PBDL) core and the hydrophilic doxorubicin hydrochloride 
(Dox·HCl) was chemically conjugated to the HPMA copolymer shell via a hydrazone 
bond. This strategy enabled the combination chemotherapy by the simultaneous Dox and 
DTX delivery.61 
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Enzyme-triggered release. Cathepsin B is a cysteine protease, which is upregulated in 
tumors and located in the lysosomes.69 This provides opportunities for the design of 
polymer nanomedicines that release their payload in the lysosomes.29,33,69 Kopecek and 
co-workers first reported the design of Dox-modified HPMA copolymers in which the 
pendant doxorubicin groups were linked to the polymer backbone via the GFLG peptide 
spacer, which is a substrate for cathepsin B.70,71,74 The authors showed that release of Dox 
in the lysosomes, in relatively close proximity to the nucleus allowed to reduce P-gp-
mediated drug efflux.77 The same concept was applied to prepare HPMA copolymers that 
were modified with other anticancer drugs such as cisplatin73 as well as paclitaxel and 
gemcitabine.75 In addition to a number of other linear PHPMA conjugates,76,78,79 the 
GFLG peptide linker has also been used to develop micellar-84,85 and dendrimer-based 
carriers that are able to release their payload in the lysosomes.80-83 The GFLG peptide 
linker has not only been used to trigger cathepsin B-mediated drug release from various 
polymer-based systems, but has also been exploited to prepare polymersomes that 
disintegrate upon exposure to this enzyme. This was accomplished by Lee et al. who used 
this peptide to connect PEG and poly(D,L-lactide) to form diblock copolymers, which 
could self-assemble to form polymersomes with an average size 124 nm. Complete 
release of the encapsulated model fluorescent dye was observed after incubation with 
cathepsin B for three days. The result was confirmed with in vitro cell studies using 
fluorescence microscopy.17  
 
 
Redox-triggered release. Redox-responsive delivery systems have been extensively 
explored for the endolysosomal release of anticancer drugs. This approach takes 
advantage from the highly reducing environment of cell cytoplasm, nucleus and 
endolysosomal pathway as compared to the extracellular matrix and circulation 
system.33,86 Disulfide bonds are most frequently used for the development of redox 
responsive delivery systems as they are readily cleaved intracellularly. Cuchelkar et al., 
for example, prepared linear HPMA polymer conjugates in which the drug was 
conjugated to the polymer backbone via disulfide linker.87,88 Similarly, Cao et al. 
designed poly(ethylene glycol)-b-poly(lactic acid) copolymer (PEG-b-PLA) micelles in 
which the drug curcumin was conjugated to the polymer chains via a disulfide bond. The 
redox-sensitive micelles could enhance curcumin delivery while avoiding premature 
release as compared to control micelles containing an ester linker.89 Poly(ethylene glycol) 
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methyl ether methacrylate-b-poly(2-hydroxyethyl methacrylate), in which the poly(2-
hydroxyethyl methacrylate) segment was modified with 3-(pyridin-2-
yldisulfanyl)propanoic acid (PDP) (PEGMEA-b-PDPHEMA), allowed the linkage of 
paclitaxel via esterification reaction and subsequent self-assembly of the amphiphilic 
copolymer into micelles.91 While the disulfide bond has been mostly used, another 
interesting motif that can be used to prepare redox-responsive polymer nanomedicines is 
the ?,?-unsaturated carbonyl group. In a recent example, Shi et al. used this motif to 
couple a 6-mercaptopurine (6-MP) prodrug to poly(ethylene glycol) monomethyl ether. In 
water, these drug conjugates self-assemble to form micelles. Drug release from these 
micelles occurs upon the influence of glutathione and proceeds via a Michael addition-
elimination pathway.97 In addition to using the reducing intracellular environment to 
trigger drug release, the elevated intracellular glutathione concentration can also be 
exploited to induce disassembly of polymer-based carriers.33,86 As an example, Liu et al. 
described self-assembled micelles based on a disulfide linked poly(methacrylic acid)-b-
poly(?-caprolactone) copolymer (PMAA-b-PCL-SS-PCL-b-PMAA), which were used for 
paclitaxel delivery.92 Hubbell et al. prepared reduction-sensitive polymersomes, which 
were based on PEG-SS-poly(propylene sulfide) (PEG-SS-PPS) diblock copolymers and 
quickly disrupted inside cells leading to fast release of the cargo.95 Poly(ethylene glycol)-
b-poly(L-lysine)-b-poly(?-caprolactone) triblock copolymers bearing a disulfide bond 
(PEG-b-PLL-SS-PCL) have also been used for the formation of redox responsive 
polymersomes. These polymersomes were stable in physiological solution (pH 7.4), 
whereas they readily disintegrated under a reductive environment similar to the 
intracellular one. Both the hydrophobic camptothecin (CPT) and the hydrophilic 
doxorubicin hydrochloride (Dox·HCl) could be loaded in the polymersome membrane 
and in the aqueous core, respectively.96 Selenium-based compounds have been also used 
recently to promote carrier disassembly as a response to glutathione as well as reactive 
oxygen species (ROS) such as hydrogen peroxide.86,98 For instance, Yan and co-workers 
designed an amphiphilic hyperbranched polymer alternating hydrophobic selenide groups 
and hydrophilic phosphate segments in the dendritic backbone. These polymers self-
assembled in water to form core-shell micelles, which could incorporate the anticancer 
drug doxorubicin. Upon exposure to the intracellular oxidative microenvironment of 
cancer cells, the selenide groups were converted into hydrophilic selenone moieties. The 
transition from amphiphilic hyperbranched precursor to hydrophobic one caused rapid 
micelles disassembly and drug release. The cytotoxicity of this system was ascribed to 
both the release of Dox and the release of selenium derivatives which can induce 
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apoptosis.101 In addition to serving as reduction sensitive linkers, that can facilitate 
intracellular drug release or the cleavage of amphiphilic block copolymers that act as the 
constituents of micellar nanoparticles or polymersomes, redox responsive bonds have also 
been explored as reversible crosslinkers.33,93 Zou et al., for instance, prepared 
polymersomes from poly(ethylene glycol)-b-poly(trimethylene carbonate-co-dithiolane 
trimethylene carbonate) (PEG-b-P(TMC-DTC)) block copolymers. The addition of a 
catalytic amount of DTT promoted the formation of stable particle cores due to disulfide 
crosslinking. Upon cellular internalization, disulfide bond cleavage allowed disassembly 
of the polymersomes and drug release.94 Based on the same principle, biodegradable 
poly(ethylene glycol)-b-poly(dithiolane trimethylene carbonate) (PEG-b-PDTC) block 
copolymer micelles were also prepared. Interestingly, doxorubicin (DOX)-loaded 
micelles showed high stability, minimal drug leakage, long circulation time and triggered 
drug release inside the tumor cells. 90 In addition to disulfide bond, the diselenide linker 
has also been used to prepare reversible crosslinked polymer nanoparticles. Deepagan et 
al., for instance, prepared diselenide-crosslinked micelles by using selenol-bearing 
triblock copolymers consisting of PEG and polypeptide derivatives. Upon Dox 
incorporation in the hydrophobic core, diselenide crosslinks were formed in the micelle 
shell. Exposure of these micelles to reactive oxygen species (ROS) resulted in cleavage of 
the hydrophobic diselenide bond into hydrophilic selenic acid derivatives and consequent 
Dox release. These diselenide cross-linked micelles were found to deliver up to 3.73-fold 
higher amount of Dox in mice tumor as compared to non-crosslinked micelles.100 The 
diselenide group was also used for the redox responsive PEGylated poly(diselenide-
phosphate) nanogels. While the polyphosphate block cross-linked by hydrophobic 
diselenide bonds formed the inner core, the PEG chains constituted the outer shell. 
Interestingly, these nanogels were found to be intrinsically cytotoxic toward cancer cells. 
This effect was attributed to the presence of overexpressed reactive peroxides and 
gluthatione in cancer cells.99 
 
1.2.1.2. Endosomal disruption.  
Endosomal disruption and cytoplasmic release are fundamental prerequisites for the 
delivery of peptide-based drugs as well as plasmid DNA and oligonucleotides,102,137 
Inefficient cytoplasmic release of these biological drugs can result in accumulation in the 
highly degradative lysosomal environment and have a negative impact on the therapeutic 
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efficacy.102 As a consequence, considerable efforts have been made to develop strategies 
that facilitate endosomal escape of polymer nanomedicines. These efforts can be broadly 
categorized in two groups (Table 1). One approach involves the use of polymers that 
possess intrinsic endosomolytic properties. A second strategy is based on the 
functionalization of the polymer or polymer nanoparticles with membrane-disrupting 
peptides. In what follows below, a number of examples of both of these two strategies 
will be described.  
 
 
Endosomolytic polymers. Endosomolytic polymers are generally cationic polymers 
that are able to interact and destabilize endolysosomal membranes.102 Poly(L-Lysine) 
(PLL) and poly(ethylenimine) (PEI) are the first examples of amino-functionalized 
polymers carriers used to enhance endosomal escape of plasmid DNA and 
oligonucleotides.102-106 Other amine functionalized polymers that have been widely used 
to provide cytosolic release of oligonucleotides and pDNA were PAMAM and 
poly(propyleneimine) (PPI) dendrimers.102,121-125 PEI has been proposed to act via the 
proton sponge effect.102,137 According to this hypothesis, PEI, and more in general 
polymers that contain a large number of secondary and tertiary amine groups with pKa 
values between physiological and lysosomal pH, can be protonated in the endosomal 
environment. Hence, upon endocytic internalization, the increased polymer positive 
charges give rise to buffering of the endosomal pH inducing ion and water influx into the 
endosomal vesicles with consequent osmotic swelling. This, together with carrier 
swelling due to electrostatic repulsions, leads to vesicle rupture and release of the cargo 
into the cytoplasm.102,137 The in vivo implementation of PLL and PEI-based delivery 
systems, however, has been hampered by two limitations. First, PLL failed to provide 
satisfactory endosomal escape due to the lack of buffering capacity.102 Second, in vitro 
and in vivo studies revealed significant toxicities of both PLL and PEI.109,115,120,144 
PAMAM and PPI dendrimers have also been shown in vitro and in vivo to be cytotoxic 
and hemolytic.121 A number of approaches has been proposed to reduce the cytotoxicity 
of PLL and PEI and enhance transfection efficiency. First, to shield the positive charges 
and to reduce toxicity, the grafting of PEG chains on PEI and PLL,24,107,111,112 as well as 
the modification of PLL with PHPMA was explored.114 Another strategy involves the 
preparation of PEI polymers that are reductively degradable inside cells minimizing the 
risk of interactions with cellular components. This was achieved using disulfide cross-
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linked low molecular-weight linear PEI carriers. The use of this polymer led to a cell 
viability of 90% after the transfection process.108 The linkage of PEI and PEG chains via 
disulfide bond was also proposed as a strategy to further reduce cytotoxicity and increase 
transfection efficiency.110 The same principle was used to prepared PLL-b-HPMA block 
copolymers containing redox-responsive disulfide bond.113,116 Derivatization of the PEI 
amine groups was also investigated. In particular, it was found that N-acylation of PEI 
with alanine nearly doubled its transfection efficiency and also lowered its toxicity.117 A 
similar result was obtained upon partial acetylation of PEI amine functionalities with 
acetic anhydride.118,119 The limited buffering capacity of PLL and the cytotoxicity of PLL 
and PEI have stimulated the development of alternative polymers that are neutral at 
physiological pH, but become charged once internalized via the endolysosomal pathway. 
Poly(L-histidine) or in general, imidazole-rich polymers, micelles and nanoparticles have 
found interest since the pKA of the imidazole group (6.15) allows a rapid transition from 
an uncharged state in the extracellular milieu to a positively charged state upon endocytic 
internalization.22,102,126,127,130,132,133 Another strategy that has been pursued is to mask 
positively charged groups with another functionality that is cleaved under acidic 
conditions and restore the positive charges. In one example, the primary amine groups of 
PLL were amidized with 1,2-dicarboxylic-cyclohexene anhydride. The negatively 
charged polymer showed low toxicity as well as low interaction with the cell membrane. 
Upon endocytic internalization and lysosomal accumulation, the acidic pH caused 
cleavage of acid β-carboxylic acid-amide bond and restoration of the positively charged 
lysine amine groups.11 Kataoka and co-workers developed a series of charge-reversal 
delivery systems that were used to deliver pDNA and small interfering RNA (siRNA). In 
one example, polyplexes assembled from poly(aspartamide) derivatives bearing 1,2-
diaminoethane side chains and pDNA were designed. While at physiological pH the 
flanking diamino groups on the polymer chains were found in a monoprotonated gauche 
form and showed minimal membrane interaction, upon endocytic internalization, the drop 
in pH caused a transition to a diprotonated anti form. Interaction of the amine groups with 
endosomal membrane led to cytoplasmic cargo release.129 In a following work, the same 
authors, designed a diblock copolymer composed of poly(ethylene glycol) and a 
polyaspartamide derivative containing a pH cleavable 2-propionic-3-methylmaleic 
(PMM) amide as an anionic protective group in the side chains. The PMM-based polymer 
was incorporated into calcium phosphate nanoparticles together with small interfearing 
RNA (siRNA) for the formation of sub-100 nm size PEGylated hybrid micelles. The 
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lower endosomal pH allowed cleavage of the PMM side chain groups with consequent 
exposure of the membrane destabilizing polyaspartamide and cytosolic delivery.134 
Stayton et al. explored another strategy to develop polymers that are hydrophilic and have 
a net neutral charge under physiological conditions, but rapidly protonate and switch into 
an endosomolytic state upon endocytic internalization. A series of well-defined block 
copolymers containing 2-(dimethylamino)ethyl methacrylate (DMAEMA) as a siRNA-
condensing block and an endosomolytic block incorporating DMAEMA, propyl acrylic 
acid (PAA) and butyl methacrylate (BMA) (DMAEMA-b-DMAEMA-co-PAA-co-BMA) 
was prepared. At physiological conditions the endosomolytic block is a hydrophilic 
polyampholyte containing both positive and negative charges. However, upon 
internalization, the drop in pH causes protonation of the acrylic acid residues resulting in 
the formation of a hydrophobic polycationic polymer able to interact and disrupt the 
endosomal membranes.128 As for other cationic polymers, in order to avoid unspecific 
interaction and minimize the cytotoxicity of positively charged PAMAM, charge-reversal 
poly(amidoamine) dendrimers, that are uncharged in the extracellular milieu, but shifts to 
a positively charged state upon endocytic internalization, were also proposed.135 
 
 
Membrane-disrupting peptides. In addition to the use of polymer or polymeric 
nanoparticles that possess intrinsic endosomolytic properties, a second strategy that has 
been used to facilitate cytosolic delivery is to functionalize the polymer or particle of 
interest, which may or may not possess endosomolytic properties by itself, with a 
membrane-disrupting peptide. This class of peptides mimics the natural endosomal 
escape properties of viruses and are usually peptide sequences that are based upon or 
derived from the respective viral membrane subunits.137 Among the variety of peptides 
that has been proposed as membrane destabilizing agents, this section will only focus on 
those sequences that have been used in combination with polymers to enhance or impart 
endosomolytic properties.  
In order to enhance PLL-mediated gene delivery, Wagner and co-workers conjugated 
PLL-modified transferrin to a peptide sequence derived from the N-terminus of the 
influenza HA2 subunit.21 While the transferrin ligand was used as receptor-binding 
module to promote receptor-mediated endocytosis, the PLL acted as pDNA binding site 
and as endosomolytic polymer. The conjugation with the influenza-derived peptide 
maximized endosomal destabilization in a pH-dependent manner. The construct resulted 
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in a substantial increase of the transferrin-mediated gene transfer. Similarly, Funhoff et 
al. conjugated an influenza-derived fusogenic peptide (INF-7) to copolymers of (2-
methyl-acrylic acid 2-((2-(dimethylamino)-ethyl)-methyl-amino)-ethyl ester) (DAMA), 
2-dimethylamino-ethyl ester 1-methyl-2-(2-methacryloylamino)-ethyl ester (HPMA-
DMAE) or DMAEMA with the amino side chain functional monomer N-(3-aminopropyl) 
methacrylamide hydrochloride (NAPMAm) using N-succinimidyl 3-(2-
pyridyldithio)propionate (SPDP) as coupling agent.138 The peptide-decorated polyplexes 
enhanced transfection activity while maintaining a similar toxicity. The INF-7 peptide 
was also used for the decoration of poly(3-guanidinopropyl methacrylate)-based 
polyplexes and resulted in two fold increase in transfection efficiency.139 Szoka et al. 
designed a 30 amino acid synthetic peptide (GALA), which contains the EALA repeat 
unit and can interact with lipid bilayers in a pH-dependent manner. The membrane 
activity of this peptide is due to the fact that it can undergo a transition from a random 
coil at pH 7.4 to an amphipathic α-helix at pH 5.145 The capability of this peptide to 
mimic pH-dependent virus-membrane interactions has been exploited to facilitate 
cytoplasmic delivery in several reports. Sasaki et al., for example, loaded pDNA inside 
PEGylated transferrin-liposomes to form core shell nanoparticles. Cholesterol-GALA, 
which inserted in the liposome membrane, and PEGylated GALA, constituting the outer 
shell, were used to induce interaction and fusion between liposomes and endosome 
membranes.23 Due to its negative charge, GALA is not able to bind electrostatically 
plasmid DNA or oligonucleotides. However, by replacing several of the negatively 
charged glutamic acid residues by positively charged lysine amino acids, Szoka et al. 
prepared a peptide that is referred to KALA and which combines membrane-disrupting 
activity with the ability to form polyplexes with DNA and oligonucleotides.145 In one 
example, KALA was used to coat the surface of PEG-g-PLL-DNA polyplexes via ionic 
interactions. The decoration of the polyplexes with KALA peptide allowed higher 
transfection efficiency.112 In a following work, KALA was used to form polyelectrolyte 
complex micelles with PEG-oligonucleotide conjugate. The anionic oligonucleotide, 
interacting with KALA, constituted the inner shell, while the outer corona was formed by 
the PEG chains. The micelles enhanced oligonucleotide uptake as well as transfection 
efficiency.140 Another peptide that has been used to enhance cytoplasmic release is 
derived from the HIV gp41 envelope glycoprotein.137 In particular, linkage of this peptide 
to PEI-based polyplexes allowed higher transfection efficiency as compared to 
unmodified polyplexes. This result was attributed to the enhanced endosomal membrane 
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destabilization, which was confirmed via confocal microscopy imaging.141 A final 
example of a peptide that has been conjugated to polymer carriers to improve endosomal 
release is Melittin (MLT). MLT does not derives from viruses, but is the main active 
component of the bee venom and has a pH independent membrane lytic activity via 
membrane pore-formation.137 The ability of this peptide to interact and disrupt 
membranes at physiological pH limits its application. In an attempt to decrease the 
cytotoxicity and confine the membrane-disrupting properties at the endosomal level, the 
conjugation to polymeric carriers was explored. To this purpose, MLT was linked to a 
HPMA-b-PLL copolymer. The system efficiently condensed DNA into 100-200 nm 
particles and resulted in higher transfection efficiency compared to control polymers 
lacking MLT.142 MLT was also used to potentiate the endosomolytic efficiency of 2 
different poly(amidoamine)s. The authors hypothesized that the use of a carrier system 
could partially shield the peptide and therefore reduce its haemolytic activity. However, 
although MLT conjugation was beneficial for endosomal disruption, at least for one of 
the conjugates, its haemolytic activity at pH 7.4 was still considered unacceptable.143  
 
 
1.2.2. Organelle specific delivery 
A large number of active compounds act on intracellular targets that are located in 
specific organelles. To direct the transport of polymer-based nanomedicines towards 
specific organelles, a number of approaches have been developed. One possibility is to 
decorate the polymer-based carrier with specific functional groups that promote targeting 
of the organelle of interest. An alternative strategy, which is used to target the Golgi 
apparatus (GA) and endoplasmic reticulum (ER), is to promote internalization via 
clathrin-independent endocytosis. Table 2 provides a summary of the various approaches 
that have been used to guide delivery of polymer-based nanomedicines to four major 
organelles, viz. the mitochondria, the nucleus and Golgi apparatus and endoplasmic 
reticulum. For several organelles, in particular the mitochondria and the nucleus, the 
number of examples that have been reported is too numerous to allow each of these to be 
cited. Table 2 instead lists several key review articles, as well as some selected examples, 
some of which will be highlighted in the remainder of this section. 
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Table 2. Overview of the strategies that have been used for organelle specific delivery of 
polymer nanomedicines.  
Organelle Targeting mechanism 
Targeting 
Signal Functionality Examples 
Mitochondria     146,147, 
148,149 
Mitochondrial 
protein import 
machinery 
Mitochondri
al targeting 
signals 
(MTSs) 
MALLRGVFIVAAKRTPF Linear 
polymers 
150 
MLSNL RILLN KAALR- 
KAHTSMVRNF RYGKP VQC 
Branched 
polymers 
151 
Transmembrane 
potential  
Delocalized 
lipophilic 
cations 
(DLCs) 
Triphenylphosphonium (TPP)  152 
Dendrimers 153,154 
Linear 
polymers 
87 
Nanoparticles 155,156 
157,158 
Polymersomes 159 
Rhodamine 123 PEGylated 
liposomes 
160  
Positive 
charges 
Histamine Micelles 130 
N-quarternary ammonium Nanoparticles 161 
Dequalinium Vesicles 162,163 
Micelles 26 
Nucleus 
 
    164 
Temporary 
disassembly of 
the nuclear 
envelope during 
mitosis 
-   165,166, 
167 
- Nanoparticles 168 
 - Linear 
polymers 
169 
 - Branched 
polymers 
170 
Nuclear pore 
complex (NPC) 
-   164 
- Linear  
polymers 
171  
NPC dilation Dexamethasone 
(Glucocorticoid receptor) 
Linear 
polymer 
172 
α,β-Importins Nuclear 
localization 
signals 
(NLSs) 
  165,166, 
167,173  
CGYGPKKKRKVGG Micelles 18  
DRQIKIWFQNRRMKWKK Nanoparticles 174 
PKKRKV Nanoparticles  175 
CVKRKKKP Linear 
polymers 
79,60 
Cytoplasmic NFkB Linear 
polymers 
176,177 
Caveolae-
mediated 
endocytosis 
Histone H3 
tail peptide 
ARTKQTARKSTGGKAPRKQL
ATKAA 
Branched 
polymers 
178,179, 
180 
Golgi 
apparatus and 
endoplasmic 
reticulum 
Caveolae-
mediated 
endocytosis 
Cholera 
Toxin  
B subunit Nanoparticles 181 
Others 
 
Pluronic Linear 
polymers 
182,183 
184 
Wheat germ agglutinin Nanoparticles 185 
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1.2.2.1. Mitochondrial delivery 
Several chemotherapeutic agents act on mitochondria by targeting the transition of cell 
metabolism, the cellular damage caused by abnormal reactive oxygen species (ROS) 
production, the disabled apoptosis pathway or mutated mitochondrial DNA (mtDNA).146 
Polymers and polymer-based particles can be used to promote the accumulation of these 
drugs in the mitochondria. To guide the transport of polymer nanomedicines and delivery 
of active compounds to this organelle, various strategies have been developed.146  
One approach that has been used to guide the delivery to the mitochondria involve the 
use of mitochondrial targeting peptides (MTS)s. MTSs are peptide sequences that allow 
the translocation of proteins, which are synthesized in the cytoplasm, to the mitochondria 
via the mitochondrial protein import machinery.146,186 MTSs have been used for the 
targeting of DNA to the mitochondria.146,147 A drawback of the use of MTSs for the 
delivery of polymer nanomedicines to the mitochondria is the limited size of the cargo 
that can be transported using this pathway. Generally, this strategy cannot be used to 
mediate mitochondrial uptake of unfolded proteins or macromolecules such as plasmid 
DNA.146,147 However, it was shown that the localization of the polymer carrier to the 
mitochondrial membrane using MTSs as a targeting (rather than translocation) signal and 
the consequent release of pDNA in close proximity of the targeted organelle, can enhance 
mitochondrial delivery.148,150 In one example, Lee et al. modified a PEI carrier with MTS 
and investigated the mitochondrial co-localization and in vitro toxicity of the targeted 
PEI/DNA complex. In vitro experiments using a rhodamine-DNA conjugate revealed that 
the use of the targeting peptide allowed higher mitochondrial localization as well as lower 
toxicity compared to naked DNA or untargeted PEI/DNA complex.150 Flierl et al. used 
another approach to overcome the size limitations. In this work, a MTS peptide-peptide 
nucleic acid (PNA) conjugate was annealed to an oligonucleotide with a complementary 
PNA sequence and the complex was transferred into the cytosol using a PEI carrier. 
While the carrier allowed endosomal escape, the MTS targeting peptide directed the 
oligonucleotide to the mitochondria.151 
A second strategy that has been used to guide delivery of polymer nanomedicines to the 
mitochondria explores the high transmembrane potential of these organelles (-180 to -200 
mV). This negative potential allows the selective accumulation of delocalized lipophilic 
cations (DLCs),146,152 such as triphenylphosphonium (TPP).149,152 Conjugation of TPP to 
PAMAM dendrimers allowed endosomal escape and efficient mitochondrial 
targeting.153,154 In a similar manner, a construct containing TPP and the photosensitizer 
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mesochlorine ce6 (Mce6) was connected to the side chains of a PHPMA conjugate via a 
disulfide linker.87 The disulfide bond was selected to promote rapid intracellular release 
and subsequent mitochondrial targeting of the TPP-Mce6 drug conjugate. The 
substitution of Mce6 with a fluorescent dye allowed to monitor the localization of the 
targeting construct in the mitochondria with confocal microscopy. Moreover, cytotoxicity 
studies revealed the higher efficacy of the targeted compound as compared to non-
targeted PHPMA-Mce6 conjugate. TPP has also been used for the targeting of 
nanoparticle-based delivery systems. For example, nanoparticles prepared by blending a 
poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol)-triphenylphosphonium block 
copolymer (PLGA-b-PEG-TPP) with non-targeted poly(D,L-lactic-co-glycolic acid)-b-
poly(ethylene glycol) (PLGA-b-PEG-OH) or poly(D,L-lactic-co-glycolic acid) (PLGA-
COOH) were found to exhibit compete endosomal escape and were found to localize in 
the mitochondria of Hela cells.155 This behavior was attributed to the cationic charge that 
facilitated endosomal escape through buffering effect and provided mitochondria 
localization. The use of the TPP functional nanoparticles for the delivery of Lonidamine 
and α-tocopheryl succinate resulted in a significant improvement of the therapeutic index 
as compared to administration of these drugs with the non-targeted TPP-modified 
nanoparticles or the free drug.155 More recently, α-tocopheryl succinate was delivered in 
combination with obatoclax (a Bcl-2 inhibitor) using TPP-coated positively charged 
nanoparticles. The nanoparticles entered into acidic lysosomes via macropinocytosis, 
followed by lysosomal escape and accumulated into mitochondria over a period of 24 
h.156 In another example, conjugation of (4-carboxybutyl)triphenylphosphonium (4-
carboxybutyl TPP) to poly(ε-caprolactone) (PCL) diol resulted in the formation of 
amphiphilic TPP-b-PCL-b-TPP (TPCL) polymers, which self-assembled into less than 50 
nm cationic nanoparticles. These nanoparticles were used for the simultaneous delivery of 
both the hydrophilic Dox·HCl and the hydrophobic Dox to the mitochondria.157 Along the 
same lines, poly(lactic acid)-b-poly(ethylene glycol) (PLA-PEG) polymersomes 
decorated with a fluorescent TPP derivative were used to mediate mitochondrial delivery 
of Dox.159 This resulted in a significantly reduced viability of cultured pancreatic cancer 
cell spheroids. Grancharov et al. prepared TPP functionalized micellar nanocarriers by 
co-assembly of poly(ethylene oxide)-b-poly(?-caprolactone)-b-poly(ethylene oxide) 
(PEO-b-PCL-b-PEO) and a poly(2-(dimethylamino)ethylmethacrylate)-b-poly(?-
caprolactone)-b-poly(2-( dimethylamino)ethylmethacrylate) (PDMAEMA-b-PCL-b-
PDMAEMA) triblock copolymer, which was partially functionalized with TPP.158 These 
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nanoparticles were used to direct the delivery of the anticancer drug curcumin to the 
mitochondria. Apart from TPP, another DLC that has been used for mitochondrial 
targeting of polymer nanomedicines is rhodamine 123 (Rho).149 Biswas et al. coupled 
Rho to amphiphilic PEG-phosphatidylethanolamine conjugates, which were subsequently 
used to prepare PEGylated liposomes.160 Enhanced mitochondrial targeting was observed 
as well as enhanced cytotoxicity upon paclitaxel incorporation as compared to untargeted 
liposomes.  
In addition to the use of mitochondrial targeting sequences or delocalized lipophilic 
cations to guide trafficking of polymer nanomedicines to the mitochondria, there are also 
several reports that describe the use of positively charged nanocarriers to enhance drug 
accumulation in the mitochondria. Zhang et al., for instance, prepared histamine 
functionalized poly(allyl glycidyl ether)-b-poly(ethylene glycol) (PAGE-b-PEG) 
micelles. It was found that the histamine functionality facilitated endosomal escape and 
enhanced doxorubicin targeting to the mitochondria as compared to free Dox.130 Chen et 
al. have prepared nanoparticles that were composed of a quaternary ammonium-
functionalized chitosan (NQC) derivative and a chitosan derivative modified with N-
glycyrrhetinic acid (GA) moieties via schiff base PEG spacer. These nanoparticles were 
used for the delivery of brucine.161 After endocytosis, the drop in pH caused Schiff base 
cleavage, which resulted in an increased positive surface charge of the particles and 
facilitated endosome disruption and cytosolic cargo release. Meanwhile, the positive 
charge on the particle surface allowed mitochondrial targeting. Brucine accumulation in 
the mitochondria of hepatocellular carcinoma HepG2 cells increased toxicity both in vitro 
and in vivo as compared to the use of the free drug. Dequalinium (DQA) is a dicationic 
amphiphilic compound generally used as antimicrobial agent but which has also found 
application in mitochondrial targeting.146,147 This compound can self-assemble to form 
vesicles called DQAsomes that have the ability to condense DNA. Those vesicles could 
escape the endosomes, localize at the mitochondrial membrane and release the pDNA in 
close proximity of the targeted organelle.163 DQA was also conjugated to PEG chains for 
the decoration of liposomes. This allowed endosomal escape and subsequent 
mitochondrial targeting.162 Targeted liposomes enhanced the cytotoxicity of the potential 
anticancer drug resveratrol compared to non-targeted carriers. A similar approach was 
used by Zhou and co-workers for the delivery of Dox and Dox-DQA conjugates to the 
mitochondria and nucleus simultaneously. Dox and Dox-DQA were delivered using 
micelles that were generated by self-assembly of a hydrazone-linked PEG-1,2-distearoyl-
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sn-glycero-3-phosphorylethanolamine (DSPE) conjugate that was modified with 
anisamide (AA), which is a tumor cell targeting ligand. When the loaded micelles were 
internalized by tumor cells, hydrazone bond cleavage allowed Dox and Dox-DQA 
release, which mainly accumulated in the nucleus and mitochondria, respectively. 26 
 
 
1.2.2.2. Nuclear delivery 
A large number of anticancer therapeutics act by interfering with DNA replication. 
Doxorubicin and other anthracyclines act by inhibiting the enzyme topoisomerase II and 
through DNA intercalation. Antimetabolites like 5-Fluorouracil and mercaptopurine are 
based on nucleoside analogs that once incorporated in the DNA prevent chain elongation, 
whereas DNA alkylating agents such as platinum (e.g. cisplatin) and nitrogen mustards 
(e.g. cyclophosphamide, ifosfamide) give rise to DNA crosslinking.187,188 Cancer gene 
therapy focuses on introducing foreign genes into cancer cells or the surrounding 
tissue.189 As a consequence, the nucleus is a main target in anticancer therapy. While 
escape from endocytic vesicles can be promoted by using, for example, endosomolytic 
polymers, access to the nucleus is further limited by the presence of a double-layer 
membrane separating and protecting the genetic material via a series of tightly regulated 
pores called the nuclear pore complex (NPC).190 There are a number of approaches that 
have been explored to enhance nuclear uptake of polymer nanomedicines. These are 
summarized in Table 2 and discussed in more detail below.  
A first pathway for polymer nanomedicines to enter the nucleus takes advantage of the 
fact that the nuclear membrane disassembles during mitosis.164-166,168 This path represents 
the primary enabler for the entry of pDNA or polyplexes into the nuclear 
compartment.165,168 A drawback of this approach, however, is that it is strictly dependent 
on the cell cycle and cannot be used in the case of non-dividing cells.165,168 An interesting 
example of the use of the mitotic cycle for nuclear delivery of polymer nanomedicines 
was described by Li et al. To enhance the nuclear translocation of the c-Myc inhibitor 
H1-S6A,F8A (H1) peptide during cell division, the authors used a combination of two 
different polymer conjugates. First, cells were treated with a PHPMA-docetaxel (DTX) 
conjugate (P-DTX), which arrested cells in the G2/M phase and prolonged the period 
when the nuclear membrane was disassembled. In a second step, the cells were treated 
with the PHPMA-H1 conjugate (P-H1), which entered the nucleus and efficiently 
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inhibited c-Myc. In vitro studies demonstrated that the administration of P-DTX followed 
by the P-H1 conjugates was significantly more effective than reverse sequential delivery 
as well as the simultaneous co-delivery or monotherapy with P-DTX or P-H1 alone.169 
Another approach reported by Shen et al. involved the use of the CDK1 inhibitor RO-
3306 to control the G2/M transition of the cell cycle and increase the proportion of 
mitotic cells during transfection. It was found that combination of RO-3306 and 
PEI/DNA complex remarkably increased the transfection efficiency.170 Moreover, the 
transfection efficiency of the PEI carrier was compared to that of the (ROS)-labile 
charge-reversal poly((2-acryloyl)ethyl(p-boronic acid benzyl)diethylammonium bromide) 
(B-PDEAEA), which was recently reported by the same authors.171 B-PDEAEA is a 
positively charged linear polymer that packages DNA into nanoparticles, but turns into a 
negatively charged polymer releasing the DNA in response to intracellular reactive 
oxygen species (ROS).171 It was demonstrated that the DNA was localized in the cell 
nucleus quickly after B-PDEAEA mediated transfection and RO-3306 co-administration 
only slightly increased the transfection efficiency.170 Based on these results, the authors 
concluded that, while most of the PEI/DNA complexes enter the nucleus in the intact 
form during mitosis, cytoplasmic DNA released from the negatively charged B-PDEAEA 
may enter the nucleus passing through the NPC.  
Passive trafficking through the nuclear pore complex (NPC) represents a second access 
path to the nucleus. However, due to the tiny size of the pores, the access through this 
way is limited to the diffusion of ions, small metabolites and molecules with molecular 
weight less than 40-60 KDa.164,165,190 As a consequence, pDNA alone, or in combination 
with cationic carrier-based polymers (polyplexes) is believed to rarely undertake this 
pathway, therefore resulting in a poor transfection efficiency.167,173,190 One approach that 
has been used to enhance nuclear permeation via NPCs involves the use of 
dexamethasone (Dex), a glucocorticoid steroid that upon binding to its nuclear receptor 
enables NPC dilation up to 140 nm.191 Low molecular weight PEI-Dex conjugates 
complexed with DNA showed enhanced translocation efficiency compared to the 
untargeted PEI-DNA system.172  
A third strategy to enhance nuclear uptake exploits the nuclear import machinery, 
which controls the translocation of cytoplasmic proteins into the nucleus by means of 
nuclear localization signals (NLS)s.173 These small cationic peptide sequences access the 
nucleus by interaction with nuclear importing proteins called importins.190 This pathway 
allows active transport of molecules that are too large to passively diffuse through the 
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NPC. Polymers and nanoparticles have been decorated with NLSs to direct the 
intracellular trafficking of both anticancer drugs and pDNA.164,167  Hoang and co-workers 
aimed to localize Auger electron emitting radionuclides in the perinuclear and nuclear 
regions of cells. To this purpose, PEG-b-PCL block copolymer micelles labeled with the 
Auger electron emitter indium-111 (111In) and loaded with the radiosensitizer 
methotrexate (MTX) were decorated with NLS peptides to promote nuclear uptake. 
Successful nuclear targeting was shown to improve the antiproliferative effect of the 
Auger electrons. Moreover, significant radiation enhancement was observed by the co-
delivery of low-dose MTX and 111In in breast cancer cell lines.18 A similar strategy has 
been used to enhance nuclear delivery of doxorubicin using NLS-modified PLGA 
nanoparticles.174 In another example, covalent conjugation of a NLS derived from the 
SV40 virus on PLGA nanospheres was demonstrated to enhance the gene transfection 
efficiency of the encapsulated pDNA.175 While decoration of polymers or polymer 
nanoparticles with NLSs provides a powerful strategy to enhance nuclear delivery, in vivo 
the positively charged nature of these peptides may lead to non-specific cellular uptake in 
the blood stream.167 One way to address this drawback is to mask the NLS such that it is 
negatively charged in circulation but upon internalization undergoes charge reversal. This 
was demonstrated by Zhong et al. for the design of an HPMA copolymer in which the 
therapeutic H1 peptide-modified with an octaarginine-NLS sequence (R8NLS-H1) was 
linked to the polymer backbone via the lysosomally cleavable linker GFLG spacer. The 
positive charges of the octaarginine-NLS peptide were modified with anionic 2, 3-
dimethylmaleicanhydrides (DMA). This allowed the shielding of the cationic properties 
of the peptide in physiological conditions as well as rapid cleavage and unmasking of the 
positively charged amino-rich residues after mild-acidic (pH 6.5) tumor tissue 
accumulation. After cellular internalization via endocytosis, the lysosomal release of the 
R8NLS-H1 peptide allowed lysosomal escape through the octaarginine motif and nuclear 
transport via the NLS sequence.79 In another report, the same authors described a 
PHPMA nanoparticle-based nuclear delivery system that was designed to successively 
reduce size upon trafficking towards the tumor environment and subsequently the 
intracellular environment. The particles were composed of an anionic DMA protected N-
3-aminopropylmethacrylamide-HPMA copolymer and a second (cationic) HPMA 
copolymer, which is functionalized via a pH cleavable hydrazone linker with a Dox 
peptide conjugate (R8NLS-Dox). The Dox-peptide conjugate included a fusion peptide 
(R8NLS) that is composed of an octaarginine motif (R8) and a NLS. The mild-acidic pH 
of the tumor environment allowed dissociation of the two conjugates and resulted in 
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enhanced cellular internalization due to reduction of carrier size. After endocytosis, a 
second reduction in size occurred in the more acidic endolysosomal compartments, which 
allowed cleavage of the hydrazone linker, R8NLS-doxorubicin release and nuclear entry 
via nuclear localization signal assistance. Based on the stepwise size reduction and on-
demand R8NLS exposure, the PNV inhibited the growth of HeLa tumors in mice by 
75%.60 Another interesting approach to enhance nuclear delivery is based on the nuclear 
factor kappa B (NFkB) transcription factor. NFkB is a transcription factor containing both 
a DNA binding domain and a NLS domain. The latter, under specific conditions, directs 
the translocation from the cytoplasm to the nucleus and vice versa. Hence, a pDNA 
containing a NFkB-binding motif was delivered in the cell cytoplasm via a PEI carrier. 
The binding of the pDNA to the cytoplasmic NFkB resulted in translocation to the 
nucleus via the NFkB NLS domain.176 Jeong et al. used reducible poly(amido 
ethylenimine)s for intracellular release of a plasmid DNA having binding sequences for 
NFkB. The highly reductive cytosolic environment allowed cytosolic release of the 
pDNA from the carrier therefore enhancing NFkB binding and nuclear targeting.177  
The nuclear delivery strategies that have been discussed so far all involve cellular 
internalization of the polymer nanomedicines via clathrin-mediated endocytosis. In a 
series of studies, Sullivan and co-workers have demonstrated the power of other 
internalization pathways, more specifically, caveolae-mediated uptake to promote 
efficient nuclear delivery.164 In a first study, Reilly et al. found that conjugation of histone 
H3 tails to PEI-based polyplexes enhanced both the rate of gene expression as well as the 
efficiency of gene transfection and reduced the dependence on endocytic pathways that 
involve lysosomal trafficking, indicating a possible increase reliance on caveolar 
uptake.178 A subsequent study that used a variety of endocytic inhibitors indeed 
demonstrated that the H3 functionalized polyplexes are internalized via caveolae-
mediated endocytosis and also indicated that the polyplexes used retrograde Golgi-to-ER 
pathways to reach the nucleus.179 Ross et al. demonstrated that H3-targeted polyplexes 
were not released into the cytoplasm after internalization, but instead entered the nucleus 
in association with ER membranes. A post-mitotic increase in nuclear localization, that 
was coincident with nuclear envelope (NE) reassembly, suggested that the nuclear entry 
via the NLS contained in the H3 tails was enhanced during nuclear envelope dismantle. 
180  
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1.2.2.3. Delivery to the Golgi apparatus (GA) and Endoplasmic Reticulum (ER).  
In the endoplasmic reticulum (ER), proteins are synthesized, folded and transported to 
the Golgi apparatus (GA) where they are modified and sorted before secretion. Interfering 
with those specific functions can be exploited as anticancer therapy.192 Moreover, the ER 
is a main Ca2+ storage and stress signals in this organelle can trigger rapid Ca2+ release 
and apoptosis.192 ER targeting is also interesting for antigen presentation in antigen 
presenting cells, which can be exploited for antitumor immunotherapy.193 So far, 
however, only a relatively small number of polymer nanomedicines designed to mediate 
delivery to the GA and ER have been reported. 
One possible strategy to guide polymer nanomedicines to the GA and ER is to exploit 
some of the intracellular trafficking pathways of bacteria toxins such as Shiga and 
Cholera toxins. These toxins are internalized by the cells via both clathrin-dependent and 
independent endocytosis. After accumulation in the early endosomes, these toxins 
retrograde through the GA and ER, therefore avoiding the highly degradative lysosomal 
environment.194 The Shiga toxin accesses the cell by binding to the globotriaosylceramide 
(Gb3) receptor before being redirected to GA and ER.194 The overexpression of Gb3 
receptor on the plasma membrane of various cancers such as lymphomas, ovarian 
carcinoma, breast and colon cancer has been recognized as an appealing opportunity to 
develop highly selective targeting methods.193,195,196 Moreover, since the targeting 
mechanism is dictated by the B subunit of the Shiga toxin, which is not toxic,197 the use 
of toxins subunits to promote GA and ER targeting was proposed.195 The Shiga toxin B 
subunit has been conjugated to low molecular weight cytotoxic compounds such as 
benzodiazepine RO5-4864,196 the topoisomerase I inhibitor Sn38196 and photosensitizer 
drugs.198,199 The Cholera B toxin subunit can be used in a conceptually similar way. 
Vivero-Escoto and co-workers, for example, conjugated the B subunit of cholera toxin 
(CT-B) to PEG-modified fluorescein isothiocyanate (FITC)-mesoporous silica 
nanoparticles.181 This work demonstrated that the cellular internalization occurred via 
both clathrin-dependent and -independent mechanisms allowing partial trafficking 
through the trans-Golgi network and the ER. These examples highlight the possibility to 
use toxins-derived subunits to target the GA and ER bypassing the degradative 
compartments, which provides new opportunities for the delivery of macromolecular 
cargo to these organelles.  
In addition to the use of bacterial toxins, Pluronic polymers and wheat germ agglutinin 
(WGA)-targeted nanoparticles have also been used to promote cellular internalization via 
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different mechanisms and in particular via caveolae-mediated endocytosis. Kabanov and 
co-workers have reported that, while the cellular internalization of P85 block copolymer 
micelles at high concentrations occurs mainly through clathrin-mediated endocytosis, P85 
unimers at concentrations below the CMC, enter the cell mainly via caveolae-mediated 
endocytosis.182 These block copolymers were seen to bypass the cell lysosomes and 
transport to the ER and then to the mitochondria.183 Shen et al. showed that coating the 
surface of silicon quantum dots with Pluronic F127 allowed selective labeling of the 
ER.184 Gao et al. reported that quantum dots labeled poly(ethylene glycol)-b-poly(lactid 
acid) (PEG-b-PLA) nanoparticles, that were decorated with wheat germ agglutinin 
(WGA) were internalized by both clathrin- and caveolae-mediated mechanisms and found 
to accumulate in the lysosomes and Golgi apparatus.185  
 
 
1.3. Monitoring Intracellular Drug Delivery 
The advances made in the field of polymer nanomedicine to control and direct active 
compounds to the proper intracellular target also call for methods that allow to monitor 
these processes. While assessing drug activity35,54 or transfection efficiency provides 
indirect evidence for successful delivery,104,125,128 these experiments do not afford 
quantitative insight into the intracellular trafficking pathways and single cell 
pharmacokinetics of the polymer nanomedicines. Detailed and quantitative information 
about the intracellular routing and release profiles of polymer nanomedicines is essential 
to further improve the performance of these delivery systems. 
Owing to the broad variety of organelle-specific fluorescent markers and the wide 
range of fluorescence probes that can be used to label polymers or polymer nanoparticles, 
fluorescence microscopy, and in particular confocal laser scanning microscopy (CLSM), 
has become the most commonly used technique to monitor intracellular delivery. 
Intracellular trafficking is generally monitored in co-localization studies between targeted 
organelles or cellular compartments and fluorescent polymer-drug systems. Often, co-
localization studies are performed in combination with other techniques such as flow 
cytometry,200,201 transmission electron microscopy (TEM)151,202,203 as well as with 
subcellular fractionation.204 In addition to fluorescence-based techniques, there are also 
various label-free methods that have been used to monitor intracellular delivery of 
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polymer nanomedicines. These label-free methods are highly attractive as they allow to 
overcome some of the drawbacks of fluorescence-based techniques such as potential 
cleavage of the label, interference of the label with biological processes and the need to 
introduce labels.205-207 
The second part of this chapter will highlight the use of the techniques mentioned 
above to study and monitor transport of polymer nanomedicines to the cytosol as well as 
specific organelles. As fluorescence microscopy and CLSM for example are very widely 
used, it is impossible to provide a comprehensive overview that covers all the work that 
has been done to monitor intracellular delivery of polymer nanomedicines. Instead, the 
aim of this section is to highlight how these techniques (or a combination thereof) can be 
used to answer specific questions with regards to the intracellular trafficking of polymer 
nanomedicines. 
 
 
1.3.1. Monitoring cytosolic delivery 
The use of the fluorescence and label-free methods allows to address a number of 
important questions that are related to the cytosolic delivery of polymer nanomedicines 
and/or the active compounds that these transport. In what follows below, selected 
examples will be presented, which illustrate the use of various fluorescence-based 
techniques to monitor (i) endolysosomal release, which occurs upon cleavage of linkers in 
polymer-drug conjugates, (ii) endosomal escape as well as (iii) the acidification kinetics 
of the endolysosomal compartments. Finally, two examples of label-free methods that 
have been used to study the intracellular trafficking and degradation of polymer 
nanomedicines in the endolysosomal compartments will be presented.  
Endolysosomal release of anticancer drugs is generally accomplished by using stimuli-
responsive drug delivery carriers that are stable under physiological conditions, but 
release the active compound upon endocytic internalization in response to an intracellular 
stimulus. In general, the most used technique to monitor endolysosomal release is CLSM. 
In particular, if the transported drug is fluorescent, the release from the carrier can be 
directly observed by tracking the fluorescent drug.48 When the active compound is non-
fluorescent, endolysosomal release can be assessed by substituting the drug with a 
fluorescent dye.17,95 Doxorubicin is very attractive not only since it is a very potent 
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chemotherapeutic, but also due to its intrinsic fluorescence. A simple experiment to 
assess escape of Dox from the endocytic pathway consists in cellular CLSM imaging 
after long cellular incubation time. A diffuse red Dox fluorescence throughout the cells 
confirms cytosolic release of Dox or Dox-linked polymer nanomedicines.80 A deeper 
understanding of the time-dependent release process can be obtained by monitoring the 
intracellular path of the drug. In this case, co-localization studies need to be performed at 
different incubation times. While the Dox red fluorescence appeared as punctual 
cytoplasmic fluorescence for short incubation times, indicating the entrapment of the 
polymer-bound drug inside the endocytic vesicles, after longer incubation time, the red 
fluorescence spreads throughout the cells confirming the release of the drug from the 
carrier. Markers for the endolysosomal vesicles as well as for the target organelle can be 
used for time-dependent co-localization studies.44,48,62  
Förster resonance energy transfer (FRET) experiments are a powerful tool to monitor 
linker cleavage and drug release from polymer conjugates. In one example, the FRET 
donor Cy5 was attached to a HPMA polymer backbone and the acceptor Cy7 was 
conjugated via the enzyme-cleavable GFLG peptide linker. Cells were incubated with the 
polymer conjugate and at different incubation times the cell lysate was analysed via 
fluorescence spectroscopy. Upon cellular internalization and exposure to the lysosomal 
enzyme cathepsin B, cleavage of the peptide linker led to separation of the two dyes and 
loss of the FRET signal.208 In another study, the same authors used the intrinsically 
fluorescent anticancer drug epirubicin (EPI) as a FRET donor to prepare PHPMA-GFLG-
EPI conjugates that also incorporated the FRET acceptor Cy5. The FRET effect, 
generated by the close proximity of the pair Cy5/EPI, significantly decreased after 24 h 
incubation due to the complete GFLG cleavage and EPI release.76 A similar approach was 
used also to determine the release of Dox from N-palmitoyl chitosan nanoparticles 
containing a Cy5 moiety as FRET acceptor. HT1080 cells were incubated with the 
nanoparticles for 24 hours and at different time points, the FRET effect was visualized 
with CLSM. For the first 30 min incubation the nanoparticles fluorescence was observed 
in the Cy5 channel, while no Dox signal was observed. After 1 hour incubation, the Cy5 
signal significantly decreased while a weak Dox signal appeared in the cytoplasm. At 
longer incubation times the Cy5 fluorescence was not observed anymore, while Dox 
signal in the cytoplasm further increased. Incubation times of 12 and 24 hours highlighted 
the accumulation of Dox in the cell nucleus.209 FRET was also used to monitor 
intracellular pH-dependent release of doxorubicin from a carbon nanodot (CDot)-based 
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drug delivery system. CDots were used both as drug carriers and as the FRET donor. The 
FRET-CDots were obtained by coupling PEG chains onto the CDot surface followed by 
trapping of doxorubicin molecules within the PEG network via π–π stacking. The close 
proximity of the CDot core and Dox generated a strong FRET signal. Upon release of 
Dox from the CDot surface, the FRET signal was quenched. This change in FRET signal 
was used to monitor the release of doxorubicin from the CDot surface as a response to the 
decreased endolysosomal pH.210 In a similar way, PEGylated quantum dots (QDs) were 
used to monitor the cytosolic release of the anticancer drug STAT3 inhibitor in response 
to cytosolic glutathione. To this purpose, CdS:Mn/ZnS QDs were functionalized via a 
disulfide linker with the STAT3 inhibitor, folate as targeting motif as well as with PEG 
chains. The surface modified QDs were then used to decorate superparamagnetic iron 
oxide nanoparticles to generate a multimodal/multifunctional nanocomposite probe. 
Conjugation of the electron rich STAT3 inhibitor and the folate ligand quenches the QDs 
luminescence. QDs luminescence is restored once the surface-bound ligands are 
detached. Hence, the modification of the QDs surface and linkage to the iron oxide core 
resulted in the formation of nanocomposites in an OFF state due to the QD quenching. 
Upon intracellular uptake, the higher glutathione concentration allowed QD and drug 
release with consequent increase in the QD fluorescence. The increased QD fluorescence 
could be used to track STAT3 release from the nanocomposite and the iron oxide core 
allowed MRI analysis of the nanocomposite in the cell cytoplasm.211 
In addition to follow drug release from polymer conjugates or polymer nanomedicines, 
a second important challenge is to monitor endosomal escape of polymer nanomedicines 
and/or their cargo. The use of CLSM and suitable labels allows to monitor either drug or 
carrier. Their intracellular trafficking can be visualized observing the co-localization, first 
with endocytic vesicles and after with the targeted cytoplasmic organelle. As an example, 
the intracellular trafficking of endosomolytic dendrimers and linear polymer-FITC 
conjugates was investigated after 6 and 12 hours incubation in cancer cells. The use of the 
lysosomal marker Lyso Tracker green allowed the determination of lysosomal co-
localization in the first 6 hours incubation. Mixed co-localization with cytoplasm, 
lysosomes and nucleus after 12 hours incubation confirmed the endolysosomal 
destabilization and cytoplasmic release.11,135 Jiang et al. used α,β-unsaturated ketone-
caged coumarin derivatives to monitor endosomal escape and consequent cytosolic 
disintegration of polymer nanocarriers. These micellar nanoparticles were obtained by 
temperature-induced self-assembly of a diblcok copolymer composed of a hydrophilic 
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PEG block and a thermosensitive poly(di(ethylene glycol) monomethyl ether 
methacrylate) that was modified with an α,β-unsaturated ketone-caged coumarin 
derivative. Upon endosomal escape, Michael addition reaction of thiols (from cytosolic 
glutathione as well as protein cysteine residues) and the α,β-unsaturated ketone groups, 
led to unmasking of the coumarin moieties resulting in a blue fluorescence as well as an 
elevation of the critical micellization temperature and disintegration of the polymer 
nanoparticles.212  
FRET has also been used to monitor polymer-mediated endosomal escape of DNA and 
RNA. In one example, a FRET-capable single stranded oligonucleotide molecular beacon 
(OMB) was used to monitor intracellular DNA release as well as its stability in the 
cytosol. The OMB contained the FRET dye pair Alexa-Fluor 488 and 594 and was used 
to form mixed polyplexes with a plasmid DNA encoding green fluorescent protein (GFP) 
using jetPEI and generation 5 (G5) PAMAM dendrimer as vectors. Confocal microscopy 
studies revealed that the OBM delivered via PAMAM was retained inside the endocytic 
vesicles up to 24 h, whereas the PEI vector allowed cytoplasmic release already after 2 h 
incubation in HEK 293A cells. Moreover, FRET confocal microscopy showed a decrease 
in FRET signal after 12 h incubation due to the cleavage of the cytoplasmic OBM 
released from the PEI carrier by cytoplasmic proteases.213 In another example QDs were 
used to monitor the endosomal escape of PEI-siRNA complexes via FRET analysis. PEI 
covalently conjugated on the surface of the QDs was complexed with cyanine dye labeled 
vascular endothelial growth factor siRNA (cy5-VEGF siRNA) to generate nanosized 
polyelectrolyte complexes (PEC). FRET was achieved between cy5-VEGF siRNA and 
PEI conjugated QDs in the complex. CLSM was used to monitor the intracellular 
trafficking and release of siRNA from the complex as a function of incubation time. The 
extent of cy5-siRNA release from the PEC was quantitatively evaluated by flow 
cytometry analysis.214  
Significant efforts have been made to monitor and measure the acidification kinetics in 
the endolysosomal system. Insights in the acidification kinetics could aid the 
development of novel polymer nanomedicines that are designed e.g. for the pH triggered 
release of drugs. In one example, Chang et al. prepared hydrophilic, fluorescent 
nanoprobes that consist of hybrid polystyrene-b-poly(acrylic acid) (PS-b-PAA) micelles 
encapsulating the hydrophobic pH responsive fluorophore N,N’-di-n-dodecyl-2,6-di(4-
methyl-piperazin-1-yl)naphthalene-1,4,5,8-tetracarboxylic acid diimide (NDI). The 
fluorescence intensity of the nanoparticles was enhanced 55-fold upon changing from 
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neutral (7.4) or basic pH (8.4) to acidic (3.4) pH. MCF-7 cells stained with 
endolysosomal markers were incubated with TAT-peptide modified nanoparticles for 1, 4 
and 8 hours and analysed both via CLSM and flow cytometry. After 8 hours, bright red 
fluorescence of the hybrid nanoparticles was found to overlap with that of the green-
fluorescent stained lysosomal compartments.200 Similarly, Lerch et al. reported the 
synthesis of polystyrene nanoparticles modified with the dual-wavelength pH-sensitive 
dye seminaphthorhodafluor-1 (SNARF-1). SNARF-1 is a fluorescent dye with emission 
maxima that shifts from λ = 580 nm to λ = 640 nm upon protonation.203 Hela cells were 
incubated with the nanoparticles and imaged at different time points. While the 
subcellular localization of the nanoparticles was mapped by TEM and co-localization 
with endolysosomal Rab family proteins using CLSM, the acidification process was 
visualized as pseudo-color CLSM images. Bao et al. prepared ratiometric pH sensors by 
decorating hyperbranched polylactide nanoparticles with both a pH sensitive as well as a 
pH-insensitive naphthalimide-based fluorophore. These probes were successfully used to 
quantitatively analyse the intracellular pH of Hela cells.215 Choi et al. developed a 
colourimetric polyaniline nanoindicator composed of silica-coated polyaniline (PANI) 
nanoparticles. The fluorophores Cy3 (? = 570) and Cy7 (? = 770) were absorbed on 
particle surface to give Cy3 and Cy7-labeled proton-sensitive nanoindicators. The ability 
of the nanoprobes to sense the endolysosomal pH was tested in HT1080 cells using 
CLSM. To this purpose, cells were incubated with the nanoprobes for 0.5, 1.5, and 4 
hours. Co-localization experiments with EEA1 as early endosomal marker and Lyso 
Tracker Blue as lysosomal marker revealed that after 30 min and 1.5 h the nanoparticles 
were located in the early endosomes, whereas after an incubation time of 4 hours the 
nanoparticles were found in the lysosomes. In the early endosomes, the fluorescence 
intensity of Cy7-labeled nanoparticles was strong whereas the Cy3 dye fluorescence was 
quenched. This is due to the fact that in the endosomes (pH 6), PANI is in its 
deprotonated form and causes quenching of the Cy3 dye. On the other hand, after 4 hours 
incubation, the decreased pH of the lysosomes resulted in PANI protonation and a shift of 
its absorption peak to 770 nm. This caused the quenching of Cy7 emission and increase 
of Cy3 fluorescence.216 Ratiometric pH sensitive probes based on silica nanoparticles 
incorporating Atto647 as pH-insensitive reference dye and FITC as pH sensor have been 
used to monitor intracellular pH upon internalization of various polyplexes. It was found 
that the FITC:Atto647 fluorescence ratio was highly correlated with the pH over the pH 
range 4 - 7.5. These particles were used to monitor real-time intracellular trafficking in 
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BT-20 cells. The environmental pH of the nanoprobes dropped from pH 7.4 to 4 over the 
first 2 hours suggesting rapid internalization via endocytosis, followed by acidification 
within endolysosomal compartments. The pH remained around 4 for 24 hours, indicating 
the inability of the nanoprobes to escape from the acidic vesicles. To further confirm that 
the nanoprobes were trapped in the endolysosomal vesicles, cells were incubated with 
both the nanoprobes and branched PEI, a polymer known to mediate endosomal 
disruption. The PEI co-treatment not only prevented a complete acidification by retaining 
the pH at 5.5 in the first few hours, but also reversed the pH to 7.4 at 24 hours post-
incubation indicating endolysosomal escape. Co-incubation of the nanoprobes and 
different endosomal disrupting polymer-DNA complexes was used to correlate the ability 
of the polymers to trigger endosomal release with the endocytic compartments 
acidification.201 Hu et al. prepared ratiometric fluorescent pH imaging probes, which also 
possess endosomolytic properties. These nanoparticles were generated from dual-labeled 
pH responsive block copolymers, which were composed of a pH-responsive N,N-
diethylaminoethyl methacrylate-co-butyl methacrylate (PDEA-b-PBMA) block 
incorporating tetramethylrhodamine (TMR) and a hydrophilic poly(N,N-
dimethylacrylamide) (PDMA) segment that incorporates a small fraction of the 
fluorescent pH sensitive dye 7-hydroxycoumarin (HCCME) (Figure 2A). While the red 
TMR emission was detected during the entire incubation period, the blue HCCME 
emission was almost not detected for the first 4 hours incubation due to the acidic 
environment. After 8 hours, the blue emission increased suggesting endosomal escape 
(Figure 2B). The presence of the internal standard TMR and the use of calibration curves 
allowed the determination of the pH gradient to which the micelles were exposed. For the 
first 5 hours, the pH was around 5, whereas for longer incubation times, such as 16 and 
24 hours, the pH was close to neutral as shown in Figure 2B. This result was confirmed 
by the co-localization between TMR and the late endosomal-lysosomal marker for the 
first 4 hours. After 8 hours, the co-localization between TMR and endocytic vesicles 
decreased going from 92% at 4 hours to less than 32% after 24 hours incubation.217  
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incubated with PCL-particle-containing medium (left) for 7 h as well as PLGA-particle-
containing medium for 2 h (right). Red regions, PCL or PLGA aggregates; yellow 
regions, lipid/phospholipids inclusions; green regions, membrane rich organelles such as 
ER, Golgi, mitochondria; blue regions, proteins of the cell body. Traces A-D represent 
the Raman spectra of the corresponding regions. Adapted with permission from T. 
Chernenko, C. Matthaus, L. Milane, L. Quintero, M. Amiji, M. Diem, Label-Free Raman 
Spectral Imaging of Intracellular Delivery and Degradation of Polymeric Nanoparticle 
Systems, Acs Nano 2009, 3 (11), 3552-3559. Copyright (2009) American Chemical 
Society.219  
 
NanoSIMS is another powerful, label-free technique to monitor cellular internalization 
and intracellular trafficking of polymer nanomedicines. NanoSIMS uses a focused 
primary ion beam to erode the sample and provides secondary ions that can be analysed 
to trace elements and isotopes. The focusing of this ion beam to a very narrow beam spot 
allows spatial resolutions down to 50 nm. The high resolution, together with the 
capability of multi-element and isotope selective analysis, resulted in the application of 
NanoSIMS in a variety of different fields such as cosmochemistry, biological 
geochemistry, materials chemistry and cell biology.222 NanoSIMS has been used to track 
the subcellular pathway drug distribution of metal-based anticancer drugs.223-225 Recently, 
the NanoSIMS technique has also been used, in combination with fluorescence 
microscopy, to monitor cellular internalization and trafficking of polymer nanomedicines. 
Proetto et al. investigated the intracellular accumulation of 15N-labeled polymer 
nanoparticles containing a covalently linked Pt(II)-based anticancer drug as well as a 
Cy5.5 fluorescent tag.226 First, HeLa cells were incubated with the nanoparticles for 4 
hours and subsequently analysed with fluorescence structured illumination microscopy 
(SIM). Co-localization of the nanoparticles with fluorescently labelled vesicles indicated 
cellular internalization via endocytosis. Analysis of 15N and 195Pt co-localization with 
NanoSIMS suggested significant release of the drug from the nanoparticles after 24 h as 
compared to 4 h incubation (Figure 4A). Figure 4B shows an overlay of SIM and 
NanoSIMS images. The overlaid images confirmed weak correlation between 195Pt with 
the carrier signals at long incubation time. This example demonstrates the feasibility of 
using NanoSIMS combined with fluorescence microscopy as a tool to simultaneously 
monitor polymer and cargo in cells in a qualitative and quantitative manner and opened 
new possibilities for the monitoring of intracellular delivery processes. 
Chap
Nano
 
40 
 
Figur
for 4 
follow
the N
195Pt 
Intere
repre
locali
incub
15N a
Proet
L. G
Giann
Isotop
Chem
 
 
1.3.2
Mit
CLSM
exper
mitoc
mode
ter 1: Cont
medicines 
e 4. (A) Tim
h (b1-3) or 
ed by imag
P inside the 
counts are 
st (ROI) at
sents 10 μm
zation of the
ation. Overl
nd fluoresce
to, C. R. An
. Nilewski, 
eschi, Cellu
ic Nanosco
ical Society
. Monitor
ochondrial 
. When th
iments are 
hondrial ma
l experimen
rolling and 
e dependen
24 h (c1-3)
ing shows c
cells. Red c
observed. T
 each of the
. (B) Ove
 fluorescent
ay of 195Pt a
nt tag is re
derton, D. H
A. M. Rush
lar Deliver
py, Acs Na
.226 
ing mitoch
targeting is
e transport
relatively st
rker.26,157 In
ts with poly
Monitoring 
t NanoSIM
. Removal o
o-localizatio
ircles are the
he averaged
 selected pl
rlay of Na
 tag (red) w
nd fluoresce
presented in
u, C. J. Szym
, N. C. Be
y of Nanop
no 2016, 10
ondrial de
 generally 
ed drug is 
raightforwar
 case of non
mer nanome
Intracellula
S analysis o
f layers of o
n (yellow) o
 ROIs selec
 15N and 19
anes are sh
noSIMS an
ith 195Pt (blu
nt tag is sho
 white. Ad
anski, Z. Z
ll, J. E. Ev
articles Rev
 (4), 4046-
livery 
assessed in 
fluorescent
d and only
-fluorescent
dicines that 
r Delivery 
f HeLa cells
rganic matt
f the 195Pt (
ted for 15N/1
5Pt signals 
own for pan
d SIM im
e) and 15N (
wn in magen
apted with p
hu, J. P. Patt
ans, G. Orr
ealed with 
4054. Copy
co-localizat
, such as e
 require the
 cargo, this 
transport flu
of Anticanc
 treated with
er from the 
red) and 15N
4N quantific
per selected
els b and c
ages showin
green) after
ta and over
ermission f
erson, J. K. 
, S. B. How
Combined O
right (2016)
ion experim
.g. doxorub
 use of an 
can be accom
orescent dy
er Polymer 
 
 Cy-15N-Pt 
cell surface 
 (green) on 
ation where 
 Region of 
. Scale bar 
g the co-
 4 and 24 h 
lay of 195Pt, 
rom M. T. 
Kammeyer, 
ell, N. C. 
ptical and 
 American 
ents using 
icin, these 
appropriate 
plished in 
e instead of 
Chapter 1: Controlling and Monitoring Intracellular Delivery of Anticancer Polymer 
Nanomedicines 
 
41 
 
the active compound. Cuchelkar et al. for example used a BOBIPY labeled PHPMA-TPP 
conjugates to validate mitochondrial targeting.87 Alternatively, modification of the active 
compound such as oligonucleotides has also been used to investigate the mitochondrial 
co-localization.151 Another possibility is to modify the polymer carrier with a suitable 
fluorescent dye.153 The use of fluorescent, or fluorescent labeled, delocalized lipophilic 
cations (DLCs) is attractive as they simultaneously allow to target the mitochondria as 
well as to visualize the localization of the polymer nanomedicines in these organelles. For 
instance, enhanced mitochondrial targeting of liposomes modified with the DLC 
rhodamine-123 (Rho) was observed by co-localization studies with stained 
mitochondria.160 In another example, PLA-PEG polymersomes were decorated with a 
naphthalene-modified TPP derivative, which enabled to directly visualize the co-
localization of these nanoparticles with MitoView stained mitochondria.159 Fluorescent 
quantum dots (QDs) have been also proposed to monitor mitochondria targeting. To this 
end, targeted and non-targeted nanoparticles were prepared by blending PLGA-b-PEG-
QD with PLGA-b-PEG-TPP and with PLGA-b-PEG-OH, respectively. Fluorescence 
microscopy analysis of treated HeLa cells indicated significantly greater mitochondrial 
uptake of targeted nanoparticles as compared to non-targeted ones as shown in Figure 
5.155  
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1.3.3. Monitoring nuclear delivery 
Nuclear targeting is generally visualized using CLSM via co-localization studies. This 
can be achieved by labeling the polymer carrier with a fluorescent dye and measuring the 
co-localization with the nucleus, which can be stained with nuclear specific markers such 
as DAPI, Hoechest 33342 and Draq 5.79,169,172 Alternatively, the cargo can be tracked in 
case of fluorescent drugs such as doxorubicin174 or when labeled pDNA are 
delivered.176,179,180 Labeling both the polymer carrier and the cargo with a fluorescent dye 
allows to monitor release of the active compound, e.g. plasmid DNA.170 In case of pDNA 
delivery, co-localization studies can also be correlated to transfection efficiency when 
reporter genes such as luciferase are used.176  
Co-localization studies via CLSM, have also been used to answer specific questions 
such as the nuclear entry of nanoparticles during cell division. Symens et al. investigated 
the ability of fluorescent carboxylated polystyrene beads (100, 200 and 500 nm), which 
were either functionalized with Pluronic F127 or dimethylamine-ethylamine (DMAEA) 
to generate PEGylated and positive charged particles, to accumulate in the cell nucleus 
using an in vitro Xenopus nuclear envelope reassembly (XNER) assay. pDNA/PEI 
fluorescent polyplexes were also tested as a comparison. It was found that, 100 and 200 
nm polystyrene particles were better included than the 500 nm ones and that positively 
charged polystyrene and PEI particles were better included than negatively charged or 
PEGylated polystyrene particles. Moreover, the coupling of chromatin-targeting peptides 
to the polystyrene beads or pDNA/PEI complex improved their inclusion by 2- to 3-fold. 
An unexpected but interesting result was obtained upon direct microinjection of the 
particles in the cytoplasm of HeLa cells. In this case, the nanoparticles were never 
observed in the nuclei of cells post-division but accumulated instead in specific 
perinuclear regions. Figure 6A represent an example of images of the distribution of 100 
nm positively charged polystyrene beads (green), pDNA/PEI polyplexes (red) and 
chromatin-targeted pDNA/PEI polyplexes (red) in Hela cells during cell division. In order 
to investigate the site of the particles, cells were stained with early endosomal and 
lysosomal markers (green) and red polystyrene beads were used instead of green ones to 
prevent signal overlap. As shown in Figure 6B, the nanoparticles were never co-localized 
with early endocytic vesicles, however, 24 hours post-injection high co-localization was 
observed with lysosomal vesicles. These results demonstrate that nanoparticles can 
accumulate in the lysosomes even if they have not been internalized via endocytosis.227 
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Combining CLSM with quantum dots mediated Förster resonance energy transfer 
(QDs-FRET) does not only allow to visualize nuclear targeting but also enables to 
monitor nucleic acid release. In one example, hydrophobic CdSe/ZnS QDs were loaded in 
the core of PEG-PCL-PEI based nanocarriers that were used to release Alexa Fluor 647 
(AF647)-labeled siRNA. In vitro experiments with SKOV3 cells revealed co-localization 
of the carrier and the siRNA in the form of intact polyplexes in the cytosol.228 Shaheen et 
al. also used QDs-FRET to monitor decondensation of pDNA in the nuclear subdomains. 
In this study, polyplexes of QD-labeled pDNA and a rhodamine-labeled cationic 
polyrotaxane (PRX) were entrapped in a tetra-lamellar multifunctional envelope-type 
nanodevice (T-MEND), which was designed to overcome the endosomal and nuclear 
membranes, respectively. CLSM was used to investigate the subcellular distribution and 
pDNA/polycation dissociation. To this end, the nuclear subdomains were distinguished 
by Hoechst 33342 staining and pDNA condensation/decondensation was quantified based 
on the pixel area of the signals derived from the QDs and rhodamine. In particular, some 
red clusters with a maximum peak at 590 nm (Rhodamine) were localized in the 
cytoplasm and nucleus, suggesting the presence of pDNA in the condensed form. Green 
signals at 550 nm (QDs), which derive from the pDNA dissociation, were localized in the 
nucleus. Finally, the pixel areas of red, green and yellow (partial dissociation) cluster, in 
the nuclear euchromatin and heterochromatin regions were independently integrated and 
quantified.229 Chen et al. investigated the intracellular uptake and dissociation of 
polyplexes through QD-FRET at different incubation times in HEK 293 cells. To this 
purpose, pDNA and the polymeric carrier were individually labeled with quantum dots 
(QDs) and Cy5 dyes, respectively, as a FRET donor and acceptor. Co-localization studies 
allowed the quantitative analysis of the distribution of released plasmid within the 
endo/lysosomal, cytosolic, and nuclear compartments. Polyplex unpacking kinetics for 
chitosan, polyethylenimine and polyphosphoramidate-based polyplexes were measured 
and found to correlate well with the transcription efficiencies.230 Bryson et al. combined 
fluorescent microscopy with MRI to visualize pDNA delivery at different biological 
length scales. This was accomplished using oligoethyleneamine-based polycations that 
incorporated either luminescent europium (Eu3+) or paramagnetic gadolinium (Gd3+) 
chelators.231 The use of Gd3+ enables MRI of bulk cells, which showed bright image 
contrast and allowed the visualization of effective intracellular delivery on the tissue 
scale. At the nm/μm length scale, pDNA delivery was measured by fluorescence 
microscopy using the Eu3+ labeled beacons and FITC labeled pDNA. Co-localization of 
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FITC-pDNA and Eu3+ polymer luminescence could be observed as cytoplasmic punctate 
staining and a lower fraction was localized in the cell nucleus, which was proposed as a 
contributing factor to the low luciferase reporter gene expression that was obtained. 
 
 
1.3.4. Monitoring Golgi Apparatus (GA) and Endoplasmic Reticulum (ER) 
delivery 
ER and GA delivery can be monitored with co-localization studies using dye-labeled 
carriers183 or fluorescent drugs232 and GA and ER compartments stained with specific 
fluorescent markers. Vivero-Escoto and co-workers performed detailed studies to assess 
the intracellular trafficking pathways of fluorescein-labeled mesoporous silica 
nanoparticles (FMSNs) that presented the cholera toxin subunit B (CTxB) tethered via a 
PEG spacer on their surface. As controls, unmodified fluorescein-labeled MSNs 
(FMSNs) and PEG modified FMSNs (PEGC-MSNs) were used. Intracellular trafficking 
was studied by CLSM using lysosomal, ER and GA specific stains. FMSNs and PEGC-
FMSNs were co-localized exclusively in the cell lysosomes. Interestingly, a significantly 
lower amount of CTxB-FMSNs was found in the lysosomes. Co-localization of CTxB-
FMSNs with the GA confirmed that a certain number of CTxB-FMSN particles targeted 
the GA following uptake and a little amount was finally localized in the ER. In a second 
step, the ability of the CTxB-FMSN particles to deliver a model fluorescent dye to ER 
was investigated. To this end, propidium iodide (PI) loaded particles were incubated with 
Hela cells for 1 hour. Imaging 24 hours post-incubation revealed the co-localization of PI 
with ER, indicating that the membrane impermeable dye was transported by the CTxB-
FMSN particles via the GA and finally accumulated in the ER.181 
QDs have also been used to monitor trafficking of polymer nanomedicines to the ER 
and GA. In one example Shen et al. prepared Si-QDs coated with Pluronic F127 and 
demonstrated the selective labeling of the ER within live human umbilical vein 
endothelial cells (HUVECs).184 Gao et al. encapsulated CdSe/ZnS QDs in the core of 
PEG-b-PLA nanoparticles, which were subsequently functionalized to present wheat 
germ agglutinin (WGA) on the surface. Co-localization studies revealed that the cellular 
uptake occurred via WGA-mediated receptor endocytosis and both clathrin and caveolae-
mediated mechanisms were involved. Intracellular tracking of the carried QDs revealed 
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co-localization of the nanoparticles with both GA and lysosomes.185 
 
 
1.4. Conclusions  
Polymer conjugates and other polymer-based nanocarriers have been shown to be very 
efficient to improve the delivery of chemotherapeutics. There are, however, still various 
important (and scientifically interesting) challenges ahead, which if they can be 
addressed, will help to further improve the performance of polymer-based anticancer 
nanomedicines. One important objective (which is outside the scope of this Thesis) is to 
improve control on biodistribution as most in vivo studies still show very significant 
accumulation of polymer nanomedicines in off-target organs. Also on the cellular level 
there are several challenges. How to design nanomedicines that are efficiently 
internalized by cancer cells? In addition to clathrin-mediated endocytosis, are there other 
internalization pathways that can be used? Can polymer nanomedicines be designed in 
such a way that their intracellular trafficking pathways can be guided to the location 
where the drug is needed? The last questions are particularly pertinent in case of delivery 
of biologics that are prone to degrade. The aim of this chapter has been to illustrate the 
progress that has been made towards answering (some of) these questions. This progress 
rests on three pillars: (i) cell biology and the continuously growing insights in cellular 
internalization and trafficking mechanisms and pathways; (ii) polymer science and the 
ever growing possibilities to synthesize carriers and particles and (iii) biological imaging 
and analysis techniques, which make it possible to study live cells and provide resolutions 
that now proves insights at the subcellular level. The examples discussed in this chapter, 
show that, while great advances have been made in controlling cellular internalization and 
intracellular trafficking pathways, there is still room and need for further improvement. 
We are confident that further advances at the exciting intersection of cell biology, 
polymer science and biological analysis and imaging will pave the way to a further 
improved polymer nanomedicines and therapies.  
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macro chain transfer agent 2 and a new radical R·. The propagation of R· results in the 
formation of a new polymer chain Pm·. The establishment of the main equilibrium 
between the two propagating species Pn·and Pm·and the dormant macro CTA 2 and 2? 
provides rapid interchange of all the radical species from a dormant to a propagating 
stage, therefore allowing equal probability for all polymer chains to grow.1,2 
As a consequence, RAFT polymerization results in the formation of α,ω-end-
functionalized polymer chains characterized by a low dispersity, a linear increase in 
molecular weight with the conversion and by a match between theoretical predictable Mn 
and experimental data, if the following conditions are fulfilled: (i) the CTA must be 
quickly consumed with a consumption rate (ktr) higher than that of the propagation (kp) in 
the pre-equilibrium stage, (ii) the dormant species (2 and 2?) and the Pn·/Pm· active 
species must exchange quickly.1,2 As a result, the optimal control in RAFT 
polymerization requires choosing an appropriate CTA for the selected monomer. The Z 
and R groups both play critical roles in determining the outcome of the polymerization.  
While the Z-group activates the thiocarbonyl double bond toward radical addition and 
stabilizes the intermediate radicals 1 and 3 (high kadd), the R-group should enable rapid 
fragmentation (kβ > k-add) as well as an efficient re-initiation process (high kiR).1,3 The 
efficiency of a CTA depends on two transfer constants Ctr (= ktr/kp) and C-tr (=k-tr/kiR), 
which take into account the reactivity of the propagating radical Pn· and the reactivity of 
the expelled radical R·, respectively. The rate constants for chain transfer (ktr and k-tr) are 
given by the following equations:2,3 
 
ktr=kadd 
k?
k-add+k?
                k-tr=k-? 
k-add
k-add+k?
                                 (1, 2) 
 
The determination of Ctr and C-tr provides important information about the CTA 
compatibility for the given monomer and polymerization conditions, while it also predicts 
the control over the polymerization.  
These transfer constants can be estimated if the consumption rate of the CTA during the 
polymerization reaction is known. The CTA consumption during the polymerization is 
generally indirectly estimated by the discrepancy between theoretical and experimental 
polymer molecular weights.45-7 However, a lot of reports also explain discrepancies 
between theoretical and experimental molecular weight as due, at least in part, to the use 
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of size exclusion chromatography (SEC) for the estimation of experimental molecular 
weights.7-10  Although the availability of standards for polymers such as poly(methyl 
methacrylate) (PMMA) or poly(styrene) (PS), allow a relatively reliable estimation of the 
molecular weight for these polymers, it is well known that the analysis of non-
conventional polymers often requires optimization in terms of standards and solvents. As 
an alternative to SEC analysis, polymer molecular weight can also be estimated via 1H-
NMR, in particular by comparing the integrals of the polymer end group signals with 
those of the polymer backbone.9,10 However, also in this case, due to the weak intensity of 
the end group-derived signals as compared to those of the polymer chains and due to the 
broad nature of polymer peaks and overlapping signals, polymer molecular weights can 
be only poorly estimated.11 These limitations can be overcome with the establishment of 
methods to directly monitor the residual CTA during RAFT polymerization. In one 
example, Chiefari et al. estimated the concentration of residual CTA in the reaction 
mixture via 1H-NMR studies.12 However, also in this case, overlapping signals and the 
broad nature of the polymer peaks make this method applicable only to limited cases. 
More recently, Han et al. monitored the cumyl dithiobenzoate (CDB) CTA conversion 
via flash chromatography combined with HPLC.5 This method allowed the correlation 
between residual CTA and polymer molecular weights determined by SEC analysis and 
showed the effect of the reaction conditions on the CTA consumption rate and therefore 
on polymerization behavior. A more simple and direct approach to monitor CTA 
consumption during the iodine transfer polymerization of vinyldiene fluoride is the one 
proposed by Boyer et al.13 In this work the author monitored the conversion of fluorinated 
CTAs via 19F-NMR studies. 
19F-NMR provides spectra with characteristics very similar to that of the proton, with 
the additional benefit of having a broader range of chemical shifts and no interference 
from the solvent peaks. For these reasons, even in the presence of compounds containing 
multiple fluorine atoms, the risk of signal overlap is drastically reduced.14 Moreover, the 
unique sensitivity of fluorine chemical shifts to local conformational and structural 
environments results in a powerful tool to monitor chemical reactions. As a result, the 
design of fluorinated CTAs (F-CTAs) for RAFT polymerization represents a direct and 
simple method to monitor CTA consumption via 19F-NMR studies. This method becomes 
even more attractive when the RAFT polymerization of fluorinated monomers is 
investigated. Fluorine-containing polymers are considered as an interesting class of 
polymers with unique features that have found applications in a variety of different 
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fields.15-17 The determination of several polymerization parameters via unique 19F-NMR 
measurement represents a very appealing opportunity for further development of these 
polymers. In this case, apart from monitoring F-CTA consumption, the use of 19F-NMR 
also allows for the determination of monomer conversion as well as the estimation of the 
experimental polymer molecular weight based on end group analysis.  
The aim of this work is to investigate the use of F-CTAs and 19F-NMR to monitor CTA 
consumption during RAFT polymerization and to demonstrate the potential of this 
approach to access several polymerization parameters during the RAFT polymerization of 
fluorinated polymers. Poly(pentafluorophenyl methacrylate) (PPFMA) was selected as a 
candidate for this study, as it is considered as an interesting active-ester precursor 
polymer for the generation of biocompatible functional polymers.8,18-22 However, the 
efficiency of the used CTA and the effect of different polymerization conditions have 
never been investigated in detail. Hence, a fluorinated label was introduced at the R group 
of the chain transfer agent 4-cyanopentanoic acid dithiobenzoate (CTA-1) to give the 
fluorinated F-CTA-1, which was used to monitor the RAFT polymerization of 
pentafluorophenyl methacrylate (PFMA) via 19F-NMR.  The first part of this work aims 
to prove that the insertion of a fluorinated label at the R position of the CTA-1 does not 
affect the polymerization process and that the CTA-derived fluorine label incorporated on 
the PPFMA α-end group can be used to determine the experimental polymer molecular 
weights via 19F-NMR analysis. The second part aims to demonstrate how 19F-NMR 
analysis can be used to monitor F-CTA-1 consumption during the RAFT polymerization 
and to investigate the effect of different polymerization conditions on the transfer 
constants. Finally, a second CTA containing fluorine on both the R and Z groups (F-
CTA-2) was synthesized in order to explore the feasibility of using F-CTAs and 19F-
NMR, not only to monitor CTA consumption during RAFT polymerization and to 
determine the molecular weights of fluorinated polymers, but also to investigate the α-ω-
end group fidelity during the polymerization process. 
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2.2. Experimental Section 
2.2.1. Materials 
All chemicals were used as received unless described. 4-Cyanopentanoic acid 
dithiobenzoate (CTA) (>97%), N-(3-dimethylaminopropyl)-N?-ethylcarbodiimide 
hydrochloride (97%) and 2,2?-azobis(2-methylpropionitrile) (98%) (AIBN), which was 
re-crystalized from methanol prior use, were purchased from Sigma-Aldrich. 1,4-Dioxane 
and trimethylamine (Et3N) were purchased from Acros Organics and 3,3,3-trifluoro-
propylamine hydrochloride was obtained from Apollo Scientific. Pentafluorophenol was 
purchased from MatrixScientific. Dichloromethane (DCM), tetrahydrofuran (THF), 
hexane and ethyl acetate were purchased from Reactolab. Sodium methoxide, elemental 
sulfur, 4-chlorobenzotrifluoride, 4, 4’-azobis (4-cyanovaleric acid) (ACVA) were 
purchased from J&K Scientific Ltd. 4’-Azobis (4-cyanovaleric acid) (ACVA) was 
crystallized from ethanol and sodium methoxide was used in 30 % solution in methanol. 
Pentafluorophenyl methacrylate (PFMA) was synthesized as reported by Eberhardt et 
al.23 1,4-Dioxane was dried under molecular sieves and Et3N was freshly distilled prior 
use. THF was dried using a Pure Solv solvent purification system prior use. 
 
2.2.2. Methods 
1H- and 19F-NMR spectra were recorded on a Bruker AV-400 instrument at room 
temperature using CDCl3 as solvent. For 1H-NMR, chemical shifts are reported relative to 
the residual proton signal of the solvent. Size exclusion chromatography (SEC) of 
PPFMA in THF was performed using an Agilent 1260 infinity system equipped with a 
refractive index (RI) Varian detector 390-LC, two PLgel 5 μm Mixed C (Agilent) 
columns and a PLgel guard column. THF was used as eluent with a flow rate of 1 
mL/min and the temperature was 40 °C. Samples were analysed using conventional 
calibration with polystyrene (PS) standards ranging from 4910 Da to 549 KDa and poly 
(methyl methacrylate) (PMMA) standards from 2370 Da to 201 KDa. SEC in DMF was 
performed with a Waters Alliance GPCV 2000 system equipped with a RI, three Styragel 
HR4, HR2 and HR 0.5 columns and a Styragel guard column. The eluent was DMF 
containing 0.01 wt % LiCl at a flow rate of 0.6 mL/min at 60 °C. Samples were analysed 
Chapter 2: Synthesis of α,ω-Fluorine Labeled PPFMA via RAFT Polymerization 
 
66 
 
using conventional calibration with poly (methyl methacrylate) (PMMA) standards 
ranging from 2200 Da to 520 KDa. 
 
2.2.3. Procedures 
Synthesis of F-CTA-1. 500.0 mg (1.79 mmol) 4-cyanopentanoic acid dithiobenzoate 
(CTA-1) and 411.6 mg (2.15 mmol) EDC HCl were dissolved in 8 mL dry DCM, the 
solution was cooled down to 0 °C and stirred under nitrogen. In a second flask, 214.0 mg 
(1.43 mmol) 3,3,3-trifluoropropyl amine hydrochloride were dissolved in 8 mL dry DCM 
and 250 μL (1.43 mmol) triethylamine were added. After 10 minutes the 3,3,3-
trifluoropropyl amine solution was added dropwise to the first solution and the reaction 
was stirred at room temperature for 2 h. The solution was washed with 5 % NaHCO3 and 
brine, dried over MgSO4 and finally dried under vacuum. The crude product was purified 
by flash chromatography using ethyl acetate / hexane 4.5:5.5 to give the dark pink 
product (73 % yield). 
 
Synthesis of F-CTA-2. 69.4 g 30 % Sodium methoxide solution (0.39 mol) was added 
to the flask at room temperature under a dry nitrogen atmosphere followed by 13.3 g 
anhydrous methanol and rapid addition of 5.4 g (0.17 mol) elemental sulfur. The mixture 
was heated in an oil bath at 70 °C with continuous stirring for 30 min. 15.0 g (0.08 mol) 
4-chlorobenzotrifluoride was then added dropwise via the addition funnel over a period of 
1 h. The reaction mixture was kept at 70 °C in nitrogen atmosphere for 10 h. After this 
time, the reaction was stopped by cooling it down to 0 °C using an ice bath. The salt was 
removed by filtration, and the solvent was removed in vacuum. 50 mL deionized water 
was then added to the residue. The solution was filtered again. The crude product was 
washed with diethyl ether (3 × 40 mL) in an extraction funnel. Diethyl ether (20 mL) and 
1.0 mol/L HCl (50 mL) were added, and the product was extracted into the ethereal layer. 
Deionized water (30 mL) and 1.0 M NaOH (60 mL) were added, and the product was 
extracted to the aqueous layer. 36.3 g (0.11 mol) potassium ferricyanide (III) was 
dissolved in 100 mL deionized water and then was added dropwise to the first solution 
via an addition funnel over a period of 1 h under vigorous stirring. Then the solution was 
transferred to an extraction funnel. 30 mL anhydrous ethyl acetate was added to wash the 
product and the product was extracted to the ethyl acetate layer. This washing process 
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was repeated two more times. The red solution was dried over anhydrous MgSO4 and in 
vacuum to remove the solvent at room temperature overnight. The obtained 4-
(trifluoromethylthiobenzoyl) disulphide was dissolved in 50 mL anhydrous ethyl acetate 
and the solution was transferred to a flask. 2.6 g (9.19 mmol) dry 4, 4’-Azobis (4-
cyanovaleric acid) was added to the flask. The reaction solution was heated at 75 °C for 
14 h. The ethyl acetate was removed in vacuum. The crude product was isolated by 
column chromatography using ethyl acetate: hexane (1:1.5) as eluent. The solvent 
mixture was removed in vacuum, and the red oily 4-cyanopentanoic acid-4-
(trifluoromethyl) dithiobenzoate was kept at 4 °C. 2.0 g (5.8 mmol) 4-cyanopentanoic 
acid-4-(trifluoromethyl) dithiobenzoate and 1.34 g (6.96 mmol) EDC HCl were dissolved 
in 20 mL of dry DCM. The solution was cooled down to 0 °C and stirred under nitrogen. 
In a second flask, 0.7 g (4.60 mmol) of 3,3,3-trifluoropropyl amine hydrochloride were 
dissolved in 10 mL dry DCM and 465 μL (4.60 mmol) triethylamine were added. After 
10 min the trifluoropropylamine solution was added dropwise to the first solution and the 
reaction was stirred at room temperature for 2 h. The solution was washed with 5% 
NaHCO3 solution and brine, dried over anhydrous MgSO4 and dried under vacuum. The 
crude product was purified by column chromatography using ethyl acetate/hexane 1:1.5 
to give the dark pink F-CTA-2.  
 
PPFMA polymerization. 1.4 g (5.56 mmol) PFMA was added to the Schlenk tube 
followed by 2.08 mL dry dioxane containing 0.0028, 0.0055 or 0.011 mmol AIBN and 
0.028, 0.055 or 0.11 mmol CTA in the case of [M:CTA] = 200, 100 and 50, respectively. 
The solutions were degassed by four freeze-pump-thaw cycles and the tubes were filled 
with argon. The flasks were immersed in an oil bath at 90 °C or 75 °C. At different time 
intervals 150 μL samples were removed, 50 μL were diluted in 400 μL CDCl3 for 19F-
NMR analysis, the remaining part was precipitated in ice-cold hexane three times. The 
isolated pink product was dried under vacuum overnight and analysed by SEC. 
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2.3. Results and Discussion 
2.3.1. Design and synthesis of the fluorinated CTAs (F-CTAs) 
Elberhardt et al. investigated the RAFT polymerization of PFMA by using the two 
different 4-cyanopentanoic acid dithiobenzoate (CTA-1) and cumyl dithiobenzoate 
CTAs.24 Both CTAs have an activating phenyl Z group and a good tertiary cumyl or 
cyanopentanoic acid leaving radical R·, which are suitable for activated monomers such 
as methacrylates. In the case of PFMA, CTA-1 was found to be a more effective CTA24 
and therefore it has been extensively used for PFMA polymerization.8,19,21,22 For this 
reason, in this study CTA-1 (Chart 1) was chosen as the precursor for the preparation of 
two fluorinated CTAs (F-CTAs). Two different factors were taken into account for the 
choice of the labels and their respective positions. First, the labels should give rise to two 
different 19F-NMR chemical shifts and those signals should be well separated from that of 
the PFMA monomer units. For this purpose, trifluoromethyl groups were selected as 
suitable labels. Second, the insertion of the labels should not affect the polymerization 
process. The modification of both the R (α-end of the polymer) and Z (ω-end of the 
polymer) CTA groups have been already explored to introduce functionalities in the 
polymer chains.25 In this particular case, the modification of the Z group, required a more 
careful selection in order to minimize the electron-withdrawing effect of the fluorinated 
label on the dithiobenzoate moiety. To this purpose, the label was introduced in para 
position of the aromatic ring. Hence, two different fluorinated derivatives, F-CTA-1 and 
F-CTA-2 were prepared (Chart 1). While F-CTA-1 contains a trifluoromethyl label in 
the R group, F-CTA-2 contains two trifluoromethyl labels in both R and Z groups. F-
CTA-1 was used to investigate the PFMA polymerization kinetics and to determine the 
experimental molecular weights and the transfer constants. In a final step, F-CTA-2 was 
used to investigate α-ω end group fidelity during PFMA RAFT polymerization. The 
synthetic scheme of the two F-CTAs, as well as the detailed characterization, is reported 
in Supporting Information in Scheme S1 and Figure S1-S4, respectively. 
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Subsequently, the monomer conversion ρ, the initial [M]0:[CTA]0  ratio and the number 
of initiator (AIBN) derived side chains df([I]0-[I]) were used to calculate the theoretical 
degree of polymerization (DPTH) as shown in Equation (4). df[I]0-[I] was expressed as 
df[I]0(1-e-kd), where kd is the rate constant for initiator decomposition at 75 °C (7.33 × 10-5 
s-1) and 90 °C (4.79 × 10-4 s-1),28 f is the initiator efficiency (f = 0.6)28 and d is the number 
of chains produced from radical-radical reaction. Since this value is not available for this 
specific system, the value reported for MMA was used (d = 1.67).4,7 The theoretical 
molecular weights (MnTH) were calculated taking into account the monomer (mM) and the 
CTA (mCTA) molecular weights as given in Equation (5). 
 
DPTH=? ?M?0
[CTA]0+df?I?0(1-e-kd)
            MnTH=DP TH× mM+mCTA              (4, 5) 
 
Experimental molecular weights of the polymers obtained using both CTA-1 and F-CTA-
1 for the different polymerization time were first determined by SEC analysis using THF 
as solvent and polystyrene (PS) as standard.  
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polydispersity values in the early stage of the process (above 1.5), which tended to 
decrease during the course of the polymerization (1.44), might indicate a slow 
consumption of both CTAs. This effect derives from the fact that, in an ideal case, the 
degree of polymerization at each particular polymerization time is expressed as 
[monomer consumed]:[CTA]0. Therefore, a CTA with a low transfer constant Ctr will be 
slowly consumed and will generate polymer chains having an experimental molecular 
weight higher than the expected. The early stage of the polymerization therefore proceeds 
via a hybrid free radical-RAFT mechanism.3,7,29 As the polymerization time increases, the 
higher CTA conversion shifts the process toward a RAFT mechanism and the 
experimental molecular weights tend to correspond with the theoretical values. This type 
of polymerization is therefore characterized by high polydispersity values in the early 
polymerization stage, which slowly decreases as the RAFT agent is consumed. This 
behavior has been extensively observed during the RAFT polymerization of methacrylate 
monomers even in the presence of the highly reactive dithiobenzoate CTAs.4,5,7,29,30 
However, since this behavior was never reported before for the given system, and since 
the use of SEC for the molecular weight determination of non-conventional polymers 
often depends on standards and solvents,7-9 the fluorinated label at the α-end group of the 
polymers prepared using F-CTA-1 was used to estimate the polymer molecular weights 
via 19F-NMR. To this end, the integral of the 19F-NMR signal generated by the three 
fluorine atoms at the α-end groups of PPFMA (a* in Figure 1A) was set at 3. As a 
consequence, the integral deriving from PFMA polymer side chains (e*) gave the 
experimental degree of polymerization (DP). The experimental molecular weights (Mn) 
were subsequently determined as shown in Equation (6). 
 
               Mn=DP × mM+mCTA                                                (6) 
 
It should be mentioned, that due to the presence of initiator-derived polymer chains, the 
determination of molecular weight by 19F-NMR, which is based on end group analysis, 
might slightly overestimate the polymer molecular weights. SEC analysis was also 
performed using different conditions previously reported in literature such as THF and 
DMF as solvents and PMMA and PS were used as standards.8,24 As shown in Figure 2B, 
a good match was found between NMR data and SEC results for the samples analyzed 
using THF as solvent and both PS and PMMA standards gave comparable results (Table 
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CTA-1 as determined by SEC (?) and F-CTA-1 as determined by SEC (?) and 19F-
NMR (?). SEC analysis was performed using THF as solvent and PS standards were 
used for conventional calibration. Dotted lines (CTA-1) and dashed lines (F-CTA-1) 
indicate the theoretical Mn (MnTH) expected for the different conditions. (C) Double 
logaritmic plot of F-CTA-1 concentration vs monomer concentration determined by 19F-
NMR, experimental points were fitted using Equation (8). 
 
2.3.3. Determination of the transfer constants Ctr and C-tr of F-CTA-1  
The next series of experiments aimed to determine the F-CTA-1 conversion and 
therefore the transfer constants Ctr and C-tr via 19F-NMR studies and to investigate the 
effect of different [M]0:[CTA]0 and temperature on the efficiency of the CTA. Chong et 
al., reported a method to estimates the transfer constants Ctr and C-tr from the decay of 
CTA concentration during the polymerization using the following Equation:4  
 
d?CTA?
d?M? ?Ctr
?CTA?
?M?+Ctr?CTA?+C-tr?2?
                                             (8) 
 
Where [CTA] and [M] are the CTA and monomer concentrations, respectively, at each 
particular polymerization time and [2], also shown in Scheme 1, is the concentration of 
dormant polymer chains which can be directly related to the [CTA] and the initial CTA 
concentration [CTA]0. Hence, if both monomer and CTA consumptions can be 
experimentally determined at each polymerization time, Equation (8) can be fitted to the 
experimental data using independent pairs of input Ctr and C-tr. The F-CTA-1 conversion 
at different polymerization time and for different polymerization conditions was 
monitored via 19F-NMR. In particular, the signal of the α-fluorinated polymer end groups 
(a*) was compared to the unreacted F-CTA-1 integral peaks (a) using Equation (9). The 
CTA concentration at each particular polymerization time was determined with Equation 
(10) and related to [M] in order to determine the transfer constants using Equations (8). 
 
?CTA ?%?= ?a
*
?a*+ ?a
 100            ?CTA?= (1-?CTA )× [CTA]0                  (9, 10) 
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Figure 2C illustrates the experimental values Ln[F-CTA-1] vs Ln[M] determined by 19F-
NMR for the different polymerization time. The fitting of these experimental data with 
Equation (8) allowed the determination of Ctr and C-tr, which were found to be 3 and 400, 
respectively (Table 1). As expected, the relatively low Ctr value, together with a 
significant C-tr contribution explained the discrepancy between predicted and 
experimental data as well as the relatively high polydispersity obtained. Desirable 
characteristics such as the straight line dependence of molar mass on conversion and low 
polydispersity (< 1.2) require indeed CTA/monomer systems having a Ctr of at least 10.3 
 
Table 1. Ctr and C-tr values for the different PFMA polymerization conditions using F-
CTA-1 and F-CTA-2. 
F-CTA [M]0 (mol/L) [M]0:[F-CTA]0 [F-CTA]0:[I]0 
Temperature 
(°C) Ctr
* C-tr* 
F-CTA-1 
 1.8 
200 10 75 3.0 400.0 
100 10 
75 3.2 390.0 
90 4.1 399.9 
50 10 
75 3.5 390.0 
90 4.7 391.0 
F-CTA-2 
100 10 90 4.0 390.1 
 50 10 90 4.8 370.1 
*Determined using Equation 8. 
 
In a following step, F-CTA-1 was used to investigate the effect of different targeted 
chain lengths, and therefore [M]0:[CTA]0 ratios on the polymerization behaviour. As 
illustrated in Figure 3, a lower [M]0:[CTA]0 ratio, resulted in an increased polymerization 
kinetics due to an higher initiator concentration and, more important, significantly 
lowered the polydispersity values. In particular, polydispersity values ranging from 1.41 
to 1.34 and 1.38 to 1.32, were found for [M]0:[CTA]0 = 100 and 50, respectively (Figure 
4A and 4B and Table S1), compared to values around 1.56-1.44 previously found for 
[M]0:[CTA]0 = 200 (Figure 2B and Table S1). However, the discrepancy between 
theoretical and experimental molecular weights was still observed. A plot of the 
experimental Ln[F-CTA-1] vs Ln[M] data is shown in Figure 5. Table 1 summarize the 
Ctr and C-tr values obtained for the polymerization conditions using different [M]0:[CTA]0 
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scope of this work and investigate the use of F-CTAs and 19F-NMR for end group 
analysis. A second fluorinated CTA derivative (F-CTA-2) bearing a fluorinated label in 
both R (α) and Z(ω) groups was prepared and used for PFMA polymerization at 90°C 
using both [M]0:[CTA]0 = 100 and [M]0:[CTA]0 = 50. The resulting kinetics and transfer 
coefficients were compared to that obtained using F-CTA-1 and confirmed that the 
insertion of the trifluoromethyl group in Z position of the CTA only slightly affected the 
polymerization process. The kinetics of the polymerizations were only slightly slower 
than that obtained for F-CTA-1 and the experimental molecular weights and 
polydispersity were also comparable (Figure S10 and Table S3). Examples of 19F-NMR 
spectra of the polymers obtained using [M]0:[CTA]0 = 50 are reported in Supporting 
Information in Figure S11-S14.  The found Ctr and C-tr values, 4.0 and 390.1 and 4.8 and 
370.1, for [M]0:[CTA]0 = 100 and 50, respectively, were close to those obtained for F-
CTA-1 as reported in Table 1 and Figure 5. One example of 19F-NMR spectrum of 
PPFMA prepared using F-CTA-2 is given in Figure 1B. The ω/α ratios were determined 
using the integrals deriving from the a* (α) and b* (ω) fluorine peaks incorporated in the 
polymer. It should be mentioned that due to the presence of initiator derived side-chains 
the ω/α values might be slightly underestimated, however, in general, when high 
[CTA]0:[I]0 ratios are used, the extent of polymer chains lacking α-end group 
functionalities can be neglect.11 The obtained ω/α ratios for the two polymerization 
conditions for the different polymerization times are reported in Table 2. It was found 
that for both conditions, the initial ω/α ratios were close to unity and only slightly 
decrease up to values around 0.86 while increasing the polymerization time. This result 
suggests that only a minor loss of ω-end group might occur during the course of the 
polymerization. 
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Table 2. Determination of ω/α end group ratios via 19F-NMR for the different PFMA 
polymerization times using F-CTA-2, [M]0:[F-CTA-2]0 = 100 and 50 and T = 90 °C. 
[M]0:[F-CTA-2]0 
Time 
(min.) ω/α 
100 
20 0.97 
40 1.07 
60 0.97 
120 0.88 
180 0.89 
240 0.93 
50 
20 0.95 
40 0.9 
60 0.92 
120 0.86 
 
 
2.4. Conclusions 
In this work the use of fluorinated chain transfer agents (F-CTAs) and 19F-NMR 
analysis was proposed as a simple method to prepare α- and α,ω-fluorine labeled PPFMA 
and to monitor PFMA RAFT polymerization.  
First, it was demonstrated that the insertion of a fluorinated label in the R group of the 
CTA-1 (F-CTA-1) had no effect on the PFMA RAFT polymerization therefore proving 
the feasibility of the proposed method. Second, the presence of the fluorinated label on 
the α-PPFMA end group allowed the determination of the experimental polymer 
molecular weights via 19F-NMR studies. The comparison of the experimental molecular 
weights with that determined via SEC analysis allowed the selection of the best 
conditions for SEC analysis of PPFMA. The estimation of F-CTA-1 conversion via 19F-
NMR allowed the determination of the transfer constants and revealed that, due to the 
slow consumption of the CTA, the early stage of the PFMA polymerization proceeds via 
a hybrid conventional free radical-RAFT mechanism. The analysis of different 
polymerization conditions suggested that the polymerization control can be slightly 
enhanced by increasing the temperature of the polymerization. Finally, a second CTA-1 
derivative bearing a fluorinated label on both R and Z groups (F-CTA-2) was used for the 
Chapter 2: Synthesis of α,ω-Fluorine Labeled PPFMA via RAFT Polymerization 
 
82 
 
preparation of α,ω-fluorinated PPFMA. Comparison between ω and α fluorine signals 
via 19F-NMR analysis was used to determine α,ω-end group fidelity. 
The use of fluorinated CTAs to monitor RAFT polymerization via 19F-NMR was found 
an easy, fast and effective approach. This method offers the opportunity to directly 
determine the CTA consumption and therefore the transfer constants during RAFT 
polymerization. Moreover, the design of CTAs containing fluorine in both R and Z 
groups allows to investigate end groups fidelity during RAFT polymerization. As 
demonstrated, this approach is particularly attractive in case of fluorinated polymers since 
it allows the determination of several polymerization parameters via a single 19F-NMR 
measurement. The α-fluorine labeled PPFMA prepared in this Chapter was used in 
Chapter 3 and Chapter 4 as a precursor polymer for the preparation of PHPMA 
polymers. 
 
This work was carried out in collaboration with Prof. Jie Chen (Biological and Medical 
Materials Research Center, Shanghai University) and the PhD student Yuejiao Young 
who contributed with the synthesis of the F-CTA-2. 
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2.6. Supporting Information 
 
Table S1. Theoretical and experimental data for different PFMA polymerization time 
using different [M]0:[CTA]0 ratios. CTA = CTA-1 or F-CTA-1. T= 75°C, solvent 
dioxane, [M]0 = 1.8 M, [CTA]0:[I]0 = 10. 
CTA [M]0:[CTA]0[CTA]0:[I]0 
Time ρa DPTHb MnTHb αc DPd Mnd SECe 
(min.) (%) (-) (g/mol) (%) (-) g/mol DP Mn Mw/Mn (-) (g/mol) (-) 
 200 10 
60 0.08 16 4311 - - - 92 23061 1.52 
120 0.15 30 7839 - - - 99 24982 1.53 
180 0.2 40 10359 - - - 103 25985 1.55 
240 0.26 52 13383 - - - 110 27610 1.55 
300 0.29 58 14895 - - - 118 29739 1.56 
360 0.35 70 17919 - - - 123 31002 1.48 
420 0.39 78 19935 - - - 133 33541 1.45 
540 0.41 82 20943 - - - - - - 
 
200 10 
60 0.06 12 3398 0.15 59 15242 79 19807 1.55 
120 0.15 30 7934 0.31 73 18770 88 22159 1.55 
180 0.21 42 10958 0.35 85 21794 88 22261 1.49 
240 0.26 52 13478 0.42 97 24818 90 22744 1.55 
300 0.31 62 15998 0.48 100 25574 101 25546 1.48 
360 0.35 70 18014 0.52 104 26582 102 25723 1.44 
420 0.4 80 20534 0.54 - - 109 27374 1.44 
540 0.43 86 22046 0.58 112 28598 - - - 
100 10 
60 0.15 15 4154 0.24 62 15998 59 14957 1.41 
120 0.27 27 7178 0.38 70 18014 65 16260 1.41 
180 0.38 38 9950 0.48 79 20282 72 18135 1.34 
240 0.48 48 12470 0.51 91 23306 75 18952 1.39 
300 0.57 57 14738 0.58 96 24566 77 19435 1.38 
360 0.67 67 17258 0.65 102 26078 84 21274 1.36 
50 10 
40 0.11 5 1760 0.19 32 8438 33 8400 1.32 
60 0.19 9 2768 0.24 40 10454 34 8601 1.34 
120 0.35 17 4784 0.37 47 12218 38 9639 1.36 
180 0.47 23 6296 0.43 54 13982 41 10374 1.36 
300 0.72 36 9446 0.56 61 15868 44 11052 1.38 
360 0.80 40 10454 0.61 63 16439 51 12727 1.32 
C
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a 
Monomer conversion determined by 19F-NMR comparing the fluorine monomer and 
polymer peaks. 
b Theoretical number-average molecular weight (MnTH) and degree of polymerization 
(DPTH) at different polymerization time calculated for each monomer conversion. 
c 
CTA conversion determined by 19F-NMR comparing the F-CTA-1 and macroF-CTA-1 
fluorine peaks. 
d 
Number-average molecular weight (Mn) and degree of polymerization (DP) calculated 
from 
19
F-NMR comparing the fluorine peaks of the macroF-CTA-1 and the PFMA 
polymer units. 
e 
Number-average molecular weight (Mn), degree of polymerization (DP) and 
polydispersity (Mw/Mn) determined by SEC in THF using conventional calibration using 
polystyrene (PS) standards. 
 
 
Table S2. PPFMA molecular weights determined by both 19F-NMR and SEC analysis 
using different solvents and standards. Polymerization conditions: CTA = F-CTA-1, 
[M]0:[CTA]0 = 200, T= 75°C, solvent dioxane, [M]0 = 1.8 M and [CTA]0:[I]0 = 10. 
CTA [M]0:[CTA]0 
DPa Mna SEC in THFPS SEC in THFPMMA SEC in DMFPMMA 
(-) (g/mol) DP Mn Mw/Mn DP Mn Mw/Mn DP Mn Mw/Mn (-) (g/mol) (-) (-) (g/mol) (-) (-) (g/mol) (-) 
 200 
59 15242 79 19807 1.55 94 23811 1.47 53 13374 1.4 
73 18770 88 22159 1.55 105 26491 1.47 45 11540 1.16 
85 21794 88 22261 1.49 105 26551 1.42 51 12752 1.22 
97 24818 90 22744 1.55 108 27159 1.47 52 12903 1.21 
100 25574 101 25546 1.48 120 30241 1.41 51 12790 1.20 
104 26582 102 25723 1.44 121 30395 1.38 51 12738 1.21 
- - 109 27374 1.44 128 32221 1.38 - - - 
a 
Number-average molecular weight (Mn) and degree of polymerization (DP) calculated 
from 
19
F-NMR comparing the fluorine peaks of the macroF-CTA-1 and the PFMA 
polymer units.  
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Table S3. Theoretical and experimental data for different PFMA polymerization time 
using different [M]0:[CTA]0 ratios. CTA = F-CTA-1 or F-CTA-2. T= 90°C, solvent 
dioxane, [M]0 = 1.8 M, [CTA]0:[I]0 = 10. 
CTA [M]0:[CTA]0 [CTA]0:[I]0 
Time ρa DPTHb MnTHb αc DPd Mnd SECe 
(min.) (%) (-) (g/mol) (%) (-) g/mol DP Mn Mw/Mn (-) (g/mol) (-) 
 
100 10 
20 0.15 15 4154 0.33 44 11462 46 11546 1.39 
40 0.27 27 7178 0.45 62 15998 47 11812 1.44 
60 0.39 39 10202 0.54 73 18770 53 13402 1.4 
120 0.54 54 13981 0.64 82 21038 56 14111 1.42 
180 0.62 62 15997 0.69 87 22298 59 14990 1.39 
50 10 
20 0.21 10 3020 0.34 33 8690 28 7112 1.3 
40 0.33 16 4532 0.43 39 10202 32 7985 1.3 
60 0.49 24 6548 0.53 44 11462 34 8477 1.32 
120 0.7 35 9194 0.61 54 13982 40 10025 1.3 
 
100 10 
20 0.11 11 3214 0.26 42 11026 55 13747 1.38 
40 0.21 21 5734 0.36 63 16318 56 14148 1.32 
60 0.3 30 8002 0.46 74 19090 62 15739 1.36 
120 0.49 49 12789 0.61 84 21610 70 17580 1.33 
180 0.55 55 14301 0.65 89 22870 73 18325 1.36 
240 0.6 60 15561 0.69 93 23715 75 18915 1.33 
50 10 
20 0.15 7 2332 0.27 30 8002 42 10552 1.24 
40 0.29 14 4096 0.41 38 10018 47 11725 1.3 
60 0.4 20 5482 0.5 46 12034 50 12576 1.24 
120 0.62 31 8254 0.59 59 15310 53 13383 1.25 
a 
Monomer conversion determined by 19F-NMR comparing the fluorine monomer and 
polymer peaks. 
b Theoretical number-average molecular weight (MnTH) and degree of polymerization 
(DPTH) at different polymerization time calculated for each monomer conversion. 
c 
CTA conversion determined by 19F-NMR comparing the F-CTA-1 and macroF-CTA-1 
fluorine peaks. 
d 
Number-average molecular weight (Mn) and degree of polymerization (DP) calculated 
from 
19
F-NMR comparing the fluorine peaks of the macroF-CTA-1 and the PFMA 
polymer units. 
e 
Number-average molecular weight (Mn), degree of polymerization (DP) and 
polydispersity (Mw/Mn) determined by SEC in THF using conventional calibration using 
polystyrene (PS) standards. 
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Figure S5. Double logarithmic plot of F-CTA-1 and F-CTA-2 concentrations vs 
monomer concentration for the polymerization of PFMA at 75 and 90°C for different 
[M]0:[CTA]0 ratios at different polymerization time. Curves are the numerical fitting 
results obtained using Equation (8). 
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3. Reversion of P-gp-Mediated Drug Resistance in 
Ovarian Carcinoma Cells with PHPMA-Zosuquidar 
Conjugates 
 
 
3.1. Introduction 
Chemotherapeutic agents are widely used to combat cancer. The onset of intrinsic or 
acquired multidrug resistance (MDR), however, a phenomenon in which cancer cells 
become resistant to an array of structurally and functionally unrelated chemotherapeutic 
agents, can lead to a poor clinical outcome.1 For instance, over 90% of the metastatic 
cancers do not respond to chemotherapy due to resistance mechanisms and result in 
therapy failure.2 One of the most common mechanisms that can lead to the resistance of 
cancer cells to chemotherapeutics is associated to the presence of membrane transporter 
proteins, which are overexpressed on cancer cells.3-8 P-glycoprotein (P-gp), in particular, 
acts as an efflux pump that decreases the intracellular concentration of the 
chemotherapeutics. Doxorubicin, daunorubicin, vincristine, vinblastine, paclitaxel, 
docetaxel and bisantrene are only a few examples of widely used anticancer drugs that are 
also P-gp substrates.1,3,9 The occurrence of P-gp mediated cross-resistance requires the 
use of higher dosages of these anticancer drugs, which further aggravates the survival rate 
of the patients due to the onset of numerous and intolerable side effects.10  
A number of approaches have been developed to combat P-gp mediated MDR. A first 
strategy is the use of low molecular weight P-gp inhibitors.3 The first two generations of 
these P-gp inhibitors, however, were hampered by relatively low binding affinities and 
selectivities requiring high dosages and resulting in unacceptable in vivo toxicity.3,10,11 
These issues could be partially resolved by a third generation of P-gp inhibitors, which 
were characterized by a higher specificity and affinity towards the P-gp transporter and 
lower toxicity.3 In spite of these refinements, the co-administration of low molecular 
weight P-gp inhibitors and chemotherapeutics still suffers some limitations. First, there is 
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the unpredictable pharmacokinetics of the two unrelated drugs, which may lead to 
different time scales for their accumulation in the target cells.10,12,13 A second problem is 
the lack of selectivity of small molecule drugs towards cancer tissues, which causes an 
undesirable accumulation of these drugs also in healthy cells.11,12, 14 It is important to 
mention that P-gp is not only expressed in cancer cells, but also in healthy tissues where 
this transporter protein plays a central role in the detoxification and protection of the 
organism against xenobiotics.1,3,11 Hence, the incapability of the P-gp inhibitors to 
distinguish between healthy and cancer tissues can enhance the distribution of the 
anticancer drugs in healthy cells and therefore further increase the chemotherapy-
associated side effects.  
A second promising avenue to address MDR exploits concepts from nanomedicine to 
co-deliver chemotherapeutics and P-gp inhibitors. Co-administration of a 
chemotherapeutic and a P-gp inhibitor with a single nanoparticle carrier or in the form of 
a single polymer conjugate offers a number of opportunities. A first consequence of the 
co-delivery of the two active compounds with a single nanoparticle or a single polymer 
carrier is that the pharmacokinetics will be governed by that of the nanoparticle or 
polymer carrier. The use of nanoparticles or polymer carriers also allows to exploit active 
or passive (enhanced permeation and retention (EPR) effect) targeting strategies that can 
enhance delivery to cancer cells and reduce off-target delivery.15 Also on the cellular 
level the use of nanoparticles or polymer conjugates to co-deliver P-gp inhibitors and 
chemotherapeutics offers advantages. Macromolecules and nanoparticles are usually 
internalized by cells via endocytosis.16-18 This process involves the compartmentalization 
of nanoparticles and polymers in the endosomes and lysosomes, which generates a barrier 
that prevents rapid efflux and also allows to release the payload deeper inside the cell and 
in closer proximity of the respective target (and as a consequence more distant from the 
membrane-bound P-gp transporter).19,20 A number of reports describe the use of polymer 
or nanoparticle-based delivery strategies to combat MDR.12,14,19-22 Minko et al. 
investigated the effect of N-(2-hydroxypropyl) methacrylamide (PHPMA) copolymers 
that carried doxorubicin (Dox) attached via the lysosomally cleavable GFLG peptide 
linker on the viability of A2780 sensitive and A2780ADR multidrug resistant human 
ovarian cancer cells.19 These experiments indicated that while the IC50 values from the 
free Dox was 38 times larger on the A2780ADR resistant cells as compared to the 
sensitive cells, the difference between these two IC50 values was only about 20% for the 
polymer-Dox conjugate. The smaller difference in IC50 value between the resistant and 
Chapter 3: Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells 
with PHPMA-Zosuquidar Conjugates 
 
101 
 
 
sensitive cells that was observed for the polymer conjugate was attributed to the 
lysosomal release of Dox in close proximity of the target and distant from the P-gp efflux 
transporter.19 Moreover, chronic exposure of the sensitive cells to the polymer conjugate 
did not induce acquired MDR effect.20 More recently, Subr et al. investigated the 
cytotoxicity of a series of PHPMA conjugates that were modified with a peptide-based P-
gp inhibitor and Dox via a pH-sensitive hydrazone linker.22 Whereas the hydrazone 
linked Dox-PHPMA conjugate did not show any cytotoxicity towards MDR cells, 
copolymers that incorporated both the P-gp inhibitor and Dox as well as co-
administration of Dox- and P-gp inhibitor-conjugates proved effective towards MDR 
cells.  
The findings summarized above indicate that spatiotemporal release of Dox is 
important to evade efflux in MDR cells. This is illustrated by the fact that lysosomal 
release of Dox led to a reduction of its efflux,19 whereas the use of the pH sensitive 
hydrazone linker, which releases Dox earlier in the endocytic pathway in the endosomes, 
did have no effect in reducing P-gp mediated resistance.22 On the other hand, the results 
obtained with the hydrazone linked Dox-PHPMA copolymer also indicate that the pH 
induced release in the early endosomes provides a relatively rapid pathway to the P-gp 
membrane transporter.22 This study attempts to capitalize on these findings and reports 
(dual functional) PHPMA conjugates that allow spatially controlled release of the 
anticancer drug Dox and the third generation P-gp inhibitor zosuquidar (Zos).3,23 The 
PHPMA conjugates presented here are not only able to simultaneously transport Zos and 
Dox into the cancer cells, but also exploit differences in the physicochemical environment 
in the endosomal and lysosomal compartments to release Zos and Dox by cleavage of two 
orthogonal linkers. Zos was attached via a pH sensitive hydrazone linker designed for 
cleavage in the endosomes,24,25 whereas Dox was conjugated via the lysosomally 
degradable GFLG peptide linker.19 The first part of this work investigates the feasibility 
of using PHPMA conjugates bearing a pendant Zos derivative via a hydrazone linker to 
overcome Dox efflux in resistant ovarian cancer cells. The second part describes a dual 
delivery system in which both drugs are conjugated to the PHPMA backbone via 
orthogonal cleavable linkers.  
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3.2. Experimental Section 
3.2.1. Materials 
4-Acetylbenzoic acid, 2,2?-azobis(2-methylpropionitrile) (AIBN), 4,4?-azobis(4-
cyanovaleric acid), 1-amino-2-propanol (HPA), 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid (CTA), cysteamine hydrochloride, N-(3-
dimethylaminopropyl)-N?-ethylcarbodiimide hydrochloride (EDC HCl), N,N?-
dicyclohexylcarbodiimide (DCC), 2,2?-dipyridyl disulphide, 4-(dimethylamino)pyridine 
(DMAP), isobutyl chloroformate, 2,6-lutidine, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (MTT), 6-maleimidocaproic acid, methacryloyl chloride, 
N-methylmorpholine, tert-butyl carbazate and tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) were obtained from Sigma Aldrich. TECP was neutralized prior 
use by treatment with 0.1 N NaOH (until pH 6.5 was achieved) and sebsequently 
lyophilized. The neutralized TCEP was then dissolved in dry methanol, filtered and dried 
under vacuum. Pentafluorophenol was purchased from MatrixScientific, 3,3,3-
Trifluoropropylamine hydrochloride was obtained from Apollo Scientific and 3,3'-
diethyloxacarbocyanine iodide (DiOC2(3)) from Life Technologies.  Fmoc-protected 
amino acids and Fmoc-Gly-Wang resin (100-200 mesh, loading 0.60 mmol/g) were 
obtained from Novabiochem. Ethyl(hydroxyimino)cyanoacetate (OxymaPure) and 2-(6-
chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) 
were purchased from IRIS Biotech. Doxorubicin hydrochloride (Dox) was purchased 
from ShangHai Biochempartner and zosuquidar trihydrochloride (Zos) was obtained from 
NCE Biomedical. Diisopropylethylamine (DIPEA), triisopropylsilane (TIS), piperidine, 
dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP) 
and trifluoroacetic acid (TFA) were obtained from VWR. Dichloromethane (DCM), 
tetrahydrofuran (THF) and diethylether were purchased from Reactolab and methanol 
(MeOH) from Merck. MeOH, DMF and THF were dried using a Pure Solv solvent 
purification system prior use. Triethylamine (Et3N) and 1,4-dioxane were purchased from 
Acros Organics. 1,4-Dioxane was dried under molecular sieves and Et3N was freshly 
distilled prior use. Pentafluorophenyl methacrylate (PFMA) was synthesized as reported 
by Eberhardt et al.26 The synthesis of the fluorinated CTA (F-CTA), 2-(pyridyldithio)-
ethylamine (PDA) and 6-maleimidocaproic acid hydrazide trifluoroacetic salt are 
described in the Supporting Information. 
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3.2.2. Methods 
1H-, 19F- and 13C-NMR spectra were recorded on a Bruker AV-400 instrument at room 
temperature. 1H-NMR spectra of polymer conjugates were performed with a relaxation 
time (d1) of 10 seconds and at least 256 scans using CD3OD, CDCl3 or D2O as solvent. 
Chemical shifts are reported relative to the residual proton signal of the solvent. Size 
exclusion chromatography (SEC) of PPFMA was performed using an Agilent 1260 
infinity system equipped with a refractive index Varian 390-LC detector, two PLgel 5 μm 
Mixed C (Agilent) columns and a PLgel guard column. THF was used as eluent with a 
flow rate of 1 mL/min and the temperature was 40 °C. Samples were analysed using 
conventional calibration with polystyrene (PS) standards ranging from 4910 Da to 549 
KDa. PHPMA conjugates were analysed with a Waters Alliance GPCV 2000 system. The 
eluent was DMF containing 0.01 wt % LiCl at a flow rate of 0.6 mL/min at 60 °C. The 
system was equipped with a refractive index detector and samples were analysed using 
conventional calibration with poly(methyl methacrylate) (PMMA) standards ranging 
from 3670 Da to 520 KDa. The mol % of Dox and 2-(pyridyldithio)-ethylamine (PDA) 
incorporated in the conjugates as well as the pH dependent release of Zos-Ket from the 
conjugates were determined by UV-Vis measurements using a Varian Cary 100 Bio 
spectrometer using quartz cuvettes. Flow cytometry analysis was performed using a BD 
Accuri C6 cytometer (BD Biosciences) equipped with a blue (488 nm) and red (640 nm) 
laser and the data were analysed using FlowJo software.  
 
3.2.3. Procedures 
Synthesis of Zos-Ket (Scheme S4). 300 mg Zos (0.47 mmol) were dissolved in 8 mL 
chloroform and stirred with 3.3 equiv. (218 μL) triethylamine (Et3N) for 15 minutes. The 
organic phase was washed twice with water, dried over MgSO4, filtered and finally dried 
under vacuum to yield zosuquidar free base. Next, 120 mg 4-acetylbenzoic acid (0.73 
mmol), 1.1 equiv. (206.3 mg) DCC and 0.2 equiv. (18 mg) DMAP were dissolved in 7 
mL dry DCM. 215 mg zosuquidar free base (0.41 mmol) were dissolved in 4 mL dry 
DCM and subsequently added to the active ester solution. The reaction was stirred under 
nitrogen at room temperature for 18 h. Following the reaction, the formed N,N'-
dicyclohexylurea was removed by filtration and the crude product was purified by flash 
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chromatography using ethyl acetate/hexane (6.5:3.5) to give the pure Zos-Ket (79 % 
yield). 1H-NMR, 19F-NMR and mass spectra are included in Figure S7-S9.  
 
Synthesis of Zos-Mal (Scheme S5). Zos-Mal was prepared according to a literature 
procedure with some small modifications.25 Briefly, 27 mg Zos-Ket (0.04 mmol) and 3 
equiv. (41 mg) 6-maleimidocaproic acid hydrazide trifluoroacetic acid salt were dissolved 
in 2 mL dry methanol and stirred at room temperature for 1.5 h. The solvent was removed 
under reduced pressure and the residue was purified by preparative TLC using 
chloroform/methanol (10:0.3) as eluent to yield Zos-Mal (60 % yield). 1H-NMR, 19F-
NMR and mass spectra are included in Figure S10-S12. 
 
Synthesis of Fmoc-GFLG-OH. Fmoc-GFLG-OH was synthesized on a CEM Liberty 
automated microwave synthesizer using Fmoc-Gly-Wang resin (0.5 mmol scale) and 
Fmoc chemistry without final Fmoc-deprotection.27 The peptide was purified by reversed 
phase high performance liquid chromatography (RP-HPLC) using a preparative HPLC 
Schimadzu LC-20A Prominence system equipped with a Vydac 218TP column (22 x 150 
mm) that was operated at a flow rate of 20 mL/min. Peptide purification was achieved 
using two mobile phases. Mobile phase A consisted of a 0.05 % (v/v) solution of TFA in 
MilliQ water and mobile phase B consisted of a 0.05 % (v/v) solution of TFA in 
acetonitrile. The peptide was purified using a linear AB gradient from 35 % (v/v) to 55 % 
(v/v) of B over a period of 45 min and subsequently characterized via RP-HPLC-MS 
using a Vydac 218TP column (4.6x150 mm). The 1H-NMR HPLC chromatogram and 
ESI mass spectra of the peptide are shown in Figure S13.  
 
Synthesis of NH2-GFLG-Dox (Scheme S6). The 200 mg Fmoc-GFLG-OH (0.32 
mmol) and 1.2 equiv. Dox (226.3 mg) were dissolved in 8 mL dry DMF. Next, 2 equiv. 
(136 μL) DIPEA were added and the solution was stirred under nitrogen in the dark for 
15 minutes. Then, 1.1 equiv. (162.7 mg) HBTU was dissolved in 1 mL dry DMF and 
subsequently added to the solution. The reaction mixture was stirred under nitrogen in the 
dark for three hours. Following the reaction, DCM was added to the solution and the 
organic phase was washed with 10 % acetic acid in water, passed over MgSO4, filtered 
and dried under vacuum to yield 320 mg Fmoc-GFLG-Dox that was used without further 
purification. Fmoc-deprotection was performed as follows: 100 mg Fmoc-GFLG-Dox 
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(0.086 mmol) were dissolved in 400 μL of 10 % piperidine in DMF and the reaction was 
stirred for 5 minutes at 0 °C. 0.5 mL of 0.5 M formic acid solution in DMF was added 
dropwise until the reaction colour turned from blue to red. Next, the product was 
immediately precipitated in ice-cold diethyl ether. The recovered product was 
resuspended in fresh diethyl ether, centrifuged 2 times and finally purified by RP-HPLC 
using a linear AB gradient from 30 % (v/v) to 45 % (v/v) of B over a period of 30 min 
(yield 86 %). The purity, higher than 99 %, was determined by RP-HPLC-MS. The 
HPLC chromatogram and ESI mass spectra of NH2-GFLG-Dox are shown in Figure 
S14.The 1H-NMR spectrum is reported in Figure S15.  
 
Synthesis of PPFMA-1 and PPFMA-2. Two different PPFMA precursors, PPFMA-1 
and PPFMA-2, were used for the synthesis of the PHPMA conjugates. The synthesis of 
these polymers is outlined in Scheme S7 and described in detail in the Supporting 
Information. Figure S16 shows a 19F-NMR spectrum of PPFMA-2. Detailed 
characteristics of PPFMA-1 and PPFMA-2 are summarized in Table S1. 
 
Synthesis of PHPMA-PDA-1 and PHPMA-PDA-2. PHPMA-PDA-1 was obtained 
via post-polymerization modification of PPFMA-1, whereas PHPMA-PDA-2 was 
prepared from PPFMA-2. For the synthesis of PHPMA-PDA-1, 800 mg PPFMA-1 (3.2 
mmol of PFMA reactive units) were dissolved in 10 mL dry DMF and 0.3 equiv. PDA 
(202.2 mg), 1.7 equiv. (417 μL) 1-amino-2-propanol (HPA) and 2 equiv. (886 μL) Et3N 
were added. For PHPMA-PDA-2, 800 mg PPFMA-2 were dissolved in 10 mL dry DMF 
and 0.4 equiv. PDA (282.9 mg), 1.6 equiv. (392 μL) 1-amino-2-propanol (HPA) and 2 
equiv. (886 μL) Et3N were added. The solutions were stirred under nitrogen at 50 °C for 
20 hours. The products were isolated by three precipitations in ice-cold diethyl ether and 
subsequently dialyzed against water/methanol for 2 days using a SpectraPor (MWCO 3.5 
KDa) membrane and finally lyophilized. The mol % of PDA moieties incorporated in 
PHPMA-PDA-1and PHPMA-PDA-2 were determined by UV-Vis and 1H-NMR 
spectroscopy and are summarized in Table S2. Details on the UV-Vis protocol are 
provided in the Supporting Information together with the UV-Vis and 1H-NMR spectra 
(Figure S17-S20). 
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Synthesis of PHPMA-Dox-PDA. The polymer intermediate containing PDA and Dox 
was prepared via post-polymerization modification of PPFMA-2. To this purpose, 60 mg 
PPFMA-2 (0.24 mmol of PFMA units) were dissolved in 3 mL dry DMF together with 
0.15 equiv. (32.8 mg) NH2-GFLG-Dox and 0.2 equiv. (7 μL) Et3N. The solution was 
stirred under nitrogen at 40 °C for 24 hours in the dark. After 24 hours, 1 mL DMF 
solution containing 0.1 equiv. (5.3 mg) PDA, 1.9 equiv. (35 μL) HPA and 2 equiv. (66 
μL) Et3N was added and the reaction was stirred for an additional 20 hours at 40 °C. The 
product was precipitated three times in ice-cold diethyl ether, dialyzed against 
water/methanol for 2 days using a SpectraPor (MWCO 3.5 KDa) membrane and finally 
lyophilized. The mol % of PDA and Dox moieties incorporated in the conjugates were 
determined by UV-Vis and NMR spectroscopy and are indicated in Table S2. The UV-
Vis procedure is provided in the Supporting Information together with the corresponding 
UV-Vis spectra (Figure S18).The 1H-NMR spectra of the PHPMA-Dox-PDA copolymer 
is included in Figure S21.  
 
Synthesis of PHPMA-Dox conjugate. 100 mg of PPFMA-2 (0.4 mmol of PFMA 
units), 0.2 equiv. (72 mg) NH2-GFLG-Dox and 0.2 equiv. (11 μL) Et3N were dissolved in 
4 mL dry DMF and stirred in the dark at 50 °C for 20 hours under nitrogen. After 24 h, 1 
mL DMF solution containing 2 equiv. (60 μL) HPA and 2 equiv. (110 μL) Et3N was 
added and the reaction was stirred at 50 °C for an additional 20 hours. Following three 
precipitations from ice-cold diethyl ether the product was dialyzed against 
water/methanol for 2 days using a SpectraPor (MWCO 3500 g/mol) membrane and 
finally lyophilized. The Dox content in the polymer conjugate was determined by UV-Vis 
and 1H-NMR spectroscopy. The corresponding 1H-NMR and UV-Vis spectra are 
included in Figure S18 and Figure S22 and the Dox content is listed in Table S2.  
 
Synthesis of PHPMA-Zos-1 and -2 and PHPMA-Dox-Zos conjugates. PHPMA-
Zos-1 and -2 and PHPMA-Dox-Zos conjugates were prepared by reacting the 
corresponding precursors (PHPMA-PDA-1, -2 and PHPMA-Dox-PDA) with an excess of 
Zos-Mal. A general procedure is as follows: 30 mg polymer intermediates were dissolved 
in 4 mL dry methanol together with 3 equiv. of freshly prepared Zos-Mal (with respect to 
the PDA). After that, 3 equiv. of neutralized TCEP were added dropwise and the solution 
stirred under nitrogen at room temperature overnight. The products were recovered by 
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three precipitations from ice-cold diethyl ether and dialyzed with a SpectraPor dialysis 
membrane (MWCO 3.5 KDa) against PBS for 5 h and against water/methanol overnight 
and finally lyophilized. The Zos contents of the polymer conjugates were determined by 
NMR spectroscopy and are listed in Table S2. 1H-NMR spectra of PHPMA-Zos-1, 
PHPMA-Zos-2 and PHPMA-Dox-Zos as well as a 19F-NMR spectra of PHPMA-Zos-2 
and PHPMA-Dox-Zos are included in Figure S23-S27. 
 
pH triggered release of Zos-Ket from the PHPMA-Zos-1 conjugate. Zos-Ket 
release from PHPMA-Zos-1 was determined with a dialysis experiment by incubating the 
polymer conjugate in 0.1 M phosphate citrate buffer at pH 7.4 and 5.5 at 37 °C. Briefly, 
2.7 mg of polymer were dissolved in 200 μL of each buffer solution and placed in 
SpectraPor micro dialysis cassettes with a molecular weight cut-off of 3.5 KDa. The 
samples were dialyzed against 2 mL of the same buffer solution. 30 % ethanol was added 
to all the buffers in order to assure the complete dissolution of the cleaved Zos-Ket at the 
tested concentrations. Over a period of 40 hours at different time intervals, 300 μL 
aliquots were taken and replaced with an equivalent buffer amount. The aliquots taken 
from the dialysis cassettes were diluted to 600 μL and the Zos-Ket content determined by 
UV-Vis spectroscopy by measuring the absorbance at λ = 240 nm using cuvettes with a 
optical path of 0.1 cm. The Zos-Ket concentration was calculated using the molar 
extinction coefficients ε = 26768 M-1 cm-1 and  ε = 25313 M-1 cm-1 (λ = 240 nm) in the 
buffer solutions at pH 7.4 and 5.5, respectively. The corresponding calibration curves are 
shown in Figure S28.  
 
Cell lines and cell cultures. The human ovarian carcinoma sensitive A2780 and 
resistant A2780ADR cell lines were kindly provided by Prof. S. O. Kelley, University of 
Toronto. Cells were cultured in RPMI 1640 glutamax (Lifetech) medium supplemented 
with 10 % fetal bovine serum (FBS) (Gibco) and 1% penicillin/streptomycin (Lifetech). 
A2780ADR cells were grown in media containing 200 nM doxorubicin in order to 
maintain the MDR-phenotype, 24 h before each experiment the medium was exchanged 
with fresh doxorubicin-free culture medium. Both cell lines were maintained in a 
humidified atmosphere containing 5 % (v/v) CO2 at 37 °C. 
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Cytotoxicity assay. Cytotoxicities were assessed using the MTT assay. To this end, 
100 ?L cell suspension, corresponding to 5000 A2780ADR and 2500 A2780 cells, were 
added to a 96-well flat bottom plate and subsequently pre-incubated for 24 h in complete 
growing medium. Then, 100 ?L of a solution containing the compounds to be evaluated 
was added and the plates were incubated for another 72 h. Subsequently, the medium was 
aspirated and 110 ?L of MTT solution (0.5 mg/mL) in medium without phenol red was 
added to each well and the plates incubated for an additional 3 h. After that, the medium 
was removed and 100 ?L DMSO was added to each well to dissolve the purple formazan 
crystals formed by the mitochondrial dehydrogenase activity of viable cells. Plates were 
incubated at 37 °C for 15 minutes and the optical density was quantified 
spectroscopically using a TECAN infinite 200 PRO plate reader. The optical density, 
directly proportional to the number of viable cells, was quantified at 570 nm using a 
reference filter at 690 nm. The absorbance of wells without cells was used as background 
and cell viabilities were calculated as a percentage relative to untreated cells. All the 
results are means from at least two independent experiments, each comprising triplicates 
per drug concentration. IC50 values (concentration of drug necessary to inhibit 50 % of the 
cells growth) and standard errors were calculated using a sigmoidal dose-response curve 
fitting. 
 
3,3'-Diethyloxacarbocyanine iodide (DiOC2(3)) efflux assay. Cells were trypsinized 
and resuspended in RPMI 1640 medium without antibiotics at a density of 1 × 106 
cells/mL and transferred into different tubes. Cells were then incubated with varying 
concentrations of the appropriate P-gp inhibitor (Zos, Zos-Ket) or Zos-polymer conjugate 
(PHPMA-Zos-1, PHPMA-Zos-2) as well as with 20 μM of the positive control 
cyclosporine A (CsA) for 3 h at 37 °C. After 20 minutes exposure to 1 μg/mL DiOC2(3) 
solution in ice, cells were washed and incubated at 37 °C with and without the tested 
compounds for an additional 90 minutes. Cells were washed twice with fresh medium, 
suspended in 500 μL of ice-cold medium and analysed by flow cytometry using the FL 1 
channel for DiOC2(3) detection. Each experiment was repeated at least twice and results 
are reported as relative fluorescence which represents the ratio between the geometric 
mean fluorescence of each sample and the positive control CsA.  
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Doxorubicin efflux assay. Cells were trypsinized and resuspended in RPMI 1640 
medium without antibiotics at a density of 1 × 106 cells/mL and transferred into different 
tubes. Cells were then incubated with RPMI 1640 medium without antibiotics containing 
10 μM of free doxorubicin or doxorubicin-polymer conjugate either alone or in 
combination with 20 μM of CsA for 4 h at 37 °C. Cells were washed twice with fresh 
medium, suspended in 500 μL of ice-cold medium and analysed by flow cytometry (Dox 
was detected in the FL 2 channel). Each experiment was repeated at least twice and 
results are reported as relative fluorescence that represents the ratio between the 
geometric mean fluorescence of each sample and the samples containing the same tested 
compounds and CsA. 
 
 
3.3. Results and Discussion 
3.3.1. PHPMA conjugate design and synthesis 
The structure and synthesis of the PHPMA conjugates investigated in this study are 
shown in Scheme 1. In addition to the dual function PHPMA conjugate that was designed 
to co-deliver Dox and Zos (PHPMA-Dox-Zos) also monofunctional conjugates, which 
present either Zos (PHPMA-Zos-1 and -2) or Dox (PHPMA-Dox) were prepared. Zos 
was attached via a pH-sensitive hydrazone linker in order to allow release in the early 
stage of the endocytic process and maximize the cytosolic concentration of Zos in 
proximity of the P-gp transporter. Dox, in contrast, was conjugated to the PHPMA 
backbone via the lysosomally cleavable GFLG peptide linker.19,28 This was done to 
enhance release of Dox in close proximity of the nucleus, which was previously 
demonstrated to mitigate the effect of P-gp-mediated Dox efflux.19 
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Table 1. Composition of the PHPMA conjugates investigated in this study. 
Conjugates 
Zos content 
(mol %) 
Dox content 
(mol %) 
1H-NMRa 19F-NMRb 1H-NMRc UVd 
PHPMA-Zos-1 2.2 - - - 
PHPMA-Zos-2 4.3 4.6 - - 
PHPMA-Dox - - 2.4 2.5 
PHPMA-Dox-Zos 0.2 0.4 2.9 2.9 
a Determined comparing the integrals of Zos signals with those of the polymer backbone 
and with the CH proton of the hydroxypropyl polymer side chains. 
b Determined comparing the integrals of fluorine signals of Zos with those of the polymer 
end group and taking into account the degree of polymerization (DP). 
c Determined comparing the integrals of the Dox signals with those of the polymer 
backbone and with the CH proton of the hydroxypropyl polymer side chains.  
d Calculated from the absorbance peak at λ = 490 nm in DMSO (ε = 12049.6 cm-1 M-1). 
 
3.3.2. pH Triggered release of Zos-Ket from the PHPMA-Zos-1 conjugate  
To verify that the incorporation of the hydrazone linker can facilitate pH triggered 
release of Zos, the PHPMA-Zos-1 was placed in microdialysis cassettes both at pH 5.5 
and 7.4 (physiological pH) and Zos release was measured spectrophotometrically. The 
results of these experiments are shown in Figure 1 and confirm that the release of Zos at 
pH 5.5 is significantly enhanced as compared to pH 7.4. It is important to note here that 
pH-induced cleavage of the hydrazone linker does not result in release of Zos but rather 
of Zos-Ket. At pH 5.5 release of Zos-Ket was found to level off at around 80 %. The 
incomplete hydrolysis of hydrazone-based polymer conjugates in model experiments has 
been previously reported.30 This behaviour was attributed to the reversible nature of the 
hydrazone bond and to the closed system used to investigate the release profile, which 
can results in the establishment of an equilibrium reaction between free drug and 
polymer-bound drug.  
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A2780ADR cells was investigated by flow cytometry experiments. For these 
experiments, 20 μM cyclosporine A (CsA), which is known to completely inhibit P-gp, 
was used as a positive control.31 Examples of flow cytometry experiments with Zos and 
Zos-Ket are presented in Supporting Information in Figure S29. Figure 2B presents the 
DiOC2(3) efflux inhibitory properties of Zos and Zos-Ket over a concentration range of 
0.1-5 μM relative to that of CsA. The results show that while 1 μM Zos led to the 
complete inhibition of DiOC(3) efflux, 5 μM Zos-Ket were necessary to achieve 78 % 
dye retention. On the other hand, more than 98 % DiOC2(3) was effluxed in the absence 
of an inhibitor. This indicates that chemical modification of Zos with 4-acetylbenzoic 
acid partially decreases its activity, however, at low micromolar concentrations the 
modified drug still retained the ability to inhibit 78 % DiOC2(3) efflux.  
In a next series of experiments, the ability of Zos and Zos-Ket to increase Dox 
cytotoxicity in resistant cells was examined by the MTT assay. Sensitive and resistant 
cells were treated with Dox concentrations ranging from 0.1 nm to 20 μM either alone or 
in combination with different concentrations of Zos and Zos-Ket. The results of these 
experiments are summarized in Figure 2C and Figure 2D. While resistant cells showed 
an expected high resistance to doxorubicin with an IC50 value of 1.441 μM, the IC50 of the 
sensitive cells was 0.013 μM. Figure 2C shows that co-administration of Dox and Zos-
Ket to resistant cells resulted in a shift of the Dox cytotoxicity curve to lower 
concentrations in a Zos-Ket-dose dependent manner. Qualitatively similar results were 
obtained when resistant cells were treated with a combination of Dox and Zos (Figure 
S30A). Table 2 compares the Dox cytotoxicity toward both cell types at various Zos and 
Zos-Ket concentrations. The results in Table 2 indicate that at equal concentrations, Zos 
is more effective as compared to Zos-Ket in preventing efflux. For instance, when 1 μM 
Zos and Zos-Ket were co-administered with Dox, the IC50 values decreased to 0.048 and 
0.068 μM, respectively, and approached the value observed for sensitive cells (0.013 
μM). These IC50 values suggest that at a concentration of 1 μM both inhibitors can 
sensitize resistant ovarian cancer cells to doxorubicin, but also indicate that the 
modification led to a slight decrease in activity, especially at low concentrations as 
evident from the higher IC50 values for Zos-Ket as compared to Zos at equal 
concentration. These results are in agreement with the efflux inhibitory experiments 
summarized in Figure 2B, which also indicate that Zos-Ket at identical concentration is 
less active as compared to Zos. Finally, as expected, the Dox IC50 values measured on the 
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sensitive A2780 cells were not affected by co-administration of Zos or Zos-Ket (Figure 
2D and Figure S30B).  
 
Table 2. Cytotoxicity of doxorubicin alone and in combination with Zos, Zos-Ket and the 
PHPMA-Zos conjugates PHPMA-Zos-1 and PHPMA-Zos-2 in sensitive A2780 and 
resistant A2780ADR cells as determined by MTT assay. 
Compound [P-gp inhibitor] (μM) 
Dox IC
50 
(μM) 
A2780 A2780ADR 
Dox - 0.013 ± 0.003 1.441 ± 0.361 
Zos 
0.01 0.022 ± 0.006 0.198 ± 0.078 
0.1 0.032 ± 0.002 0.051 ± 0.014 
1 0.017 ± 0.002 0.048 ± 0.006 
Zos-Ket 
0.01 0.020 ± 0.006 1.441 ± 0.361  
0.1 0.010 ± 0.004 0.341 ± 0.071 
1 0.011 ± 0.004 0.068 ± 0.006 
PHPMA-Zos-1 
0.01 0.008 ± 0.001 0.174 ± 0.010 
0.1 0.006 ± 0.004 0.053 ± 0.017 
1 0.007 ± 0.003 0.018 ± 0.007 
PHPMA-Zos-2 
0.01 0.012 ± 0.002 1.098 ± 0.194 
0.1 0.011 ± 0.007 0.069 ± 0.025 
1 0.013 ± 0.003 0.053 ± 0.015 
 
3.3.4. Cytotoxicity and P-gp inhibitory activity of PHPMA-Zos conjugates  
In a next series of experiments, the cytotoxicity and P-gp inhibitory activity of 
PHPMA-Zos conjugates PHPMA-Zos-1 and PHPMA-Zos-2, which contain 2.2 and 4.5 
mol % Zos, respectively, were investigated. The results of the MTT assay experiments 
that were done to assess the cytotoxicity are summarized in Figure 3A. The data in this 
figure show that both polymers were nontoxic towards both cell lines within the 
concentration range investigated. In contrast, at a concentration of 10  μM both Zos and 
Zos-Ket resulted in a significant reduced viability of A2780 cells (Figure 2A).  
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incubation was investigated by flow cytometry. Figure S29C and D shows examples of 
flow cytometry results which were obtained with PHPMA-Zos-1 and PHPMA-Zos-2. 
From these flow cytometry experiments, the P-gp inhibitory activity of the polymer 
conjugates was related and expressed as a percentage relative to the CsA positive control. 
Figure 3B, which summarizes the results obtained from duplicate experiments, clearly 
shows that incubation of the cells with 5 μM of polymer-bound drug led to complete 
inhibition of DiOC2(3) efflux. In contrast, it was shown in the previous section that the 
same concentration of free Zos-Ket resulted only in 78 % dye retention. Moreover, 
Figure 3B also shows  that the activity of PHPMA-Zos-2 is slightly lower than that of 
PHPMA-Zos-1 at 0.1 and 1 μM polymer-bound Zos-Ket. The enhanced P-gp inhibitory 
activity of PHPMA-Zos-1 as compared to free Zos-Ket at equal Zos-concentrations may 
be interpreted in terms of the enhanced internalization of the polymer-bound drug. In a 
next series of experiments A2780ADR cells were exposed to the polymer-Zos conjugates 
at three concentrations and Dox IC50 values were determined using the MTT assay. The 
results of these experiments are summarized in Figure3C and D and in Table 2. Similar 
to what has been observed for free Zos-Ket, the IC50 values of the resistant cells reached a 
minimum when 1 μM of polymer-bound Zos-Ket was co-administered with Dox. 
However, it is worth mentioning that at lower concentrations, the IC50 values of the 
polymer-bound Zos-Ket were significantly lower than those previously found for free 
Zos-Ket and were almost in the same range as those found for Zos. For instance, 0.1 μM 
of Zos-Ket delivered as PHPMA-Zos-1 and PHPMA-Zos-2 decreased the Dox IC50 to 
0.053 and 0.069 μM, respectively, whereas these values were 0.051 μM for free Zos and 
0.341 μM for Zos-Ket. Moreover, similar to what was observed when free drugs were 
used, the co-administration of both polymers and Dox did not show any effect on the 
sensitive A2780 cells (Figure S30C and D). 
 
3.3.5. Efflux inhibition and cytotoxicity of PHPMA-Dox conjugates 
In a final set of experiments, the efflux inhibition properties and cytotoxicity of the 
different polymer-bound Dox conjugates were evaluated. To this end, first the intrinsic 
cytotoxicity of PHPMA-Dox was determined and the accumulation of Dox in the 
A2780ADR cells when administered using the different polymer conjugates compared, 
before assessing the cytostatic activity of PHPMA-Dox-Zos conjugate. To determine the 
cytotoxicity of the PHPMA-Dox conjugate, cells were incubated with a range of 
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concentrations of PHPMA-Dox and their viability was determined by MTT assay. Figure 
S31 illustrates the cytotoxicity curves of PHPMA-Dox as well as free Dox in both 
sensitive and resistant cells and the calculated IC50 values are listed in Table S3. While 
the IC50 of free Dox in resistant cells was 1.441 μM, the IC50 of the sensitive cells was 
0.013 μM. The concentration of PHPMA-Dox necessary to lower the cell viability to 
values around 50 % was much higher for both cell lines (around 20 μM for sensitive and 
100 μM for resistant cells). The IC50 values for free Dox indicate a resistance ratio of 111, 
whereas a value around 5 is estimated when doxorubicin is delivered as PHPMA-Dox. 
These results are in agreement with previously published data19 and suggest that, while 
the IC50 values of the polymer conjugate are increased as compared to the free Dox, the 
resistance ratio is significantly decreased. 
Second, Dox accumulation in A2780ADR cells when administered as free drug or 
delivered as PHPMA-Dox (2.4 mol % of Dox) or PHPMA-Dox-Zos (2.9 mol % of Dox 
and 0.2 mol % of Zos) conjugates was investigated by flow cytometry experiments. Cells 
were incubated with 10 μM Dox or polymer-bound Dox, either alone or in combination 
with 20 μM of the positive control CsA for 4 h. In the case of PHPMA-Dox-Zos, the 
calculated concentration of polymer-bound Zos-Ket is 0.7 μM. CsA was used to 
determine the maximum Dox accumulation in each experiment, allowing for the direct 
comparison of the results while neglecting eventual different cellular internalization rates 
of the tested compounds. Flow cytometry data from these experiments are shown in 
Figure S32 and the Dox retention, expressed as a percentage relative to the Csa positive 
control cells, are presented in Figure 4A. The results in Figure 4A show that Dox 
retention was lowest when cells were treated with free Dox. At a Dox concentration of 10 
μM treating A2780 ADR cells with PHPMA-Dox or PHPMA-Dox-Zos resulted in a 8 
and 10 fold higher accumulation of Dox, respectively, as compared to the use of free 
Dox. These results confirm that (i) the administration of polymer-bound Dox decreases 
drug efflux from resistant cells and (ii) dual delivery of Dox and Zos using a single 
polymer conjugate even further reduces drug efflux by inhibiting the P-gp transporter.  
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IC50 value for the PHPMA-Dox-Zos conjugate. Cell incubation with increasing amount of 
polymer-bound Dox, would also cause cell exposure to increasing concentrations of the 
polymer-bound P-gp inhibitor. Hence, for this particular experiment, the cell viability was 
determined at a selected Dox concentration. Based on the mol % of functionalization of 
the polymer carrier with the two drugs, the concentration of Zos was calculated. The 
selected Dox concentration in each experiment was 20 μM, which is close to the IC50 of 
PHPMA-Dox in sensitive cells and do not significantly affect the viability of the resistant 
cells. Since the ratio between the concentration of Dox and the concentration of the 
inhibitor was 14.5 in the PHPMA-Dox-Zos conjugate, in all the experiments the 
concentration of polymer-bound inhibitor was 1.4 μM. Figure 4B illustrates that the 
treatment of sensitive cells with the PHPMA-Dox conjugate, either alone or in 
combination with 2 μM of the inhibitors (Zos, Zos-Ket and PHPMA-Zos-1), led to an 
approximate cell viability of 50 % (Experiments using PHPMA-Dox in combination with 
1 μM inhibitors led to comparable results, data not shown). On the other hand, while the 
viability of the resistant cells in the presence of PHPMA-Dox was 83 %, the co-
administration of the this conjugate with the inhibitors led to cell viabilities comparable to 
that of sensitive cells. Finally, treatment of the resistant cells with the dual functional 
PHPMA-Dox-Zos conjugate also resulted in a cell viability of ~50% similar to what was 
obtained for the co-administration of PHPMA-Dox with Zos, Zos-Ket or PHPMA-Zos-1. 
While in vitro co-administration of PHPMA-Dox with a polymer-bound P-gp inhibitor is 
equal effective in mitigating the effect of drug efflux on the viability of A2780ADR cells 
as using the dual functional PHPMA-Dox-Zos conjugate, the use of a combination 
polymer therapeutic offer a number of advantages in vivo. Most important, the use of a 
single polymer carrier allows to overcome challenges that are due to difference in the 
pharmacokinetics of the two low molar mass drugs, since the pharmacokinetic of the 
conjugate is dictated and can be controlled by engineering the polymer conjugate. 
Another benefit of the use of a dual functional conjugate such as PHPMA-Dox-Zos is that 
it allows to administer and intracellularly deliver the chemotherapeutic and the P-gp 
inhibitor at a precisely defined and controlled ratio.32 
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3.4. Conclusions 
This Chapter has described the design and in vitro activity studies of a dual-functional 
PHPMA conjugate that allows spatially controlled release of the anticancer drug Dox and 
the third generation P-gp inhibitor Zos by using two orthogonal cleavable linkers. The 
first part of this work investigated the feasibility of using PHPMA conjugates bearing a 
Zos derivative via a hydrazone linker as an effective polymeric system to overcome Dox 
efflux in resistant ovarian cancer cells. The P-gp inhibitor Zos was modified to Zos-Ket 
and subsequently attached to the PHPMA backbone via a hydrazone linker. In vitro 
activity studies using both resistant A2780ADR and sensitive A2780 ovarian carcinoma 
cells revealed that the modification of Zos did not significantly hinder its activity at the 
highest concentration of interest and resulted with any additional cytotoxicity. Two 
different PHPMA-Zos conjugates containing 2.2 (PHPMA-Zos-1) and 4.3 (PHPMA-Zos-
2) mol % of Zos-Ket, respectively, were successfully prepared. First, both conjugates 
showed a reduced intrinsic cytotoxicity in sensitive cells compared to free inhibitors. 
Second, it was found that the polymer-mediated delivery of Zos-Ket enhanced its activity 
and therefore increased Dox cytotoxicity in resistant ovarian carcinoma cells. The second 
part of this work investigated the design of the dual delivery system in which both drugs 
were conjugated to the PHPMA backbone via orthogonal cleavable linkers. Two different 
conjugates containing either the anticancer drug Dox alone (PHPMA-Dox) or in 
combination with Zos (PHPMA-Dox-Zos) were prepared and their activity was compared 
with in vitro studies. The ability of the control PHPMA-Dox conjugate to partially 
overcome MDR effect in the resistant A2780ADR cells was confirmed. Finally, it was 
demonstrated that the presence of the two drugs attached to the polymer backbone via 
orthogonal cleavable linkers enhanced P-gp inhibition as compared to the PHPMA-Dox 
conjugate and led to a doxorubicin cytotoxicity comparable to that of the sensitive A2780 
cells. This result is of great interest for in vivo applications, in which the use of a single 
polymer carrier for the delivery of drug combinations allow simultaneous intracellular 
accumulation of the two drugs in a predetermined therapeutic ratio. 
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4. Monitoring Uptake and Intracellular Trafficking of 
Poly(N-(2-hydroxypropyl) methacrylamide) (PHPMA) 
 
 
4.1. Introduction 
Polymer nanomedicine is a very attractive approach for the delivery of small molecule 
therapeutics in particular for the treatment of cancer.1 The use of polymer conjugates and 
polymer nanocarriers can help to increase plasma half-life and drug bioavailability,1,2 
while also allowing passive tumor targeting by the enhanced permeation and retention 
(EPR) effect.2,3  
Although enhanced drug bioavailability and efficient tumor targeting are important to 
maximize the efficacy of anticancer drugs and reduce side effects, the location of drug 
targets in specific well-defined subcellular compartments, makes intracellular transport of 
polymer nanomedicine a critical step for a successful treatment outcome. After 
extravasation in the cancer tissue, polymers gain access to the cell interior via 
endocytosis.4,5 This process starts with the engulfment of the cargo in the cell membrane 
and results in the formation of intracellular vesicles called early endosomes, which are 
characterized by slightly acidic pH. The internalized material is then shuttled from the 
early endosomes to the higher acidic late endosomes, before being finally sorted to the 
cell lysosomes, where the enzymatic digestion takes place.6 The physiochemical and 
biochemical parameters that characterize the endolysosomal compartments have been 
explored to trigger drug release from the polymer carrier.5,7 In particular, the highly acidic 
lysosomal environment and the presence of degradative enzymes have been exploited to 
trigger intracellular drug release.7 
Poly(N-(2-hydroxypropyl) methacrylamide) (PHPMA)-based carriers, first developed 
by Kope?ek and Duncan in the 1970s, have been extensively used for the preparation of 
polymer conjugates for the endolysosomal release of anticancer drugs.8-10 HPMA-
doxorubicin, HPMA-camptothecin, HPMA-paclitaxel and HPMA-platinates conjugates 
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are some examples of HPMA polymer conjugates that have entered clinical trials for 
therapeutic validation in the last decade.8,11  
The interest in exploring PHPMA-based conjugates as chemotherapeutics has also 
triggered a need to study and understand the internalization and intracellular trafficking of 
these nanomedicines. Based on to the availability of a wide range of chemical 
functionalities for polymer labeling and to the use of intrinsic fluorescent drugs, 
fluorescence based techniques have been most frequently used to monitor PHPMA 
internalization and intracellular trafficking.5,11 While early attempts to investigate time-
dependent PHPMA cellular uptake consisted in the quantification of intracellular 
fluorescent dyes (PHPMA-dye conjugates)12 or intrinsic fluorescent drugs (PHPMA-drug 
conjugates)13 via fluorescence spectroscopy, or via radioassay, in the case of I125 modified 
drugs,13 nowadays flow cytometry is the most utilized method to monitor the cellular 
uptake of PHPMA. Time and concentration-dependent uptake have been evaluated by 
detecting the internalized PHPMA-drug conjugates, in case of fluorescent drugs,14,15 or 
PHPMA-dye conjugates.16-18 Whereas flow cytometry is sufficient to give information 
about cellular uptake, the most used approach to study intracellular trafficking of PHPMA 
in the endosomal pathway is confocal fluorescence microscopy. Initially, these 
approaches were based on the subcellular localization of fluorescent drugs. For instance, 
6 hours exposure of cells to a PHPMA-mesochlorin e6 (Mce6) conjugate resulted in 
polymer accumulation in the lysosomes.19 A similar approach was used to monitor the 
cleavage of a lysosomal sensitive linker (GFLG) and consequent doxorubicin (Dox) 
release from PHPMA conjugates.13 Duncan and co-workers combined subcellular 
fractionation techniques with confocal microscopy to determine Dox release from a 
PHPMA-GFLG-Dox conjugate.14 5 hours incubation of cells with the polymer conjugate 
resulted in both punctuate cytoplasmic doxorubicin fluorescence and disperse signal, 
which was attributed to doxorubicin release from the carrier. While these studies 
confirmed polymer accumulation in the lysosomes and in some cases drug release by 
action of lysosomal enzymes after long incubation time, investigation of carrier 
trafficking in the endolysosomal pathway is also important for further improvement of 
such delivery systems. Jensen et al. monitored time-dependent PHPMA intracellular 
trafficking by using PHPMA-dye conjugates, however, in this study they did not use 
endosomal and lysosomal fluorescent markers which allow co-localization studies with 
the endocytic vesicles.12 Other reports mainly focused on studying the effect of antibody 
conjugation or insertion of charged and hydrophobic moieties on the cellular 
Chapter 4: Monitoring Uptake and Intracellular Trafficking of Poly(N-(2-hydroxypropyl) 
methacrylamide) (PHPMA) 
 
159 
 
 
internalization and accumulation in the late endosomal vesicles of PHPMA 
copolymers.17,18 Although these studies have given valuable insight into the early 
endocytic trafficking of different PHPMA conjugates, the investigation of the complete 
time-frame of the endocytic process, from early endosomal PHPMA uptake to lysosome 
loading, would allow an estimation of time-dependent exposure of the polymer to the 
different endolysosomal environments.  
Although detailed co-localization experiments and careful data interpretations can be 
used for these purposes, it has often been argued that the modification of polymer carriers 
with fluorescent dyes can lead to several drawbacks. First, exposure of the polymer-dye 
conjugates to the highly degradative cellular environments can result in the cleavage of 
the fluorescent dye from the polymer carrier.20-22 Second, the fluorescent label can 
interfere with biological processes23 and finally, concentration- or pH-dependent dye 
quenching, might lead to additional artifacts.5,20 Additional challenges arise when this 
approach is used to monitor, not only polymer intracellular trafficking, but also polymer-
mediated drug delivery. In this case, both polymer and drug need to be tracked at the 
subcellular level. To this end, unless an intrinsic fluorescent drug is used, the drug need to 
be substituted with a fluorescent dye, therefore further differentiating the system from the 
designed one. Fluorescent carrier and drug need to be monitored simultaneously and co-
localization studies with several stained organelles can result in very complicated assays. 
Moreover, reported co-localization studies generally lack quantitative information.5,22 
Therefore, the establishment of label-free techniques that can be used in combination with 
fluorescence-based approaches and that allow both qualitative and quantitative studies are 
desirable for a deeper understanding of the polymer-cell interaction and for further 
monitoring intracellular drug delivery processes. Nanoscale Secondary Ion Mass 
Spectrometry (NanoSIMS) is particularly attractive technique since it allows high spatial 
resolution (down to 50 nm) and it offers the possibility to obtain quantitative information 
while also excluding the need for bulky labels.24 NanoSIMS allows the semi-quantitative 
analysis of multi-elements and isotopes by sample erosion via a focused ion primary 
beam.24 Recently, Proetto et al. combined NanoSIMS with fluorescence microscopy to 
image intracellular platinum-based anticancer drugs linked to a 15N-labeled fluorescent 
polymer carrier.25 While fluorescence microscopy allowed subcellular carrier co-
localization with endocytic vesicles, NanoSIMS analysis was used to simultaneously 
quantify and compare both internalized carrier and drug. Implementation of this 
technique in the field of polymer nanomedicines would offer the possibility to use 
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isotopes or elements rather than bulky labels, as well as to quantify polymer-mediated 
delivery processes. 
The first aim of this work is to use fluorescence-based techniques to study PHPMA 
cellular uptake and to investigate endolysosomal trafficking by determining correlation 
coefficients with both endosomal and lysosomal vesicles. Additional, the rest of this 
Chapter demonstrates how NanoSIMS can be used to monitor polymer subcellular 
localization. PHPMA was prepared from a PPFMA polymer precursor which was 
obtained via reversible-addition fragmentation chain transfer (RAFT) polymerization. In 
this study, the chain transfer agent (CTA) was used to introduce both a fluorescent label 
and a fluorinated one at both ω- and α-polymer end groups, these labels enabled polymer 
detection via fluorescence-based techniques and NanoSIMS, respectively. The first part 
of this work investigates the cellular uptake of PHPMA using flow cytometry analysis 
and correlates the obtained results with cell division occurring during the time-frame of 
the experiment. The second part investigates the intracellular trafficking of the polymer 
by co-localization studies with both early endosomal and lysosomal vesicles via confocal 
fluorescence microscopy. Imaging of several cells per each incubation time, experiment 
repetitions and calculation of correlation coefficients, was accomplished to determine the 
PHPMA dynamic profile in the endosomal pathway. Finally, the last part of this work 
investigates the possibility to use NanoSIMS analysis and transmission electron 
microscopy (TEM) for co-localization studies of the internalized polymer. While 
NanoSIMS was used to map the fluorine-containing PHPMA in cells, the combination 
with TEM enabled the visualization of intracellular vesicles and compartments for 
polymer subcellular localization. Detailed co-localization studies with endocytic vesicles 
via fluorescence microscopy and the implementation of novel techniques such as 
NanoSIMS combined with TEM are particularly relevant in the field of polymer 
nanomedicines since they can allow a fully characterization of intracellular drug delivery 
processes.  
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4.2. Experimental Section 
 
4.2.1. Materials 
Annexin V-Alexa Fluor 647 conjugate, Annexin buffer, CellLight lysosomes-GFP, 
CellLight early endosomes-GFP, Rhodamine Red C2 maleimide and CellTrace Violet 
were purchased from Life Technologies. 1 mM Staurosporine solution in DMSO, 2-(4-
amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI), poly-D-Lysine 
hydrobromide, tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 1-amino-2-propanol 
(HPA), sodium borohydride (NaBH4), Sephadex G 15 and 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) were purchased from Sigma-Aldrich. Pentafluorophenol was purchased 
from MatrixScientific and triethylamine (Et3N) and 1,4-dioxane were from Acros 
Organics. 3,3,3-Trifluoropropylamine hydrochloride was obtained from Apollo Scientific 
and  dimethylformamide (DMF), from VWR. The solvents were dried using a Pure Solv 
solvent purification system.  
 
4.2.2. Methods 
1H- and 19F-NMR spectra were recorded on a Bruker AV III-400 instrument at 
room temperature. 1H-NMR spectra of polymers were recorded with a relaxation 
time (d1) of 10 seconds and at least 256 scans using CD3OD and CDCl3 as solvents. 
Chemical shifts are reported relative to the residual proton signal of the solvent.Size 
exclusion chromatography (SEC) of PPFMA in THF was performed using an 
Agilent 1260 infinity system equipped with a refractive index (RI) Varian 390-LC, 
two PLgel 5 μm Mixed C (Agilent) columns and a PLgel guard column. THF was 
used as eluent with a flow rate of 1 mL/min and the temperature was 40 °C. 
Samples were analysed using conventional calibration with polystyrene (PS) 
standards ranging from 4910 Da to 549 KDa. UV-Vis spectroscopy was carried out 
using a Varian Cary 100 Bio spectrometer using quartz cuvettes and flow cytometry 
was performed using a LSRII cytometer (BD Biosciences) equipped with a violet 
(405 nm), blue (488 nm), green (561 nm) and red (640 nm) lasers and the data were 
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analysed using FlowJo software. Cells were imaged using a transmission electron 
microscope (Tecnai Spirit, FEI). 
Confocal microscopy and co-localization studies. Images were acquired on Zeiss 
LSM700 microscope with a Plan-Apochromat 63x/1.40 Oil objective, a pixel size of 70 
nm and pinhole 48 μm. 4 to 6 images were acquired per each incubation time and the 
experiments were replicated 3 times. Under the microscope, both polymer chains and 
vesicles resemble disks which suggested to use an object based co-localization analysis. 
Unfortunately, due to the resolution limit of microscopy, some individual objects could 
not be distinguished from others. Hence, the object based analysis relying on the measure 
of distances between closest neighbor objects would have been biased. For this reason, 
Mander’s coefficients were determined at the different time points.26 Since the different 
images showed different number of cells per field and the cells could exhibit different 
size and different levels of expression of the fusion constructs, some “Region Of Interest” 
(ROIs) were manually drawn to outline the fields of interest. Since different cells 
expressed different levels of the fusion protein GFP, and the image could present 
different background due to sample preparation or microscopy variability (staining batch 
and laser power fluctuation), a global (histogram-derived) thresholding method was used 
rather than only one cut-off value for all of the images. The chosen methods, selected by 
visual inspection of thresholded images, were Moments27 and IsoData28 respectively for 
vesicular compartments and polymer images. To perform the analysis, the Fiji 
distribution of ImageJ,29 the JACoP plugin30 and a customized Action Bar “BIOP JACoP 
Tools” [ref Action bar]31 enabling batch processing, were used.  
NanoSIMS. For the subcellular detection of the fluorinated PHPMA, samples were 
analyzed using a NanoSIMS 50L instrument. For anion analysis, the NanoSIMS uses a 
Cs+ primary beam that can be scanned over a squared surface to produce elemental 
images. The probe size (diameter of the Cs+ beam) was ~150 nm. During this study, 
typical images were collected in ultra-high vacuum condition (5 10-10 mbars). Images size 
was 38x38 μm with a 256x256 pixel image resolution and a dwell time of 5000 μs per 
pixel. The NanoSIMS detectors were set up to collect 12C14N?, 19F? and 32S? secondary 
ions simultaneously in the absence of any isobaric interference. Each image was acquired 
following the same protocol: a phase of pre-implantation where the Cs+ beam was 
scanned over the surface in order to remove the gold layer from the area of interest and to 
implant Cs+ into the sample; and an acquisition phase consisting of five successive scans 
Chapter 4: Monitoring Uptake and Intracellular Trafficking of Poly(N-(2-hydroxypropyl) 
methacrylamide) (PHPMA) 
 
163 
 
 
over the surface during which data were collected and were later cumulated during the 
data reduction.  
4.2.3. Procedures 
The 19F-CTA and the 19F-PPFMA were synthesized according to the procedure 
described in Chapter 1 and Chapter 2, respectively. The 19F- and 1H-NMR spectra of 
19F-PPFMA are included in Figure S1 and S2. Polymer molecular weight, determined by 
both NMR and SEC analysis are given in Table S1. 
 
19F-PHPMA. 100 mg (0.397 mmol PFMA reactive units) 19F-PPFMA were dissolved 
in 5 mL dry DMF, 2 equiv. (61 μL) 1-amino-2-propanol (HPA) and 2 equiv. (110 μL) 
Et3N were added and the reaction was stirred at 50°C for 20 h. The product was isolated 
by three precipitations in ice-cold diethyl ether and subsequently dialyzed against water. 
The 1H-NMR is shown in Figure S3. 
 
19F-PHPMA-Rhodamine conjugate. Modification of polymer end group with 
fluorescent dye was performed as previously reported with some modifications.32 20 mg 
(0.00129 mmol end group) 19F-PHPMA (Mn = 17151 g/mol) were dissolved in 3 mL 0.5 
M NaBH4 solution and stirred at room temperature for 2 h. The solution was dialyzed 
against water for 48 hours and the product was lyophilized. In a second step, 10 mg of 
product (0.6 μmol end group) were dissolved in dry DMF, 5 equivalents (0.8 mg 0.0032 
mmol) neutralized TCEP were added and the solution was stirred overnight under argon. 
After 20 h, 5 equivalents (2.1 mg) Rhodamine Red C2 maleimide were added together 
with one drop DBU. The solution was stirred under argon at room temperature for other 
24 h. The solution was dialyzed against water overnight using a SpectraPor (MWCO 3.5 
KDa) membrane to remove the DMF and finally lyophilized. The product was purified by 
passing it through a Sephadex G 15 column. The purification was repeated twice.  
 
Cell line and cell culture. HeLa cells were cultured in DMEM (high glucose) medium 
supplemented with 10 % fetal bovine serum (FBS) (Gibco) and 1% 
penicillin/streptomycin (Lifetech). Cells were maintained in a humidified atmosphere 
containing 5 % (v/v) of CO2 at 37 °C. 
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Cell preparation for fluorescence microscopy. HeLa cells were seeded on 13 mm 
sterilized poly-D-Lysine-coated coverslips in 24-well plates at a density of 25000 cells 
per well and incubated in 450 μL medium for 18 h. 17 μL (PPC 35) CellLight early 
endosomes GFP and 20 μL (PPC 40) CellLight lysosomes GFP were added to the cell 
medium and the cells were further incubated for 24 h. During this period, the cell medium 
was replaced by free phenol red-DMEM medium containing 0.6 mg/mL 19F-PHPMA-
Rhodamine and the cells were incubated for 15 h, 4 h, 2 h, 40 min and finally 10 min. For 
the 15 h incubation sample, the polymer solution was supplemented with the CellLight 
constructs in order to keep the cell exposure to the constructs constant among the 
different incubation times. At the end of the time-course experiment, the cells were 
washed three times with DMEM without phenol red and twice with PBS and finally fixed 
using 2 % paraformaldehyde and 1 % glutaraldehyde solution in phosphate buffer (PB) 
(pH 7.4, 0.1 M) for one hour at room temperature. Cells were than washed twice with 
cacodylate buffer (pH 7.4, 0.1 M) and stained with 0.5 μg/mL DAPI solution in the same 
buffer for 6 minutes. Cells were washed four times and kept in cacodylate buffer during 
fluorescence microscopy analysis. Three independent experiments were performed. 
 
Sample preparation for TEM and NanoSIMS analysis. After fluorescence 
microscopy, cells were post-fixed for 60 minutes in a solution of 1% osmium tetraoxide 
and 1.5% potassium ferrocyanide in ice-cold cacodylate buffer 0.1 M. This was followed 
by staining with 0.1 g thiocarbohydrazide in 10 mL double distilled water solution for 20 
min at room temperatute. Subsequently, staining with 1% osmium tetraoxide in 
cacodylate buffer solution was performed for 30 min. Then, the samples were dehydrated 
in an ascending alcohol series (1 X 50%, 1 X 70%, 2 X 96%, 2 X 100%, 3 minutes each) 
and resin embedded with Durcupan resin, which was then hardened overnight at 65 ?C. 
70 nm-thick sections were cut and placed on TEM finder grids. The grids and sections 
were gold-coated prior to NanoSIMS analysis to avoid charging effects. 
 
Cell viability assay and polymer internalization kinetics. Cell viability was assessed 
using Annexin V-Alexa Fluor 647/DAPI assay via flow cytometry. Hela cells were 
seeded and grown in the same conditions used for fluorescence microscopy analysis. 
Untreated cells were used as negative control and cells treated with Staurosporine were 
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used as positive control. To this purpose, 1 μL of 1 mM Staurosporine stock solution was 
add to each mL of medium and cells were incubated for 24 h. Treated cells were 
incubated with 0.6 mg/mL 19F-PHPMA-Rhodamine for 24 h, 15 h, 4 h, 2 h, 40 min and 
10 min. Cells were gently trypsinized, collected in 10 mL tubes and washed with PBS 
twice. Negative control cells were kept on ice until analysis. Positive control cells and 
cells treated with the polymer were re-suspended in 100 μL Annexin buffer (1X) 
containing 1 μg/mL DAPI at a density of 1 x 106 cells/mL. 5 μL of Annexin-V-Alexa 
Fluor 647 was then added to each tube and cells were incubated at room temperature for 
15 minutes. Untreated cells stained only with DAPI and only with Annexin V-Alexa 
Fluor 647 were also prepared and used as controls. After the incubation period, 400 μL of 
Annexin buffer was added to each tube and cells were kept in ice until analyzed by flow 
cytometry. Cells were analyzed using FL 9 channel for DAPI and FL 6 for Alexa Fluor 
647. In order to determine polymer internalization kinetics, intracellular Rhodamine was 
detected using FL 2 channel. Two independent experiments were performed and 10000 
events were collected. 
 
CellTrace Violet proliferation assay. CellTrace Violet proliferation assay was used to 
investigate cell division during the time-course of the experiment. To this purpose, cells 
were trypsinized and incubated at 37°C for 20 min in 5 mL PBS containing 5 μL 
CellTrace Violet stock solution in DMSO. After this time, 25 mL medium were added 
and the cells were incubated for further 5 minutes. Cells were centrifuged, resuspended in 
fresh medium and seeded. One sample of cells was centrifuged, resuspended in PBS and 
analyzed by flow cytometry using FL 9 channel for CellTrace Violet detection (Seeding 
time). After 18 hour, cells were treated with the polymer solution for 24 h, 15 h, 4 h, 40 
min and 10 min. For each incubation time, prior to adding the polymer solution, one 
sample of cells was trypsinized, washed with PBS and analyzed by flow cytometry. At 
the end of the time course experiment, cells incubated with the polymer solution for the 
different times were collected, washed with PBS and analyzed by flow cytometry (End 
time). Comparison between CellTrace Violet-cell fluorescence at the “Seeding time”, 
prior to each polymer addition and at the end of the time-course experiment “End time” 
allowed the determination of the time-dependent cell division occurring during the 
experiment. 
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4.3. Results and Discussion 
4.3.1. 19F-PHPMA-Rhodamine design and synthesis 
The first step of this work consisted in the design of a HPMA polymer containing two 
different labels that are suitable for both fluorescence-based studies and NanoSIMS 
analysis. While Rhodamine Red was chosen as fluorescent dye, fluorine, an element not 
present in biological environments was selected as NanoSIMS probe. Although the aim of 
this work is to investigate the intracellular trafficking of PHPMA via fluorescence 
microscopy and to demonstrate the feasibility of using NanoSIMS and TEM to track the 
internalized polymer, the HPMA polymer containing both fluorine and Rhodamine Red 
(19F-PHPMA-Rhodamine) was synthesized using an approach that would be suitable for 
further design of polymer-drug conjugates. Two different aspects were taken into account 
for the selection of the appropriate approach. First, it has been demonstrated that 
parameters such as polymer chain size and composition need to be carefully considered 
while studying polymer internalization and trafficking.16 Based on these results, the 
preparation of polymers via post-polymerization modification offers several advantages 
in comparison to direct polymerization of functional monomers. This method allows the 
preparation of polymers characterized by the same chain length distribution and 
polydispersity, but different side chain functionalities.33 Moreover, the side chain 
functionalities can be randomly distributed along the polymer chains therefore avoiding 
structural heterogeneities that can lead to different polymer architectures33 and therefore 
result in different cellular uptake.16 The second aspect that was considered for the choice 
of the synthetic approach is the polymer labelling. Although PHPMA-dye conjugates are 
generally prepared by conjugating the dye to the polymer side chains,13,16-18 the use of the 
polymer end groups for label insertion would offer the opportunity to preserve polymer 
side chains for further drug conjugation. To this purpose, RAFT polymerization is 
particularly attractive since it allows the synthesis of polymer possessing functional α-ε 
end groups, that can be used for direct label insertion or that can be used to introduce 
functionalities.34 Post-polymerization modification of these functionalities have been 
proposed as a way to couple labels to the polymer end groups.32,34 
Hence, 19F-PHPMA was prepared via post-polymerization modification of a 
poly(pentafluorophenyl methacrylate) (PPFMA) precursor. PPFMA was selected since it 
can be polymerized by RAFT polymerization and since the post-polymerization 
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In the next step, flow cytometry was used to trace the time-dependent polymer uptake. 
Both concentration-dependent and time-dependent uptake of PHPMA-drug and PHPMA-
dye conjugates, as well as PHPMA-derived copolymers have been widely investigated by 
flow cytometry experiments.14,16-18 However, cell division during the incubation period 
was never considered for results interpretation. Cell division has been instead considered 
for the interpretation of nanoparticles kinetics uptake results.21,36 Kim et al. demonstrated 
that, especially for long incubation times, cell division can lead to an apparent decrease in 
polymer uptake.37 Therefore, the aim of these experiments was to relate the time-
dependent polymer uptake to cell division. First, cells were incubated with the polymer 
for different incubation times and analyzed by flow cytometry to determine time-
dependent polymer uptake. Increase in Rhodamine fluorescence over time, as compared 
to control cells is illustrated in Figure 2B, while the result from a duplicate experiment is 
reported in Figure S6. Figure 2C summarize the results from these two experiments and 
represents them as Rhodamine-geometric mean fluorescence intensity (normalized to the 
geometric mean fluorescence of untreated cells) as a function of time. This plot clearly 
shows that a prolonged cell exposure to the polymer solution resulted in enhanced 
polymer uptake. While a rapid fluorescence intensity increase was observed within the 
first 10 minutes incubation, slower polymer uptake was observed for the subsequent time 
points and in particular, a consistent decrease in polymer uptake rate was observed 
between 15 and 24 h incubation. In order to prove that the significant reduced polymer 
uptake at long incubation time is the result of cell division, a CellTrace violet 
proliferation assay was performed. CellTrace Violet diffuse into the cells and binds 
covalently to intracellular amines. Hence, determination of the cell-associated CellTrace 
Violet fluorescence provides information about cell proliferation. In particular, a decrease 
in time-dependent fluorescence can be used as an indication of cell division. In order 
investigate whether cell division occurs during the time frame of the experiment, cells 
were treated in the same conditions as for the polymer uptake study and flow cytometry 
was used to detect CellTrace Violet associated fluorescence. Figure 2D summarizes the 
CellTrace Violet assay results, while the complete flow cytometry plots, as well as the 
correspondent geometric mean fluorescence values, are reported in Figure S7. For all 
experiments, cells were seeded 18 hours before starting the time course polymer 
incubation. This initial cell population fluorescence is indicated in Figure 2D as “Seeding 
time”. Prior polymer addition, for each of the incubation time, one sample of cells was 
analyzed by flow cytometry in order to determine the cell population fluorescence at the 
beginning of the time-course experiment. The fluorescence of cells analyzed at the end of 
Chapter 4: Monitoring Uptake and Intracellular Trafficking of Poly(N-(2-hydroxypropyl) 
methacrylamide) (PHPMA) 
 
171 
 
 
the experiment is indicated in Figure 2D as “End time”. The shift between “Seeding 
time” and “End Time” fluorescence suggests that during this time frame, the cells 
underwent at least two division cycles. The geometric mean fluorescence of cells 
analyzed prior polymer addition for the time points “10 min”, “40 min” “2 h” and “4 h” 
overlaps with that of the cells at the end of the time-course experiment “End time”. This 
result indicates that both cell division cycles occurred prior polymer addition. On the 
contrary, for the time points “15 h” and “24 h”, cell fluorescence values prior polymer 
addition were found in between the “Seeding time” and “End time” values. This suggests 
that, in this case, cells underwent at least one division cycle during the polymer 
incubation period. These results corroborate the kinetics uptake data and suggest that, in 
presence of continuous source of polymer and at longer incubation time, at least 15 hours 
in this particular case, the competition between cell division and polymer uptake can 
result in the establishment of an apparent polymer uptake saturation.  
 
4.3.3. Intracellular trafficking studies of PHPMA via confocal microscopy 
After determining time-dependent polymer uptake and cell division by flow cytometry, 
the effect of time-dependent co-localization with the endolysosomal vesicles was 
investigated. In particular, co-localization studies between Rhodamine-labeled HPMA 
polymer and early endosomes (EE, initial endocytosis step) and lysosomes (L, final 
endocytosis step), were performed in order to investigate the endocytosis process time-
frame. To this purpose, Hela cells expressing GFP either in the early endosomes or in the 
lysosomes, were incubated with the polymer for 15 h, 4 h, 2 h, 40 min and 10 min, fixed 
and imaged by confocal microscopy. Results of co-localization studies after 24 h polymer 
incubation are not reported since this long incubation period did not lead to any additional 
information. Representative pictures of observations at 10 min and 4 h polymer 
incubation for both cells expressing GFP in the EE and L are shown in Figure 3. Images 
of the different time points for one experiment are reported in Supporting Information in 
Figure S8 and Figure S9 for EE and L, respectively. Two different image analysis were 
performed in order to investigate the dynamic of the endocytosis process and to determine 
the time dependent polymer co-localization with both endosomal and lysosomal vesicles. 
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lysosomal vesicles enlargement.39 This effect was confirmed by the transmission electron 
microscopy (TEM) image of the cells. Figure S10 shows representative images of control 
cells as well as cells treated with the polymer for 4 h as well as 15 h. It was found that 
cells exposed to the polymer solution resulted in higher amount of lysosomal vesicles as 
compared to control cells, as indicated by the numerous dark electron rich vesicles 
observed. Area ratio analysis revealed for both endosomes and lysosomes co-localization 
experiments a substantial Ch2 (Rhodamine, 19F-PHPMA-Rhodamine) area ratio increase 
over incubation time. Figure 4B and 4D indicate that more and more polymer enters the 
cells over the investigated time frame, as already observed by flow cytometry analysis.  
The second analysis performed aimed to estimate the co-localization between 19F-
PHPMA-Rhodamine and endolysosomal vesicles (EE and L). To this purpose, Mander’s 
coefficients were determined. These coefficients are proportional to the amount of 
fluorescence of the co-localizing pixels in each channel. Values ranging from 0 to 1 
express the fraction of intensity in a channel that is located in pixels where there is above 
zero (or threshold) intensity in the other channel.26 Hence, in this particular case, for Ch1 
(GFP, EE or L) and for Ch2 (Rhodamine, 19F-PHPMA-Rhodamine), M1 and M2, 
respectively, are expressed as shown in Equations (1) and (2).26 
 
M1= 
? GFPi,coloci
?GFPi                  M2= 
? Rhoi,coloci
?Rhoi                                   (1, 2) 
 
The obtained Mander’s coefficient plots are shown in Figure 5. In particular, “Mander’s 
Coefficient of Channel 1” (M1, GFP, EE or L) is shown on the x axis, while the 
“Mander’s Coefficient of Channel 2” (M2, Rhodamine, 19F-PHPMA-Rhodamine) is 
shown on the y axis. While panels A and C illustrate the area subdivision of the plots, 
panels B and D represent the results obtained for the different incubation times. Each dot 
corresponds to one analyzed image deriving from three independent experiments. Figure 
5B illustrates the Mander’s coefficients determined for images of cells expressing the 
endosomal GFP. At the earliest time point “10 min”, the found M1 values are very low 
(all below 0.25, mostly below 0.125), suggesting little co-localization of Ch1 intensities 
(GFP, EE) with the Ch2 (Rhodamine, 19F-PHPMA-Rhodamine). On the other side, higher 
M2 values were observed, variable from 0 to 1, suggesting that some cells showed little, 
while other high, co-localization of Ch2 (Rhodamine, 19F-PHPMA-Rhodamine) 
intensities with Ch1 (GFP, EE). These results suggests that, at the earliest time point, the 
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polymer already entered some of the early endosomes, but just a few vesicles are 
occupied (M1 values are low). At the time point “40 min” the M1 values shift slightly to 
the right while the M2 decreases. At the time point “2 h” the M2 values further decreases. 
Time points “4 h” and “15 h” shows a more variable cell population but always 
characterized by higher M1 values compared to M2. Hence, after the first time point, 
while the M1 values slightly increase, suggesting that more EE are involved in the 
endocytosis process, the M2 values decreases, indicating that more and more of the 
internalized polymer is not localized inside the endosomal vesicles. This result, together 
with the increase of the Ch2 area ratio over time (Figure 4B) suggests that the 
internalized polymer chains, firstly detected in the endosomal vesicles, continue their 
route to another compartment, most probably the cell lysosomes. In order to prove this 
hypothesis, the same analysis was performed for lysosomal co-localization. Mander’s 
coefficients analysis (Figure 5D) revealed that at the earliest time point “10 min”, the M1 
values are very low (mostly below 0.25), suggesting little co-localization of Ch1 
intensities with the Ch2. On the other side, the M2 values are highly variable from 0 to 1. 
These results suggest that even at the earliest time point, a few polymer chains have 
already reached some cell’s lysosomes (variable M2 values), but just a few of the 
lysosomes are involved in the process (M1 values are low). At the time point “40 min”, 
M1 and M2 increase and values are more homogenous. This suggests that more polymer 
chains trafficked to the lysosomes, and therefore more lysosomes have been being 
occupied. At the following time points “2 h” to “15 h”, M1 values increase gradually, 
suggesting that more and more lysosomes are taking part to the process.  
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lysosomes is particularly relevant since the environmental parameters that characterize 
these vesicles can be exploited to trigger intracellular drug release from PHPMA 
carriers.7  
 
4.3.4. Subcellular polymer localization via NanoSIMS and TEM  
Although flow cytometry analysis and confocal fluorescence microscopy can estimate 
polymer uptake and its transit through the endolysosomal pathway, the establishments of 
new approaches to monitor polymer intracellular trafficking that also offer the possibility 
to minimize polymer labelling and give quantitative information is of great interest to 
fully characterize these processes. The last part of this work aims to demonstrate that the 
insertion of fluorine on the polymer end group allow intracellular polymer detection by 
NanoSIMS. Further combination with transmission electron microscopy (TEM) was 
explored as a method to localize the polymer in the endocytic pathway.  
For this proof-of-concept study, samples of cells treated with the polymer for 4 and 15 
h, which showed a preponderant polymer co-localization with the cell lysosomes were 
selected. Untreated cells were also used as a control. After confocal microscopy the 
samples were embedded in resin, cut as 70 nm sections and first imaged by TEM. 
Representative images are reported in Figure S10. As already anticipated, cells exposed 
to the polymer solution resulted in higher amount of lysosomal vesicles as compared to 
control cells. Next, samples were analysed by NanoSIMS. Example of secondary ion 
maps of control cells, as well as cells incubated with the polymer for 4 h and 15 h are 
shown in Figure 6 and Figure S11. These results suggest that fluorine-containing 
polymers can be detected as localized signals in the cell cytoplasm and that longer 
polymer incubation time result in more punctuate cytoplasmic fluorine signals.  
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The first part of this work focused on polymer uptake studies by flow cytometry and 
highlighted the influence of cell division on the polymer uptake kinetics. PHPMA 
internalization rate was found to be very fast in the first 10 minutes incubation. Longer 
polymer incubation times led instead to a slower uptake rate and an apparent saturation 
was observed after 15 hour incubation. Cell proliferation assay suggested that this effect 
does not derive from a reduced uptake rate but is a consequence of cell division which 
causes the division of the internalized material between daughter cells. 
In a second step, confocal fluorescence microscopy allowed co-localization studies 
between the internalized polymer and both early endosomal and lysosomal vesicles. 
Analysis of the area ratio of the polymer-associated Rhodamine signal, as compared to 
the selected ROIs confirmed an increase polymer uptake over time. Mander’s coefficients 
were calculated and used to estimate the association of the polymer with endosomes and 
lysosomes expressing GFP. Co-localization studies suggested that the endocytosis 
process occur very rapidly upon cell incubation with the polymer. While the first 10 
minutes incubation resulted in the highest endosomal co-localization, increased polymer 
incubation resulted in a significant reduction of polymer co-localization with these 
vesicles. On the contrary, lower correlation with lysosomal vesicles was observed in the 
first 10 minutes incubation, as compared to longer incubation times. Cell exposure to the 
polymer solution for at least 2 hours led to almost complete co-localization of the 
internalized polymer with the lysosomes. Longer cell exposure to the polymer solution 
resulted in an enhanced correlation between lysosomal vesicles and fluorescent polymer 
indicating that over time more and more lysosomal vesicles take part to the process. 
The last part of this work explored the use of NanoSIMS to map the internalized 
polymer. First, the fluorine label on the polymer could be detected as subcellular 
punctuate cytoplasmic fluorine signal. Second, a strong correlation between fluorine and 
sulfur was observed. Cell imaging via TEM prior NanoSIMS analysis confirmed the 
correlation between both the punctuate sulfur and fluorine signals with electron rich 
lysosomal vesicles. Although further studies are required, this proof-of-concept study 
suggests that while NanoSIMS analysis can be used to localize polymer in sulfur rich 
lysosomes, the combination with TEM is a very promising method to simultaneously map 
subcellular distribution of internalized polymer in several cell compartments.  
Both the optimization of fluorescence-based methods as well as the establishment of 
new techniques to monitor the subcellular fate of polymer carriers is fundamental for the 
development of more advance drug delivery systems. 
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5. Conclusions and Perspectives 
Polymer nanomedicine is a rapidly expanding field that has found application in the 
treatment of cancer as well as other diseases. Both the use of controlled radical 
polymerization techniques as well as the development of new methods and tools to 
monitor intracellular trafficking and delivery of polymers are essential for the design of 
more advanced delivery systems. This Thesis described the use of RAFT polymerization 
for the preparation of dual functional PHPMA polymers that allow to control the 
intracellular delivery of anticancer drug combinations and to monitor PHPMA 
intracellular trafficking.   
Following an introduction to the field of polymer nanomedicine, which presented the 
different approaches that have been proposed to control and monitor intracellular 
polymer-mediated anticancer drug delivery in Chapter 1, Chapter 2 described the 
preparation of α- and α,ω-fluorinated PPFMA by using CTAs containing a fluorinated 
label in the R (F-CTA-1) or in both R and Z (F-CTA-2) groups. While the use of F-CTA-
1 led to the preparation of α-fluorinated PPFMA and was used to determine the 
experimental polymer molecular weights as well as transfer constants via 19F-NMR 
studies, the second CTA derivative (F-CTA-2) was used for the preparation of the α,ω-
fluorinated PPFMA in order to determine α,ω-end group fidelity. It was demonstrated 
that the use of F-CTAs for the RAFT polymerization of FPMA does not affect the 
polymerization behavior therefore suggesting that this is a suitable method for the 
preparation of α- and α,ω-labeled PPFMA derivatives. The α-fluorinated PPFMA was 
later used as a precursor polymer for the preparation of PHPMA polymers in Chapter 3 
and Chapter 4. This method is not only limited to PPFMA or fluorinated polymers, but 
can be applied to a wide range of polymers prepared by RAFT polymerization. Insertion 
of the fluorinated labels at the polymer α- and ω-end groups can be used as a general 
method to study CTA consumption as well as end group fidelity during the 
polymerization process via 19F-NMR studies. 
In Chapter 3, post-polymerization modification of the precursor PPFMA led to the 
preparation of a dual-functional PHPMA conjugate for the endolysosomal release of the 
anticancer drug doxorubicin (Dox) and the third generation P-gp inhibitor zosuquidar 
(Zos) by using two orthogonal cleavable linkers. First, PHPMA conjugates bearing a Zos 
derivative connected to the polymer carrier via a hydrazone linker was tested. In vitro 
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activity studies using both resistant A2780ADR and sensitive A2780 ovarian carcinoma 
cells revealed that this is an effective polymeric system to overcome Dox efflux in 
resistant ovarian cancer cells. The second part of this work investigated the activity of the 
dual delivery system in which both drugs were conjugated to the PHPMA via orthogonal 
cleavable linkers. In vitro activity studies of two different conjugates containing either the 
anticancer drug Dox alone (PHPMA-Dox) or in combination with Zos (PHPMA-Dox-
Zos) demonstrated that the presence of the two drugs attached to the polymer backbone 
via orthogonal cleavable linkers can enhance P-gp inhibition and therefore Dox 
cytotoxicity in the resistant cancer cells.  
In Chapter 4, post-polymerization modification of the α-fluorinated PPFMA prepared 
in Chapter 1 allowed the synthesis of a dual-labeled PHPMA conjugate containing the 
fluorinated label as well as a fluorescent dye in the polymer end groups. While the 
fluorescent label allowed to study polymer uptake and intracellular trafficking using 
fluorescence-based techniques, the fluorinated label was used for NanoSIMS studies. 
Both flow cytometry and confocal microscopy suggested a very rapid PHPMA cellular 
uptake upon cell exposure to the polymer solution. The investigation of cell proliferation 
during the time-frame of the experiment revealed that the apparent polymer uptake 
saturation after long incubation time derives from division of the internalized polymer 
between daughter cells. Co-localization studies with endosomal and lysosomal vesicles 
expressing GFP confirmed the early endosomal trafficking of the PHPMA and the final 
accumulation of the polymer in the cell lysosomes. Preponderant polymer localization in 
the cell lysosomes was observed after 2 hours incubation and longer exposure of the cells 
to the polymer solution resulted in an increase amount of lysosomal vesicles involved in 
the process. The last part of this Chapter demonstrated the feasibility of using NanoSIMS 
to map the subcellular distribution of the fluorinated PHPMA. Combination with TEM 
confirmed the correlation of polymer-associated fluorine signals with sulfur rich 
lysosomal vesicles and demonstrated the potential of this method to map the subcellular 
polymer distribution with several cell compartments simultaneously. 
NanoSIMS and its combination with TEM was found a very promising approach to 
monitor PHPMA intracellular trafficking. However, this proof-of-concept study 
represents only a first step toward the implementation of this technique in the field of 
polymer nanomedicine. First, the screening of different nonessential elements and 
isotope-labelled PHPMA, the investigation of time-dependent polymer trafficking and 
quantitative analysis are necessary to fully estimate the potential of this technique. 
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Second, the use of this technique to monitor not only intracellular trafficking, but also 
intracellular drug release should be considered. The approach presented in this Thesis 
offered the opportunity to prepare precursor PPFMA polymers containing labels at the 
polymer end groups, while at the same time preserving polymer side chains for further 
modification to PHPMA-anticancer drug conjugates. Hence, the use of isotope-labelled 
drugs would offer the opportunity to track both carrier and drugs at the subcellular level. 
This would be particularly interesting to investigate delivery systems such that described 
in Chapter 3, in which multiple drugs are linked to the polymer carrier and are designed 
to be release in a stepwise manner and to interact with different intracellular targets. 
Analysis via both NanoSIMS and TEM would allow to address multiple objectives such 
as (i) the determination of polymer intracellular trafficking time-frame, (ii) the 
simultaneous visualization of polymer and drugs in the endolysosomal compartments, 
(iii) the quantification of drug release kinetics from the polymer carrier as a response to 
the different endolysosomal environments and (iv) the determination of the ultimate 
intracellular fate of both carrier and drugs. 
Finally, it is worth to emphasize that this approach is not limited to PHPMA-based 
polymers, but it can be applied to a wide range of polymers of different composition and 
architecture that are prepared via RAFT polymerization. The development of a general 
method to address the above mentioned objectives is of great impact in the field of 
polymer nanomedicines since the establishment of techniques and methods able to 
simultaneously map several intracellular compartments and that allow for quantitative 
analysis, while avoiding the use of bulky labels are object of constant investigation. 
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